DONALDSON CO INC, 10-K filed on 9/26/2025
Annual Report
v3.25.2
Cover - USD ($)
 12 Months Ended
Jul. 31, 2025
Sep. 12, 2025
Jan. 31, 2025
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Current Fiscal Year End Date --07-31    
Document Period End Date Jul. 31, 2025    
Document Transition Report false    
Entity File Number 1-7891    
Entity Registrant Name DONALDSON COMPANY, INC.    
Entity Incorporation, State DE    
Entity Tax Identification Number 41-0222640    
Entity Address, Street Address 1400 West 94th Street    
Entity Address, City Minneapolis    
Entity Address, State MN    
Entity Address, Postal Zip Code 55431    
City Area Code 952    
Local Phone Number 887-3131    
Title of each class Common Stock, $5.00 par value    
Trading Symbol(s) DCI    
Name of each exchange on which registered NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Emerging Growth Company false    
Entity Small Business false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error false    
Entity Shell Company false    
Entity Public Float     $ 8,462,489,351
Entity Common Stock, Shares Outstanding   115,907,357  
Documents Incorporated by Reference
Portions of the registrant’s Proxy Statement for its 2025 annual meeting of stockholders (the “2025 Proxy Statement”) are incorporated by reference in Part III, as specifically set forth in Part III.
    
Entity Central Index Key 0000029644    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Amendment Flag false    
v3.25.2
Audit Information
 12 Months Ended
Jul. 31, 2025
Auditor Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Minneapolis, Minnesota
Auditor Firm ID 238
v3.25.2
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Income Statement [Abstract]      
Net sales $ 3,690.9 $ 3,586.3 $ 3,430.8
Cost of sales 2,404.7 2,311.9 2,270.2
Gross profit 1,286.2 1,274.4 1,160.6
Selling, general and administrative 641.0 636.7 602.3
Loss on impairment of intangible assets 62.0 0.0 0.0
Research and development 87.8 93.6 78.1
Operating expenses 790.8 730.3 680.4
Operating income 495.4 544.1 480.2
Interest expense 24.2 21.4 19.2
Other income, net (21.0) (12.6) (7.7)
Earnings before income taxes 492.2 535.3 468.7
Income taxes 125.2 121.3 109.9
Net earnings $ 367.0 $ 414.0 $ 358.8
Weighted average shares – basic (in shares) 118.7 120.7 121.8
Weighted average shares – diluted (in shares) 120.4 122.6 123.6
Net earnings per share – basic (in usd per share) $ 3.09 $ 3.43 $ 2.95
Net earnings per share – diluted (in usd per share) $ 3.05 $ 3.38 $ 2.90
v3.25.2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Statement of Comprehensive Income [Abstract]      
Net earnings $ 367.0 $ 414.0 $ 358.8
Other comprehensive income:      
Foreign currency translation income (loss) 29.6 (24.2) 34.0
Pension liability adjustment, net of deferred taxes of $2.3, $0.8 and $(0.3), respectively (7.5) (1.9) 0.3
Derivatives:      
Loss on hedging derivatives, net of deferred taxes of $1.3, $0.2 and $0.5, respectively (4.2) (0.6) (1.4)
Reclassification of hedging derivatives to net earnings, net of taxes of $(0.1), $0.0 and $(0.1), respectively 0.3 0.3 0.2
Total derivatives (3.9) (0.3) (1.2)
Net other comprehensive income (loss) 18.2 (26.4) 33.1
Comprehensive income $ 385.2 $ 387.6 $ 391.9
v3.25.2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Statement of Comprehensive Income [Abstract]      
Pension liability adjustment, net of deferred taxes $ 2.3 $ 0.8 $ (0.3)
(Loss) gain on hedging derivatives, net of deferred taxes 1.3 0.2 0.5
Reclassification of hedging derivatives to net earnings, net of taxes $ (0.1) $ (0.0) $ (0.1)
v3.25.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Current assets:    
Cash and cash equivalents $ 180.4 $ 232.7
Accounts receivable, less allowances of $2.9 and $6.3, respectively 662.2 629.7
Inventories, net 513.6 476.7
Prepaid expenses and other current assets 105.5 99.0
Total current assets 1,461.7 1,438.1
Property, Plant and Equipment, Net 644.5 645.5
Goodwill 493.6 478.4
Intangible assets, net 97.4 171.9
Other long-term assets 280.0 180.4
Total assets 2,977.2 2,914.3
Current liabilities:    
Short-term borrowings 31.2 28.3
Current maturities of long-term debt 6.7 25.0
Accounts payable 368.6 379.4
Accrued employee compensation and related taxes 144.3 140.9
Income taxes payable 43.9 42.6
Other current liabilities 162.5 166.3
Total current liabilities 757.2 782.5
Long-term debt 630.4 483.4
Non-current income taxes payable 19.0 39.8
Deferred income taxes 10.5 16.1
Other long-term liabilities 106.6 103.4
Total liabilities 1,523.7 1,425.2
Commitments and contingencies (Note 18)
Stockholders’ equity:    
Preferred stock, $1.00 par value, 1,000,000 shares authorized, none issued 0.0 0.0
Common stock, $5.00 par value, 240,000,000 shares authorized, 151,643,194 shares issued 758.2 758.2
Additional paid-in capital 35.8 26.8
Retained earnings 2,610.1 2,377.5
Accumulated other comprehensive loss (180.7) (198.9)
Treasury stock, 35,600,740 and 31,533,192 shares, respectively, at cost (1,769.9) (1,474.5)
Total stockholders’ equity 1,453.5 1,489.1
Total liabilities and stockholders’ equity $ 2,977.2 $ 2,914.3
v3.25.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Statement of Financial Position [Abstract]    
Accounts receivable, allowance $ 2.9 $ 6.3
Preferred stock, par value (in usd per share) $ 1.00 $ 1.00
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in usd per share) $ 5.00 $ 5.00
Common stock, shares authorized (in shares) 240,000,000 240,000,000
Common stock, shares issued (in shares) 151,643,194 151,643,194
Treasury stock, shares (in shares) 35,600,740 31,533,192
v3.25.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Operating Activities      
Net earnings $ 367.0 $ 414.0 $ 358.8
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation and amortization 99.5 98.4 92.3
Equity in earnings of affiliates, net of distributions (3.6) (4.7) (1.0)
Deferred income taxes (24.0) (24.3) (15.3)
Stock-based compensation expense 24.0 22.0 20.4
Loss on impairment of intangible assets 62.0 0.0 0.0
Other, net (5.9) 3.7 7.3
Changes in operating assets and liabilities, excluding effect of acquired businesses:      
Accounts receivable, net (21.4) (39.4) 30.1
Inventories, net (32.2) (65.6) 99.8
Prepaid expenses and other current assets 6.3 (28.3) 16.8
Accounts payable (5.5) 80.3 (39.0)
Income taxes payable (34.4) 4.4 (11.5)
Accrued employee compensation and related taxes and other current liabilities (13.0) 32.0 (14.2)
Net cash provided by operating activities 418.8 492.5 544.5
Investing Activities      
Purchases of property, plant and equipment (78.9) (85.6) (118.5)
Proceeds from sale of property, plant and equipment 2.1 0.7 0.4
Equity investment (71.2) 0.0 0.0
Acquisitions, net of cash acquired (2.4) (2.0) (209.2)
Net cash used in investing activities (150.4) (86.9) (327.3)
Financing Activities      
Proceeds from long-term debt 388.1 119.7 189.2
Repayments of long-term debt (265.0) (228.8) (219.6)
Change in short-term borrowings 1.2 (5.7) 30.4
Purchase of treasury stock (331.5) (162.7) (141.8)
Payment of contingent consideration (5.5) (1.7) 0.0
Dividends paid (131.9) (122.8) (114.4)
Tax withholding for stock compensation transactions (5.7) (8.0) (4.3)
Exercise of stock options 28.6 54.1 38.3
Net cash used in financing activities (321.7) (355.9) (222.2)
Effect of exchange rate changes on cash 1.0 (4.1) (1.2)
(Decrease) increase in cash and cash equivalents (52.3) 45.6 (6.2)
Cash and cash equivalents, beginning of year 232.7 187.1 193.3
Cash and cash equivalents, end of year 180.4 232.7 187.1
Supplemental Cash Flow Information      
Income taxes paid 176.2 147.8 140.9
Interest paid 22.2 23.4 20.9
Supplemental Disclosure of Non-Cash Operating and Investing Transactions      
Accrued property, plant and equipment additions 10.7 14.2 18.5
Leased assets obtained in exchange for new operating lease liabilities $ 24.0 $ 22.7 $ 32.3
v3.25.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Stock
Beginning balance at Jul. 31, 2022 $ 1,133.2 $ 758.2 $ 17.0 $ 1,845.7 $ (205.6) $ (1,282.1)
Comprehensive income            
Net earnings 358.8     358.8    
Foreign currency translation 34.0       34.0  
Pension liability adjustment, net of deferred taxes 0.3       0.3  
Losses on hedging derivatives, net of deferred taxes (1.4)       (1.4)  
Reclassification of losses on hedging derivatives to net earnings 0.2       0.2  
Comprehensive income 391.9          
Treasury stock acquired (141.8)         (141.8)
Stock options exercised 36.9   (5.2)     42.1
Stock compensation expense 20.4   20.2     0.2
Deferred stock and other activity (3.5)   (7.2) (0.3)   4.0
Dividends declared (116.4)     (116.4)    
Ending balance at Jul. 31, 2023 1,320.7 758.2 24.8 2,087.8 (172.5) (1,377.6)
Comprehensive income            
Net earnings 414.0     414.0    
Foreign currency translation (24.2)       (24.2)  
Pension liability adjustment, net of deferred taxes (1.9)       (1.9)  
Losses on hedging derivatives, net of deferred taxes (0.6)       (0.6)  
Reclassification of losses on hedging derivatives to net earnings 0.3       0.3  
Comprehensive income 387.6          
Treasury stock acquired (163.3)         (163.3)
Stock options exercised 53.0   (6.4)     59.4
Stock compensation expense 22.0   21.8     0.2
Deferred stock and other activity (6.0)   (13.4) 0.6   6.8
Dividends declared (124.9)     (124.9)    
Ending balance at Jul. 31, 2024 1,489.1 758.2 26.8 2,377.5 (198.9) (1,474.5)
Comprehensive income            
Net earnings 367.0     367.0    
Foreign currency translation 29.6       29.6  
Pension liability adjustment, net of deferred taxes (7.5)       (7.5)  
Losses on hedging derivatives, net of deferred taxes (4.2)       (4.2)  
Reclassification of losses on hedging derivatives to net earnings 0.3       0.3  
Comprehensive income 385.2          
Treasury stock acquired (333.6)         (333.6)
Stock options exercised 28.4   (4.1)     32.5
Stock compensation expense 24.0   23.9     0.1
Deferred stock and other activity (5.4)   (10.8) (0.2)   5.6
Dividends declared (134.2)     (134.2)    
Ending balance at Jul. 31, 2025 $ 1,453.5 $ 758.2 $ 35.8 $ 2,610.1 $ (180.7) $ (1,769.9)
v3.25.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (Parenthetical) - $ / shares
 3 Months Ended 12 Months Ended
Jul. 31, 2025
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Statement of Stockholders' Equity [Abstract]        
Dividends declared (in usd per share) $ 0.300 $ 1.14 $ 1.04 $ 0.96
v3.25.2
Summary of Significant Accounting Policies
 12 Months Ended
Jul. 31, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 1. Summary of Significant Accounting Policies
Description of Business
Donaldson Company, Inc. (the Company) is a global leader in technology-led filtration products and solutions. The Company’s core strengths include leading filtration technology, diverse business and a global presence. Products are manufactured and sold around the world to original equipment manufacturers (OEMs), distributors, dealers and directly to end users.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of the Company and all its majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
The Company’s joint ventures are not majority-owned and are accounted for under the equity method. The Company is party to joint ventures with Advanced Filtration Systems Inc. (AFSI) and PT Panata Jaya Mandiri (PTPJM), as well as a non-controlling interest in Medica S.p.A. (Medica), all of which are considered related parties. The investment and earnings from joint ventures are not material.
Certain reclassifications to previously reported financial information have been made to conform to the current period presentation.
Use of Estimates
The preparation of the Company’s financial statements in conformity with generally accepted accounting principles (GAAP) in the United States (U.S.) requires management to make estimates and assumptions that affect the amount of assets and liabilities and the disclosures regarding contingent assets and liabilities at period end and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Operating Environment
Foreign Currency Translation
For most foreign operations, local currencies are considered the functional currency. Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at fiscal year end exchange rates and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as a cumulative translation adjustment, a component of accumulated other comprehensive loss on the Consolidated Balance Sheets. Elements of the Consolidated Statements of Earnings are translated at average exchange rates in effect during the fiscal year. Foreign currency transaction losses are included in other income, net in the Consolidated Statements of Earnings and were $2.5 million, $1.7 million and $6.4 million in the years ended July 31, 2025, 2024 and 2023, respectively.
Cash Equivalents
The Company considers all highly liquid temporary investments with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at cost which approximates market value.
Revenue Recognition
Revenue is measured as the amount of consideration the Company expects to receive in exchange for the fulfillment of performance obligations. The transaction price of a contract could be reduced by variable consideration including volume purchase rebates and discounts, product refunds and returns. At the time of sale to a customer, the Company records an estimate of variable consideration as a reduction from gross sales. The Company primarily relies on historical experience and anticipated future performance to estimate the variable consideration. Revenue is recognized to the extent it is probable a significant reversal of revenue will not occur when the contingency is resolved. The Company accounts for amounts billed to customers for reimbursement of shipping and handling costs by recording these amounts as revenue and accruing costs when the related revenue is recognized.
For most customer contracts, the Company recognizes revenue at a point in time when control of the goods or services is transferred to the customer. For product sales, control is typically deemed to have transferred in accordance with the shipping terms, either at the time of shipment from the plants or distribution centers or the time of delivery to the customers. Revenue is recognized for services upon completion of those services. Payment terms vary by customer and the geographic location of the customer. The Company’s contracts with customers do not include significant financing components or non-cash consideration.
The Company has some contracts with customers where the performance obligations are satisfied over time. Certain customer contracts provide the Company with an enforceable right to payment of the transaction price for performance completed to date and the Company uses either an input or an output method of production to measure the progress towards the completion of the performance obligation in these arrangements, depending on the nature of the contract. The timing of revenue recognized from these products is slightly accelerated compared to revenue recognized at the time of shipment or delivery.
The Company generally does not incur significant incremental costs related to obtaining or fulfilling a contract prior to the start of a project. The Company may incur certain fulfillment costs such as initial design or mobilization costs which are capitalized if they relate directly to the contract, if they are expected to generate resources that will be used to satisfy the Company’s performance obligation under the contract and if they are expected to be recovered through revenues generated under the contract. Such costs, which are amortized over the life of the respective project, were not material for any period presented.
The Company does not pay upfront sales commissions on contracts when the related contract period is greater than one year and thus has not capitalized any amounts as of July 31, 2025 and 2024, see Note 3.
Shipping and Handling
Shipping and handling costs on products sold of $95.3 million, $91.5 million and $91.2 million are classified as a component of selling, general and administrative expenses in the Consolidated Statements of Earnings for the years ended July 31, 2025, 2024 and 2023, respectively.
Accounts Receivable, Net and Allowance for Doubtful Accounts
Accounts receivable, net are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of credit losses in its existing accounts receivable. The Company determines the allowance based on utilization of a combination of aging schedules with reserve rates applied to both current and aged receivables using historical write-off experience, regional economic data and evaluation of specific customer accounts for risk of loss and changes in current or projected conditions to calculate the allowances related to accounts receivable, net. The Company reviews its allowance for doubtful accounts monthly. Account balances are reviewed on a pooled basis by reporting unit and geographic region and are reserved when the Company determines it is probable the receivable will not be recovered. The Company reduces the receivable and corresponding allowance when it confirms an account is uncollectible.
Factoring Arrangements
The Company has agreements with financial institutions to sell certain trade receivables from customers without recourse. The Company accounts for trade receivable transfers as sales and de-recognizes the sold receivables from the Consolidated Balance Sheets. During fiscal 2025 and 2024, the Company sold receivables under factoring agreements of $86.1 million and $29.9 million, respectively. Costs incurred on these sales during the years ended July 31, 2025 and 2024 were $4.1 million and $1.7 million, respectively, and are included in the cost of sales within the Consolidated Statements of Earnings. Cash received from selling receivables in fiscal 2025 and 2024 of $82.0 million and $28.2 million, respectively, is presented as a change in accounts receivable within the operating section of the Consolidated Statements of Cash Flow.
Inventories
Inventories are stated at the lower of cost and net realizable value. U.S. inventories are valued using the last-in, first-out (LIFO) method while the non-U.S. inventories are valued using the first-in, first-out (FIFO) method. Inventories valued at LIFO were approximately 34.4% and 35.3% of total inventories as of July 31, 2025 and 2024, respectively. For inventories valued under the LIFO method, the FIFO cost exceeded the LIFO carrying values by $60.3 million and $51.3 million as of July 31, 2025 and 2024, respectively. Results of operations for all periods presented were not materially affected by the liquidation of LIFO inventory.
Property, Plant and Equipment
Property, plant and equipment are stated at cost. Additions, improvements or major renewals are capitalized while expenditures that do not enhance or extend the asset’s useful life are expensed as incurred. Depreciation is computed using the straight-line method. Depreciation expense was $85.6 million, $82.8 million and $80.9 million in the years ended July 31, 2025, 2024 and 2023, respectively. The estimated useful lives of property, plant and equipment are 10 to 40 years for buildings, including building improvements and three to 10 years for machinery and equipment, see Note 5.
Internal-Use Software and Cloud Computing Arrangements
The Company capitalizes direct costs of materials and services used in the development and purchase of internal-use software. Amounts capitalized are amortized on a straight-line basis over a period of two to six years and are reported as a component of property, plant and equipment.
The Company capitalizes certain costs incurred during the application development stage of implementation of internal-use software in cloud computing arrangements. Amounts capitalized are amortized on a straight-line basis over a period of three to 10 years and are reported as a component of other long-term assets.
Goodwill and Intangible Assets
Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations under the purchase method of accounting. Goodwill is assessed for impairment annually or if an event occurs or circumstances change that would indicate the carrying amount may be impaired. The Company performed its annual impairment assessment during the third quarter of fiscal 2025. The goodwill impairment assessment is conducted at a reporting unit level, which is one level below the operating segment level and utilizes either a qualitative or quantitative assessment. The Company determined the fair value for all its reporting units was substantially in excess of their respective carrying values and there were no indicators of impairment for any of the reporting units evaluated. An impairment loss would be recognized when the carrying amount of a reporting unit’s net assets exceeds the estimated fair value of the reporting unit, see Note 6.
Intangible assets, comprised of customer relationships, trademarks, technology and patents and non-compete agreements, are amortized on a straight-line basis over their estimated useful lives of three to 22 years.
Business Combinations
The Company allocates the purchase price of acquired businesses to the estimated fair values of the assets acquired and liabilities assumed, as well as any contingent consideration, where applicable, as of the date of acquisition. The fair values of the long-lived assets acquired, primarily intangible assets, are determined using calculations which can be complex and require significant judgment. Estimates include many factors such as the nature of the acquired company’s business, its historical financial position and results, technology obsolescence, customer retention rates, discount rates, royalty rates and expected future performance. Independent valuation specialists are used to assist in determining certain fair value calculations.
During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Any adjustments required after the measurement period are recorded in the Consolidated Statements of Earnings.
Recoverability of Long-Lived Assets
The Company reviews its long-lived assets, including identifiable intangibles, for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If impairment indicators are present and the estimated future undiscounted cash flows are less than the carrying value of the assets, the carrying value is reduced to the fair market value.
In fiscal 2025, the Company identified a triggering event related to certain asset groups and performed a valuation of certain long-lived intangible assets in accordance with ASC 360, Impairment and Disposal of Long-Lived Assets. The Company used a discounted cash flow analysis to estimate the fair value of each long-lived asset group. As a result of the valuation, the Company recorded $62.0 million of impairment expense related to intangible assets in the Company’s bioprocessing businesses within the Life Sciences segment during the third quarter of fiscal 2025. The impairment expense was included in Loss on impairment of intangible assets in the Consolidated Statements of Earnings. Of the impairment expense, $46.6 million was related to Univercells Technologies, reflecting lower-than-anticipated bioprocessing capital spending, particularly for early-stage assets, while drug development timelines are longer than previously anticipated. The remaining $15.4 million of impairment expense was related to Solaris as market demand for industrial bioreactors had significantly declined. There were no other indicators of impairment or impairment charges recorded for the year ended July 31, 2025 and no indicators of impairment or impairment charges recorded for the year ended July 31, 2024.
Income Taxes
The provision for income taxes is computed based on the pretax income reported for financial statement purposes. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are anticipated to reverse. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not a tax benefit will not be realized.
The Company maintains a reserve for uncertain tax benefits. Benefits of tax return positions are recognized in the financial statements when the position is more likely than not to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that is greater than 50% likely to be realized, in the Company’s judgment, see Note 8.
Leases
The Company determines whether an arrangement that provides control over the use of an asset to the Company is a lease. The Company recognizes a lease liability and corresponding right-of-use asset on the Consolidated Balance Sheets based on the present value of future lease payments and recognizes lease expense on a straight-line basis over the lease term. Operating lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term (or at fair values in the case of those leases assumed in an acquisition). Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets and are expensed on a straight-line basis over the lease term. Variable lease expense is immaterial and primarily includes leases with payments indexed to inflation when the index changes after lease commencement.
The Company has elected to separate payments for lease components from non-lease components for all asset classes. Lease agreements may include extension, termination or purchase options, all of which are considered in calculating the lease liability and right-of-use asset when it is reasonably certain the Company will exercise an option. The Company’s incremental borrowing rate on the commencement date is used to calculate the present value of future payments for most leases since the rate implicit in the lease is generally not readily determinable. These rates are assessed on a quarterly basis for measurement of new lease obligations, see Note 9.
Stock-Based Compensation
Stock-based compensation expense is recognized using the fair value method for all awards, see Note 13.
Treasury Stock
Repurchased common stock is stated at cost, determined on an average cost basis and is presented as a reduction of stockholders’ equity on the Consolidated Balance Sheets.
Research and Development Expenses
Research and development expenses include scientific research costs such as salaries, facility costs, testing, technical information technology and administrative expenditures. Research and development expenses are for the application of scientific advances to the development of new and improved products and their uses. Substantially all research and development is performed in-house. Expenses are charged against earnings in the year incurred.
Foreign Currency Forward Contracts - Cash Flow Hedges and Derivatives Not Designated as Hedging Instruments
The Company buys materials from foreign suppliers. Those transactions can be denominated in those suppliers’ local currency. The Company also sells to customers in foreign countries. Those transactions can be denominated in those customers’ local currency. Both of these transaction types can create volatility in the Company’s financial statements. The Company uses foreign currency forward contracts to manage those exposures and fluctuations. These contracts generally mature in 15 months or less, which is consistent with the forecasts of the related purchases and sales. Certain contracts are designated as cash flow hedges, whereas the remaining contracts, most of which are related to certain intercompany transactions which offset balance sheet exposure, are not designated as hedging instruments, see Notes 12, 15 and 16.
Net Investment Hedges
The Company uses fixed-to-fixed cross-currency swap agreements to hedge its exposure to adverse foreign currency exchange rate movements for its operations in Europe. The Company has elected the spot method for designating these contracts as net investment hedges. The maturity dates range from 2027 to 2029, see Notes 12, 15 and 16.
Interest Rate Swaps - Cash Flow Hedges
The Company uses swap agreements to hedge exposure related to interest expense and to manage its exposure to interest rate movements. The Company enters into interest rate swap agreements designated as cash flow hedges to hedge future fixed-rate debt issuances, which effectively fix a portion of interest payments.
Product Warranties
The Company provides for estimated warranty expense at the time of sale and accrues for specific items at the time their existence is known and the amounts are determinable. The Company estimates warranty expense on certain products at the time of sale using quantitative measures based on historical warranty claim experience and evaluation of specific customer warranty issues, see Note 18.
New Significant Accounting Standards Recently Adopted
In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions,” which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair values; it also requires additional disclosures, including the nature and remaining duration of such restrictions. The guidance is effective for fiscal years beginning after December 15, 2023, with early application permitted. The Company adopted ASU 2022-03 in the first quarter of fiscal 2025. The adoption did not have an impact on its Consolidated Financial Statements or Condensed Consolidated Financial Statements.
In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), “Improvements to Reportable Segment Disclosures,” which improves the segment disclosures to include reportable segment’s expenses. The guidance is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. This ASU is applicable beginning with annual reporting for the Company’s fiscal 2025 and interim reporting for the first quarter of the Company’s fiscal 2026. The Company adopted ASU 2023-07 in the fourth quarter of fiscal 2025 for its fiscal year ended July 31, 2025 and all interim periods thereafter.
New Significant Accounting Standards Not Yet Adopted
The Company considers the applicability and impact of the FASB’s ASUs issued but not yet adopted.
In November 2024, FASB issued ASU No. 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40), “Disaggregation of Income Statement Expenses,” which improves disclosures about a company’s expenses and provides more detailed information about the types of expenses in commonly presented expense captions. The guidance is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. This ASU is applicable beginning with annual reporting for the Company’s fiscal 2028 and interim reporting for the first quarter of the Company’s fiscal 2029. The Company will adopt ASU 2024-03 for the annual reporting period ending July 31, 2028 and for interim reporting periods thereafter. The Company is in the process of evaluating the impact of the ASU on its related disclosures.
In December 2023, FASB issued ASU No. 2023-09, Income Taxes (Topic 740), “Improvements to Income Tax Disclosures,” which enhances the transparency and decision usefulness of income tax disclosures. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU is applicable beginning with annual reporting for the Company’s fiscal 2026 and interim reporting for the first quarter of the Company’s fiscal 2027. The Company will adopt ASU 2023-09 for the annual reporting period ending July 31, 2026 and for interim reporting periods thereafter. The Company does not expect adoption of this standard will have a material impact on the Consolidated Financial Statements and is in the process of evaluating the effects of this guidance on its related disclosures.
In October 2023, FASB issued ASU No. 2023-06, "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative," which modifies the disclosure or presentation requirements of various FASB topics in the Codification. The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-K becomes effective, with early adoption prohibited. The Company is in the process of evaluating the impact of the ASU on its related disclosures.
v3.25.2
Acquisitions and Equity Method Investments
 12 Months Ended
Jul. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Acquisitions and Equity Method Investments
Note 2. Acquisitions and Equity Method Investments
Acquisitions
There have been no material acquisitions in fiscal 2025 or 2024.
Equity Method Investments
On August 9, 2024, the Company acquired a 49% non-controlling stake in Medica, headquartered in Medolla, Italy, for cash consideration of approximately €62.1 million, or $67.9 million and capitalized transaction costs of approximately €5.1 million, or $5.8 million. Medica is a leader in hollow fiber membrane filtration technology for medical applications and water purification. The Company has the option to acquire the remaining 51% stake in three years. The investment is accounted for under the equity method of accounting. The earnings from the investment were not material for the year ended July 31, 2025.
v3.25.2
Revenue
 12 Months Ended
Jul. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3. Revenue
The Company recognizes revenue on a wide range of filtration solutions sold to customers in many industries around the globe. Most of the Company’s performance obligations within customer sales contracts are for manufactured filtration systems and replacement parts. The Company also performs limited services and installation. Customer contracts may include multiple performance obligations and the transaction price is allocated to each distinct performance obligation based on its relative standalone selling price.
Revenue Disaggregation
Net sales, generally disaggregated by location where the customer’s order was placed, were as follows (in millions):
Year Ended July 31,
202520242023
U.S. and Canada$1,632.3 $1,583.1 $1,464.7 
Europe, Middle East and Africa (EMEA)1,027.2 1,012.9 1,007.8 
Asia Pacific (APAC)635.7 601.5 608.8 
Latin America (LATAM)395.7 388.8 349.5 
Total net sales$3,690.9 $3,586.3 $3,430.8 
See Note 19 for net sales disaggregated by segment and business unit.
Contract Assets and Liabilities
The satisfaction of performance obligations and the resulting recognition of revenue typically correspond with billing of the customer. In limited circumstances, the customer may be billed at a time later than when revenue is recognized, resulting in contract assets, which are reported in other current assets on the Consolidated Balance Sheets. Contract assets were $24.3 million and $15.9 million as of July 31, 2025 and 2024, respectively. In other limited circumstances, the customer may make a payment at a time earlier than when revenue is recognized and prior to the satisfaction of performance obligations, resulting in contract liabilities, which are reported in deferred revenue on the Consolidated Balance Sheets. Contract liabilities were $20.8 million and $19.7 million as of July 31, 2025 and 2024, respectively.
The Company will recognize revenue in future periods related to remaining performance obligations for certain open contracts. Generally, these contracts have terms of one year or less. The amount of revenue related to unsatisfied performance obligations in which the original duration of the contract is greater than one year is not significant. None of the Company’s contracts contained a significant financing component.
v3.25.2
Inventories, Net
 12 Months Ended
Jul. 31, 2025
Inventory Disclosure [Abstract]  
Inventories, Net
Note 4. Inventories, Net
The components of inventories, net were as follows (in millions):
July 31,
20252024
Raw materials$175.5 $177.4 
Work in process69.6 61.2 
Finished products268.5 238.1 
Total inventories, net$513.6 $476.7 
v3.25.2
Property, Plant and Equipment, Net
 12 Months Ended
Jul. 31, 2025
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, Net
Note 5. Property, Plant and Equipment, Net
The components of property, plant and equipment, net were as follows (in millions):
July 31,
20252024
Land$29.5 $29.5 
Buildings493.8 451.9 
Machinery and equipment1,118.6 1,052.1 
Computer software129.5 134.7 
Construction in progress31.5 68.4 
Less accumulated depreciation(1,158.4)(1,091.1)
Total property, plant and equipment, net$644.5 $645.5 
v3.25.2
Goodwill and Intangible Assets
 12 Months Ended
Jul. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Note 6. Goodwill and Intangible Assets
Goodwill
The Company allocates goodwill to reporting units within its Mobile Solutions, Industrial Solutions and Life Sciences segments. There were no dispositions or impairment charges recorded during the years ended July 31, 2025, 2024 and 2023. Goodwill is assessed for impairment annually during the third quarter of the fiscal year, or more frequently if events or changes in circumstances indicate the asset may be impaired. The Company performed its annual impairment assessment during the third quarter of fiscal 2025 and did not record any impairment as a result of this assessment.
Goodwill by reportable segment was as follows (in millions):
Mobile
Solutions
Segment		Industrial
Solutions
Segment		Life Sciences SegmentTotal
Goodwill
Balance as of July 31, 2023$25.5 $289.1 $166.5 $481.1 
Goodwill acquired— 1.9 — 1.9 
Purchase price adjustments— — (1.1)(1.1)
Foreign exchange translation(0.1)(1.1)(2.3)(3.5)
 Balance as of July 31, 2024$25.4 $289.9 $163.1 $478.4 
Goodwill acquired— 3.2 — 3.2 
Foreign exchange translation— 5.1 6.9 12.0 
Balance as of July 31, 2025$25.4 $298.2 $170.0 $493.6 
Intangible Assets
Intangible asset classes were as follows (in millions):
Year Ended July 31, 2025
Weighted Amortizable Life (in Years)Gross Carrying AmountAccumulated AmortizationNet
Customer relationships8.5$74.7 $(43.7)$31.0 
Trademarks6.73.8 (2.0)1.8 
Technology and patents
16.682.9 (19.1)63.8 
Non-compete agreements2.92.5 (1.7)0.8 
Total intangible assets$163.9 $(66.5)$97.4 
Year Ended July 31, 2024
Weighted Amortizable Life (in Years)Gross Carrying AmountAccumulated AmortizationNet
Customer relationships9.4$77.4 $(39.9)$37.5 
Trademarks8.114.2 (3.8)10.4 
Technology and patents
16.7142.4 (20.4)122.0 
Non-compete agreements2.73.9 (1.9)2.0 
Total intangible assets$237.9 $(66.0)$171.9 
In the third quarter of fiscal 2025, the Company identified a triggering event related to certain asset groups and performed a valuation of certain long-lived intangible assets in accordance with ASC 360, Impairment and Disposal of Long-Lived Assets. The Company used a discounted cash flow analysis to estimate the fair value of each long-lived asset group. Estimates and assumptions are utilized in the valuations, including discounted projected cash flows, earnings before interest, taxes, depreciation and amortization margins, terminal value growth rates, revenue growth rates, discount rates and the determination of comparable publicly traded companies. As a result of the valuation, the Company recorded $62.0 million of impairment expense related to intangible assets in the Company’s bioprocessing businesses within the Life Sciences segment, including $53.1 million of impairment expense related to technology and patents, $7.7 million of impairment expense related to trademarks, $1.0 million of impairment expense related to customer relationships and $0.2 of impairment expense related to non-compete agreements. The impairment expense was included in loss on impairment of intangible assets in the Consolidated Statements of Earnings. Of the impairment expense, $46.6 million was related to Univercells Technologies, reflecting lower-than-anticipated bioprocessing capital spending, particularly for early-stage assets, while drug development timelines are longer than previously anticipated. The remaining $15.4 million of impairment expense was related to Solaris as market demand for industrial bioreactors had significantly declined.
The Company recognized a foreign currency translation gain of $3.0 million in fiscal 2025 and a translation loss of $1.4 million in fiscal 2024.
Intangible asset amortization expense was $13.9 million, $15.7 million and $11.4 million for the fiscal 2025, 2024 and 2023, respectively and is included in operating expenses in the Consolidated Statements of Earnings. Amortization expense relating to existing intangible assets as of July 31, 2025 was as follows (in millions):
2026$9.4 
20279.0 
20288.6 
20297.5 
20307.1 
Thereafter55.8 
Total amortization expense$97.4 
v3.25.2
Short-Term Borrowings and Long-Term Debt
 12 Months Ended
Jul. 31, 2025
Debt Disclosure [Abstract]  
Short-Term Borrowings and Long-Term Debt
Note 7. Short-Term Borrowings and Long-Term Debt
Short-Term Borrowings
Short-term borrowings were as follows (in millions):
European Commercial Paper ProgramU.S. Credit FacilitiesEuropean Operations Credit FacilitiesRest of the World Credit FacilitiesTotal
Year Ended July 31,
2025202420252024202520242025202420252024
Available credit facilities$114.5 $108.3 $100.0 $100.0 $50.3 $48.4 $52.7 $46.7 $317.5 $303.4 
Reductions to borrowing capacity:
Outstanding borrowings — 22.8 31.2 0.2 — — — 5.3 31.2 28.3 
Other non-borrowing reductions— — — — 30.1 38.9 28.7 25.7 58.8 64.6 
Total reductions— 22.8 31.2 0.2 30.1 38.9 28.7 31.0 90.0 92.9 
Remaining borrowing capacity$114.5 $85.5 $68.8 $99.8 $20.2 $9.5 $24.0 $15.7 $227.5 $210.5 
Weighted average interest rate as of July 31, 2025 and 2024
N/A4.34 %5.20 %6.44 %N/AN/AN/A0.56 %5.20 %3.62 %
Other non-borrowing reductions include financial instruments such as bank guarantees and foreign currency exchange instruments. Commitment fees for the years ended July 31, 2025 and 2024 were not material.
Long-Term Debt
Long-term debt was as follows:
Interest RateOutstanding Balance
(in millions)
Financial InstrumentFixed or VariableAmountMaturity DateJuly 31, 2025July 31, 2024July 31, 2025July 31, 2024
Unsecured term loan
Variable
$200.0  millionJune 12, 20285.57 %— %200.0 — 
Unsecured senior notesFixed
$125.0 million
June 17, 20303.18 %3.18 %125.0 125.0 
Unsecured senior notes
Fixed
$100.0 million
August 5, 20312.50 %2.50 %100.0 100.0 
Unsecured revolving credit facilityVariable
$600.0 million
June 12, 20305.44 %6.44 %60.0 110.0 
Unsecured term loanVariable
 €80.0 million
March 26, 20292.83 %4.69 %91.6 86.6 
Unsecured senior notes
Fixed
$50.0 million
November 5, 20282.12 %2.12 %50.0 50.0 
Unsecured senior notesFixed
$25.0 million
April 16, 20252.93 %2.93 %— 25.0 
Unsecured term loanVariable¥1.0  billionJuly 31, 20281.28 %0.76 %6.7 6.7 
Unsecured term loanVariable¥1.0  billionJuly 15, 20261.20 %0.68 %6.7 6.7 
Debt issuance costs, net(2.9)(1.6)
Subtotal637.1 — 508.4 
Less current maturities(6.7)(25.0)
Total long-term debt$630.4 $483.4 
During the fourth quarter of fiscal 2025, the Company entered into an amendment to its $500.0 million revolving credit facility. The amendment provides for the following modifications to the existing agreement: (i) the maturity date of the revolving credit facility was extended from May 21, 2026 to June 12, 2030, (ii) the aggregate revolving credit limit was increased from $500.0 million to $600.0 million, (iii) a new term loan facility was added in the amount of $200.0 million with a maturity date of June 12, 2028, which was fully advanced on the closing date, (iv) the revolving credit facility was repaid in part with the proceeds of the term loan facility, and (v) the incremental credit facility option was increased from $250.0 million to $350.0 million and may be in the form of an increase to the revolving credit facility and/or incremental term loans. The Company’s $600.0 million revolving credit facility is with a group of lenders and allows for borrowings in multiple currencies. The interest rate is calculated using the appropriate benchmark rate plus the applicable rate, which varies depending on the Company’s leverage ratio and the applicable benchmark rate. The borrowing availability can be reduced or terminated early at the option of the Company. The Company can request to increase the revolving credit facility by up to $350.0 million through an accordion feature, subject to terms of the credit facility agreement, including written notification and lender acceptance. Borrowings are automatically rolled over until the credit facility maturity date, unless the agreement is terminated early or the Company is found to be in default. The total facility includes a commitment fee of 0.08% to 0.25%, depending on the Company’s leverage ratio.
Certain debt agreements contain financial covenants related to interest coverage and leverage ratios, as well as other non-financial covenants. As of July 31, 2025, the Company was in compliance with all such covenants.
The Company has long-term borrowing capacity of $532.1 million available for further borrowing under the existing credit facility as of July 31, 2025. The remaining borrowing capacity has been reduced for standby letters of credit as discussed in Note 17.
Future maturities of the Company’s long-term debt as of July 31, 2025 were as follows (in millions):
2026$6.7 
2027— 
2028206.7 
2029141.6 
2030185.0 
Thereafter100.0 
Total future maturities payments640.0 
Less debt issuance costs, net(2.9)
Total future maturities payments, net of debt issuance costs$637.1 
v3.25.2
Income Taxes
 12 Months Ended
Jul. 31, 2025
Income Tax Disclosure [Abstract]  
Income Taxes
Note 8. Income Taxes
The components of earnings before income taxes were as follows (in millions):
Year Ended July 31,
202520242023
U.S.$245.5 $233.4 $178.0 
Foreign246.7 301.9 290.7 
Total$492.2 $535.3 $468.7 
The components of the provision for income taxes were as follows (in millions):
Year Ended July 31,
202520242023
Current
Federal$52.0 $47.2 $38.1 
State9.2 8.8 7.3 
Foreign88.0 89.6 79.8 
Total current149.2 145.6 125.2 
Deferred
Federal(13.5)(16.1)(13.3)
State(1.3)(1.7)(1.8)
Foreign(9.2)(6.5)(0.2)
Total deferred(24.0)(24.3)(15.3)
Total provision for income taxes$125.2 $121.3 $109.9 
The reconciliation of the U.S. statutory federal income tax rate with the effective income tax rate was as follows:
Year Ended July 31,
202520242023
U.S. statutory federal income tax rate21.0 %21.0 %21.0 %
State income taxes1.8 1.2 0.9 
Foreign operations2.5 2.7 3.8 
Global intangible low tax income
0.2 0.2 0.2 
Foreign derived intangible income
(1.5)(1.3)(1.6)
Research and development credit(1.0)(0.9)(0.7)
Change in unrecognized tax benefits0.2 1.2 — 
Tax benefits on stock-based compensation (0.9)(1.2)(0.7)
Change in valuation allowance related to impairment
2.6 — — 
Other0.5 (0.2)0.5 
Effective income tax rate25.4 %22.7 %23.4 %
The tax effects of temporary differences that give rise to deferred tax assets and liabilities were as follows (in millions):
July 31,
20252024
Deferred tax assets
Accrued expenses$14.6 $14.3 
Compensation and retirement plans30.4 26.6 
Capitalization of R&D costs42.1 32.9 
Net operating loss (NOL) and tax credit carryforwards26.7 17.6 
Operating lease assets15.5 15.6 
Other12.6 6.2 
Gross deferred tax assets141.9 113.2 
Valuation allowance(30.0)(9.1)
Deferred tax assets, net of valuation allowance111.9 104.1 
Deferred tax liabilities
Depreciation and amortization(55.9)(74.5)
Operating lease liabilities(15.1)(14.9)
Other(2.8)(3.8)
Deferred tax liabilities(73.8)(93.2)
Net deferred tax asset (liability)
$38.1 $10.9 
On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted into U.S. law, which primarily modified tax provisions from the 2017 Tax Cuts and Jobs Act that include but are not limited to the reinstatement of 100% bonus depreciation, the deduction of U.S.-based research expenditures, the deduction of interest expense, the deduction for foreign-derived intangible income (FDII), the tax and related foreign tax credit on Global Intangible Low-Taxed Income (GILTI), and the base-erosion anti-abuse tax (BEAT).
The impact of the enacted legislation effective for the Company's current fiscal year is the permanent reinstatement of 100% bonus depreciation. The other provisions within the OBBBA have staggered effective dates to be phased in between fiscal years 2026 and 2027, and the Company continues to evaluate the future impact of these provisions.
The activity in the NOL and tax credit valuation allowances was as follows (in millions):
Year Ended July 31,
202520242023
Balance as of beginning of year$(9.1)$(6.4)$(3.4)
Additions charged to costs and expenses(14.0)(3.6)(3.0)
Deductions from reserves0.4 0.9 — 
Balance as of end of year$(22.7)$(9.1)$(6.4)
As of July 31, 2025, the Company had deferred tax assets related to U.S. federal foreign tax credits of $10.7 million, related to state research and development credits of $3.8 million and related to foreign operating loss carryovers of $10.6 million. The U.S. federal tax credits will expire after 10 years, the state portion after one to 20 years and the foreign portion has an indefinite carryover period. As of July 31, 2025, the Company had provided $22.7 million for a valuation allowance against certain of these deferred tax assets based on management’s determination it is more likely than not the tax benefits related to these assets will not be realized.
As of July 31, 2025, the total undistributed earnings of the Company’s non-U.S. subsidiaries were $1.5 billion, of which $1.1 billion were not considered indefinitely reinvested. The Company is subject to foreign withholding taxes on a small portion of these earnings distributable in the future in the form of dividends. Thus, the Company provides for foreign withholding taxes payable upon future dividend distributions of the earnings not considered indefinitely reinvested annually. For the year ended July 31, 2025, the Company recognized a tax charge of $6.0 million related to these foreign withholding taxes. The remaining $396.7 million of earnings are considered indefinitely reinvested and it is not practicable to estimate, within any reasonable range, the additional taxes that may be payable on the potential distribution of the portion of the undistributed earnings considered indefinitely reinvested.
The transition tax related to the U.S. Tax Cuts and Jobs Act of 2017 on undistributed earnings was accrued in fiscal 2018 and it is payable over an eight year period. The final $22.1 million installment of the transition tax will be paid within 12 months and is classified in the current income tax payable on the Consolidated Balance Sheets as of July 31, 2025.
The reconciliation of the beginning and ending amount of gross unrecognized tax benefits was as follows (in millions):
Year Ended July 31,
202520242023
Balance as of beginning of year$20.8 $15.0 $15.2 
Additions for tax positions of the current year3.3 2.8 2.5 
Additions for tax positions of prior years0.6 6.2 — 
Reductions for tax positions of prior years— (0.1)0.1 
Reductions due to lapse of applicable statute of limitations(2.7)(3.1)(2.8)
Balance as of end of year$22.0 $20.8 $15.0 
The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income taxes in the Consolidated Statements of Earnings. As of July 31, 2025 and 2024, accrued interest and penalties on a gross basis were $2.7 million and $2.2 million, respectively. During the year ended July 31, 2025, the Company recognized interest expense, net of tax benefit, of $0.8 million. If the Company were to prevail on all unrecognized tax benefits recorded, substantially all the unrecognized tax benefits would benefit the effective tax rate. With an average statute of limitations of five years, up to $2.8 million of the unrecognized tax benefits could potentially expire in the next 12 months, unless extended by an audit.
The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The U.S. Internal Revenue Service has completed examinations of the Company’s U.S. federal income tax returns through fiscal 2021. With few exceptions, the Company is no longer subject to state and foreign income tax examinations by tax authorities for years before fiscal 2020.
The Company believes it is remote that any adjustment necessary to the reserve for income taxes for the next 12 months will be material. However, it is possible the ultimate resolution of audits or disputes may result in a material change to the Company’s reserve for income taxes, although the quantification of such potential adjustments cannot be made at this time.
v3.25.2
Leases
 12 Months Ended
Jul. 31, 2025
Leases [Abstract]  
Leases
Note 9. Leases
The Company enters into operating leases primarily for office, production and warehouse facilities, production and non-production equipment, automobiles and computer equipment. As of July 31, 2025 and 2024, the Company had no material financing lease obligations.
The Company’s operating lease costs were as follows (in millions):
Year Ended July 31,
20252024
Operating lease cost$33.5 $29.5 
Short-term lease cost3.3 3.0 
Total lease costs$36.8 $32.5 
Supplemental balance sheet information for the Company was as follows (in millions):
July 31,
Balance Sheet Location20252024
Right-of-use lease assetsOther long-term assets$60.5 $59.7 
Current lease liabilitiesOther current liabilities$24.1 $20.2 
Long-term lease liabilitiesOther long-term liabilities$37.8 $41.3 
Additional information related to operating leases was as follows:
July 31,
20252024
Weighted average remaining lease term (years)4.13.5
Weighted average discount rate6.44 %4.61 %
Remaining payments for operating leases having initial terms of more than one year as of July 31, 2025 were as follows (in millions):
2026$26.4 
202719.8 
202812.5 
20295.5 
20302.2 
Thereafter0.3 
Total future lease payments66.7 
Less imputed interest4.8 
Present value of future lease payments$61.9 
v3.25.2
Earnings Per Share
 12 Months Ended
Jul. 31, 2025
Earnings Per Share [Abstract]  
Earnings Per Share
Note 10. Earnings Per Share
Basic net earnings per share (EPS) is computed by dividing net earnings by the weighted average number of outstanding common shares. Diluted net EPS is computed by dividing net earnings by the weighted average number of outstanding common shares and common share equivalents relating to stock options and other stock incentive plans.
Basic and diluted net EPS calculations were as follows (in millions, except per share amounts):
Year Ended July 31,
202520242023
Net earnings$367.0 $414.0 $358.8 
Weighted average common shares outstanding
Weighted average common shares – basic118.7 120.7 121.8 
Dilutive impact of stock-based awards1.7 1.9 1.8 
Weighted average common shares – diluted120.4 122.6 123.6 
Net EPS – basic$3.09 $3.43 $2.95 
Net EPS – diluted$3.05 $3.38 $2.90 
Stock options excluded from net EPS calculation0.70.00.0
v3.25.2
Stockholders' Equity
 12 Months Ended
Jul. 31, 2025
Stockholders' Equity Note [Abstract]  
Stockholders' Equity
Note 11. Stockholders’ Equity
Share Repurchases
In November 2023, the Board of Directors authorized the repurchase of up to 12.0 million shares of common stock under the Company’s stock repurchase plan, replacing the Company’s previous stock repurchase plan dated May 31, 2019. This repurchase authorization is effective until terminated by the Board of Directors. During the year ended July 31, 2025, the Company repurchased 4.9 million shares for $333.6 million. During the year ended July 31, 2024, the Company repurchased 2.5 million shares for $163.3 million. As of July 31, 2025, the Company had remaining authorization to repurchase 5.9 million shares under the November 2023 stock repurchase plan.
Treasury stock share activity was as follows:
Year Ended July 31,
20252024
Balance as of beginning of year31,533,192 30,528,696 
Stock repurchases4,875,000 2,465,000 
Net issuance upon exercise of stock options(678,540)(1,294,475)
Issuance under compensation plans(121,769)(149,329)
Other activity(7,143)(16,700)
Balance as of end of year35,600,740 31,533,192 
Dividends Paid and Declared
Dividends paid were $1.11 and $1.02 per common share for the years ended July 31, 2025 and 2024, respectively. On July 25, 2025, the Company’s Board of Directors declared a cash dividend in the amount of 30.0 cents per common share, payable August 27, 2025, to stockholders of record as of August 12, 2025.
v3.25.2
Accumulated Other Comprehensive Loss
 12 Months Ended
Jul. 31, 2025
Equity [Abstract]  
Accumulated Other Comprehensive Loss
Note 12. Accumulated Other Comprehensive Loss
Changes in accumulated other comprehensive loss for the years ended July 31, 2025 and 2024 were as follows (in millions):
Foreign
Currency
Translation
Adjustment		Pension
Benefits		Derivative
Financial
Instruments		Total
Balance as of July 31, 2024, net of tax$(133.8)$(69.1)$4.0 $(198.9)
Other comprehensive income (loss) before reclassifications and tax
29.6 (11.1)(1)(5.5)13.0 
Tax benefit— 2.6 1.3 3.9 
Other comprehensive income (loss) before reclassifications, net of tax
29.6 (8.5)(4.2)16.9 
Reclassifications, before tax— 1.3 (2)0.4 1.7 
Tax expense— (0.3)(0.1)(0.4)
Reclassifications, net of tax— 1.0 0.3 (3)1.3 
Other comprehensive income (loss), net of tax
29.6 (7.5)(3.9)18.2 
Balance as of July 31, 2025, net of tax$(104.2)$(76.6)$0.1 $(180.7)
Balance as of July 31, 2023, net of tax$(109.6)$(67.2)$4.3 $(172.5)
Other comprehensive loss before reclassifications and tax
(24.2)(9.0)(1)(0.8)(34.0)
Tax benefit
— 2.3 0.2 2.5 
Other comprehensive loss before reclassifications, net of tax
(24.2)(6.7)(0.6)(31.5)
Reclassifications, before tax— 6.3 (2)0.3 6.6 
Tax expense
— (1.5)— (1.5)
Reclassifications, net of tax— 4.8 0.3 (3)5.1 
Other comprehensive loss, net of tax
(24.2)(1.9)(0.3)(26.4)
Balance as of July 31, 2024, net of tax$(133.8)$(69.1)$4.0 $(198.9)
(1)In fiscal 2024, pension settlement accounting was triggered. In addition, pension curtailment accounting was triggered in fiscal 2024. Remeasurements of the Company’s pension obligations resulted in an increase of $11.1 million and $9.0 million in fiscal 2025 and 2024, respectively, to accumulated other comprehensive loss on the Consolidated Balance Sheets, see Note 14.
(2)Amounts include reclassifications of $0.0 million and $4.8 million, a foreign currency translation gain of $0.9 million and loss of $0.1 million and net amortization of prior service costs and actuarial losses of $2.2 million and $1.4 million in fiscal 2025 and 2024, respectively. Amounts are included in other income, net in the Consolidated Statements of Earnings, see Note 14.
(3)Relates to designated foreign currency forward contracts that were reclassified from accumulated other comprehensive loss on the Consolidated Balance Sheets to net sales, cost of sales and operating expenses in the Consolidated Statements of Earnings, see Note 15.
v3.25.2
Stock-Based Compensation
 12 Months Ended
Jul. 31, 2025
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Stock-Based Compensation
Note 13. Stock-Based Compensation
The Company recognizes compensation expense for all stock-based awards based on the grant date fair value of the award. Stock-based awards consist primarily of non-qualified stock options, performance-based awards, restricted stock awards and restricted stock units. Grants related to restricted stock awards and restricted stock units are immaterial. The Company issues treasury shares for stock options and performance-based awards.
Stock Options
The exercise price of options granted is equal to the market price of the Company’s common stock at the date of the grant. Options are generally exercisable for up to ten years from the date of grant and vest in equal increments over three years.
Pretax stock-based compensation expense associated with options was $16.1 million, $14.2 million and $12.4 million for the years ended July 31, 2025, 2024 and 2023, respectively.
Fair value is calculated using the Black-Scholes option pricing model. The weighted average fair value for options granted during the years ended July 31, 2025, 2024 and 2023 was $21.67, $19.00 and $15.67 per share, respectively.
The fair value of these awards was determined using the following inputs:
Year Ended July 31,
202520242023
Risk-free interest rate
3.6% - 4.5%
3.8% - 4.6%
3.8% - 4.2%
Expected volatility
26.1% - 27.0%
26.8% - 27.2%
26.8% - 27.5%
Expected dividend yield1.6 %1.6 %1.6 %
Expected life:
Director grants8 years8 years8 years
Officer grants7 years7 years7 years
Non-officer grants7 years7 years7 years
Option activity was as follows:
 OptionsWeighted
Average Exercise
Price
Balance outstanding as of July 31, 20246,163,056 $50.57 
Granted800,025 72.87 
Exercised(692,308)42.46 
Expired/forfeited(47,693)63.45 
Balance outstanding as of July 31, 20256,223,080 $54.24 
The total intrinsic value of options exercised during the years ended July 31, 2025, 2024 and 2023 was $20.2 million, $35.9 million and $20.2 million, respectively.
The number of shares authorized as of July 31, 2025 for outstanding options and future grants was 11,144,365. Forfeited options are recorded as an offset to operating expenses in the Consolidated Statements of Earnings in the period in which they occur.
Outstanding and exercisable stock options as of July 31, 2025 were as follows:
Range of Exercise PricesNumber
Outstanding		Weighted
Average
Remaining
Contractual
Life (Years)		Weighted
Average
Exercise
Price		Number
Exercisable		Weighted
Average
Remaining
Contractual
Life (Years)		Weighted
Average
Exercise
Price
$28.00 to $37.99
231,143 0.4$28.17 231,143 0.4$28.17 
$38.00 to $47.99
1,625,429 3.244.85 1,625,429 3.244.85 
$48.00 to $57.99
1,519,987 5.651.44 1,251,934 5.351.56 
$58.00 to $67.99
2,096,337 6.259.66 1,537,904 5.459.40 
$68.00 and above
750,184 9.273.13 1,629 8.772.68 
6,223,080 5.4$54.24 4,648,039 4.4$50.65 
As of July 31, 2025, the aggregate intrinsic value of stock options outstanding and exercisable was $111.2 million and $99.1 million, respectively.
For the year ended July 31, 2025, activity for non-vested stock options that contain vesting provisions was as follows:
OptionsWeighted
Average Grant
Date Fair
Value
Balance outstanding as of beginning of year1,657,970 $17.02 
Granted800,025 21.67 
Vested(835,261)16.24 
Forfeited(47,693)19.29 
Balance outstanding as of end of year1,575,041 $19.73 
As of July 31, 2025, there was $8.9 million of total unrecognized compensation expense related to non-vested stock options, which is expected to be recognized over the remaining vesting period during fiscal 2026, 2027 and 2028.
Performance-Based Awards
Performance-based awards are payable in common stock and are based on a formula that measures Company performance over a three year period. These awards are settled after three years with payouts ranging from 0% to 200% of the target award depending on achievement. Pretax performance-based awards expense was $5.7 million, $5.8 million and $6.3 million for the years ended July 31, 2025, 2024 and 2023, respectively.
The weighted average grant date fair value related to the Company’s performance-based awards was as follows:
Year Ended July 31,
202520242023
Weighted average grant date fair value$73.18 $59.66 $50.89 
Performance-based awards for non-vested activity were as follows:
Performance SharesWeighted
Average Grant
Date Fair
Value
Balance outstanding as of July 31, 2024
227,900 $55.31 
Granted111,900 73.18 
Vested(106,723)50.89 
Forfeited(35,393)64.39 
Balance outstanding as of July 31, 2025
197,684 $66.19 
As of July 31, 2025, there was $6.1 million of total unrecognized compensation expense related to non-vested performance-based awards, which is expected to be recognized over the remaining vesting period during fiscal 2026 and 2027. Forfeited performance-based awards are recorded as an offset to operating expenses in the Consolidated Statements of Earnings in the period in which they occur.
v3.25.2
Employee Benefit Plans
 12 Months Ended
Jul. 31, 2025
Retirement Benefits, Description [Abstract]  
Employee Benefit Plans
Note 14. Employee Benefit Plans
Defined Benefit Pension Plans
The Company has defined benefit pension plans for certain hourly and salaried employees. They consist of plans in the U.S., Belgium, Germany, Mexico and the United Kingdom. These plans generally provide pension benefits based on years of service and compensation level. Components of net periodic pension costs other than the service cost component are included in other income, net in the Consolidated Statements of Earnings.
Net periodic pension costs for the Company’s pension plans were as follows (in millions):
Year Ended July 31,
202520242023
Net periodic pension costs
Service cost$4.3 $5.2 $6.7 
Interest cost19.6 20.4 17.0 
Expected return on assets(25.7)(25.7)(25.3)
Prior service cost amortization— 0.1 — 
Actuarial loss amortization2.3 1.5 2.1 
Settlement loss
— 4.9 5.5 
Curtailment loss
— 0.2 0.2 
Net periodic pension costs0.5 6.6 6.2 
Other changes recognized in other comprehensive loss:
Prior service cost— 0.1 (0.4)
Net actuarial loss
(11.6)(9.1)(5.9)
Amortization of prior service cost— 0.3 0.2 
Amortization of net actuarial loss2.3 6.4 7.7 
Total recognized in other comprehensive loss
(9.3)(2.3)1.6 
Total recognized in net periodic pension costs and other comprehensive loss
$(9.8)$(8.9)$(4.6)
The changes in projected benefit obligations, fair value of plan assets and funded status of the Company’s pension plans for the years ended July 31, 2025 and 2024 were as follows (in millions):
Year Ended July 31,
20252024
Change in projected benefit obligation
Projected benefit obligation, beginning of year$403.7 $401.1 
Service cost4.3 5.2 
Interest cost19.6 20.4 
Plan amendments— (0.1)
Participant contributions0.8 0.8 
Actuarial (gain) loss
(7.1)11.7 
Foreign currency exchange rates6.5 (1.8)
Settlements paid— (15.6)
Acquisition
— 0.6 
Benefits paid(25.4)(18.6)
Projected benefit obligation, end of year402.4 403.7 
Change in fair value of plan assets
Fair value of plan assets, beginning of year413.3 416.0 
Actual return on plan assets8.1 28.4 
Company contributions2.7 2.8 
Participant contributions0.8 0.8 
Foreign currency exchange rates5.6 (1.1)
Settlements paid— (15.6)
Acquisition
— 0.6 
Benefits paid(25.4)(18.6)
Fair value of plan assets, end of year405.1 413.3 
Funded status of plans, end of year
$2.7 $9.6 
Amounts recognized on the Consolidated Balance Sheets
Other long-term assets$33.9 $35.8 
Other current liabilities(1.4)(1.5)
Other long-term liabilities(29.8)(24.7)
Net recognized asset $2.7 $9.6 
The net overfunded status of $2.7 million and $9.6 million as of July 31, 2025 and 2024, respectively, is recognized on the Consolidated Balance Sheets. The pension-related accumulated other comprehensive loss as of July 31, 2025 and 2024, prior to the consideration of income taxes, was $120.5 million and $111.3 million, respectively, and consisted primarily of unrecognized actuarial losses. The accumulated benefit obligation for all defined benefit pension plans was $380.5 million and $385.1 million as of July 31, 2025 and 2024, respectively. The decrease in the accumulated benefit obligation during fiscal 2025 is due to actuarial gains. Pension settlement accounting was triggered in fiscal 2024 as a result of the amount of lump sum distributions in the defined benefit pension plans exceeding the service and interest cost threshold.
The projected benefit obligation and fair value of plan assets for pension plans with projected benefit obligations in excess of plan assets were $82.8 million and $51.6 million, respectively, as of July 31, 2025 and $75.3 million and $49.1 million, respectively, as of July 31, 2024.
The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with accumulated benefit obligations in excess of plan assets were $82.8 million, $60.6 million and $51.6 million, respectively, as of July 31, 2025 and $17.7 million, $16.4 million and $7.3 million, respectively, as of July 31, 2024.
Assumptions
The significant assumptions used in determining the actuarial present value of the projected benefit obligation were as follows:
Year Ended July 31,
20252024
U.S. plans
Discount rate5.60 %5.44 %
Rate of compensation increaseN/AN/A
Non-U.S. plans
Discount rate4.82 %4.33 %
Rate of compensation increase3.07 %3.05 %
The weighted average discount rates, expected returns on plan assets and rates of increase in future compensation levels used to determine the net periodic pension costs were as follows:
Year Ended July 31,
202520242023
U.S. plans
Discount rate5.44 %5.58 %4.62 %
Expected rate of return on plan assets6.41 %6.16 %5.66 %
Rate of compensation increaseN/AN/AN/A
Non-U.S. plans
Discount rate4.33 %4.80 %3.26 %
Expected rate of return on plan assets4.88 %5.01 %4.39 %
Rate of compensation increase3.02 %3.05 %3.12 %
Discount Rates
The Company’s objective in selecting a discount rate is to select the best estimate of the rate at which the benefit obligations could be effectively settled on the measurement date, taking into account the nature and duration of the benefit obligations of the plan. In making this best estimate, the Company looks at the rates of return on high-quality fixed-income investments currently available and expected to be available, during the period to maturity of the benefits. This process includes assessing the universe of bonds available on the measurement date with a quality rating of Aa or better. Similar appropriate benchmarks are used to determine the discount rate for the non-U.S. plans.
Expected Long-Term Rate of Return on Plan Assets
The Company considers historical returns and future expected returns for each asset class, as well as the target asset allocation to develop the assumption for each of its U.S. pension plans. The assumption for non-U.S. pension plans reflects the investment allocation and expected total portfolio returns specific to each plan and country.
Mortality Rates
The Company’s actuary uses the Pri-2012 mortality table issued by the Society of Actuaries during the pre-retirement period and the Mercer Industry Longevity Experience Study (MILES) table for the Auto, Industrial Goods and Transportation industry group for post-retirement mortality, both reflecting the Scale MMP-2021 mortality improvement projection scale for its U.S. pension plans. These assumptions were used for determining the benefit obligations as of July 31, 2025 and for developing the annual expense for its U.S. pension plans for the fiscal year ending July 31, 2026. The Company follows the local actuaries’ recommendations for non-U.S. pension plans.
Service and Interest Costs
The Company uses a full yield curve approach to estimate service and interest costs by applying specific spot rates along the yield curve used to determine the benefit obligation of relevant projected cash outflows. This method provides a precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rate on the yield curve.
Investments
Global Equity Securities 
Global equity securities consist primarily of publicly traded U.S. and non-U.S. equities, mutual funds, collective investment trusts, diversified growth investment funds and private equity. Publicly traded equities and index funds are valued at the closing price reported in the active market in which the individual securities are traded. Private equity consists of interests in partnerships that invest in U.S. and non-U.S. equity and debt securities. This may include a diversified mix of partnership interests including buyouts, restructured or distressed debt, growth equity, mezzanine or subordinated debt, real estate, special situation partnerships and venture capital investments. Interests in these funds are valued at net asset value (NAV).
Fixed Income Securities
Fixed income securities consist primarily of investment and non-investment grade debt securities, debt securities issued by the U.S. Treasury, multi-asset credit investment funds and exchange-traded funds. Government, corporate and other bonds and notes, interest rate and inflation swaps, physical inflation-linked and nominal gilts, synthetic gilts, money market instruments and cash are valued at the closing price reported if they are traded on an active market or if they are traded at yields currently available on comparable securities of issuers with similar credit ratings. Fixed income securities also include smaller allocations to alternative investments, private equity and alternative fixed income investments. Alternative investments consist primarily of private placement funds, private equity investments and alternative fixed income-like investments. Private equity consists of interests in partnerships that invest in U.S. and non-U.S. equity and debt securities. This may include a diversified mix of partnership interests including buyouts, restructured or distressed debt, growth equity, mezzanine or subordinated debt, real estate, special situation partnerships and venture capital investments. Alternative fixed income securities consist primarily of private partnership interests in hedge funds. Interests in these funds are valued at NAV, which is determined by the administrator or custodian of the fund based on the fair value of the underlying assets owned by the fund less its liabilities.
Insurance Contracts
Insurance contracts are individual contracts whereby an insurance company offers a guaranteed minimum interest return. The Company does not have any influence on the investment decisions made by the insurer. European insurers, in general, are strictly regulated by an external control mechanism and have to invest for their guaranteed interest products within certain boundaries. Typically, they have a strategic asset allocation with 80% to 90% fixed income products and 10% to 20% equity-type products, including real estate.
Real Assets Funds
Real assets funds consist of interests in partnerships that invest in private real estate and commodities investments. Interests in partnerships are valued using NAV.
Fair Value of Plan Assets
Fair value measurements of plan assets are reported in one of three levels based on the lowest level of significant input used. For Level 1, inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities. For Level 2, inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. For Level 3, inputs to the fair value measurement are unobservable inputs or are based on valuation techniques.
The estimated fair value of pension plan assets and their respective levels in the fair value hierarchy by asset category were as follows (in millions):
Level 1Level 2Level 3Total
Balances as of July 31, 2025
Cash and cash equivalents$0.3 $2.9 $— $3.2 
Global equity securities3.9 55.2 — 59.1 
Fixed income securities5.0 22.1 — 27.1 
Insurance contracts— — 49.5 49.5 
Total investments in the fair value hierarchy$9.2 $80.2 $49.5 138.9 
Investments using NAV as practical expedient269.3 
Total investment, at fair value
408.2 
Accrued expense
(3.1)
Total assets
$405.1 
Balances as of July 31, 2024
Cash and cash equivalents$2.4 $0.5 $— $2.9 
Global equity securities58.2 54.5 — 112.7 
Fixed income securities80.4 128.0 — 208.4 
Insurance contracts— — 42.7 42.7 
Total investments in the fair value hierarchy$141.0 $183.0 $42.7 366.7 
Investments using NAV as practical expedient44.2 
Total investment, at fair value
410.9 
Accrued income
2.4 
Total assets
$413.3 
Certain investments, valued at NAV, had the following unfunded commitments and/or redemption restrictions (in millions):
July 31, 2025July 31, 2024
NAVUnfunded CommitmentsNAVUnfunded CommitmentsRedemption Frequency
(If Currently Eligible)		Redemption Notice (Days)
Global equity securities$37.8 $1.8 $31.1 $1.8 
Daily and Not Eligible(1)
N/A
Fixed income securities228.6 — 10.2 — Daily and Quarterly
0 - 60
Real asset funds2.9 4.2 2.9 4.2 
Not Eligible(1)
N/A
Total U.S. assets$269.3 $6.0 $44.2 $6.0 
(1)Cannot be redeemed without the consent of the Investment Manager. Although it is not probable that such investments will be sold, it is possible to sell these investments in the secondary market.
The changes in the fair values of the pension plans’ Level 3 assets were as follows (in millions):
Year Ended July 31,
202520242023
Balance as of beginning of year$42.7 $41.3 $35.4 
Unrealized gains3.3 3.4 2.7 
Foreign currency exchange2.6 (0.8)3.0 
Purchases and sales, net0.9 (1.2)0.2 
Balance as of end of year$49.5 $42.7 $41.3 
Investment Policies and Strategies
For U.S. pension plans, the Company uses a total return on investment approach to achieve a long-term return on plan assets, with what the Company believes to be a prudent level of risk for the purpose of meeting its retirement income commitments to employees. The U.S. pension plans’ investments are diversified to assist in managing risk. During the year ended July 31, 2025, the Company’s asset allocation was as follows:
Salaried Pension PlanHourly Pension Plan
Global equity securities15 %15 %
Fixed income securities85 85 
Total100 %100 %
The target allocation guidelines are determined in conjunction with the Company’s investment consultant and through the use of modeling the risk/return trade-offs among asset classes utilizing assumptions about expected annual return, expected volatility/standard deviation of returns and expected correlations with other asset classes.
For non-U.S. plans, the general investment objectives are to maintain a suitably diversified portfolio of secure assets with appropriate liquidity that will generate income and capital growth to meet, together with any new contributions from members and the Company, the cost of current and future benefits. Investment policy and performance is measured and monitored on an ongoing basis.
Estimated Contributions and Future Payments
The Company’s general funding policy is to make at least the minimum required contributions as required by applicable regulations, plus any additional amounts it determines to be appropriate. The Company made contributions of $2.7 million to its pension plans during the year ended July 31, 2025. Future required pension plan contributions may change significantly depending on the actual rate of return on plan assets, discount rates and regulatory requirements.
Estimated future benefit required payments for the Company’s pension plans as of July 31, 2025 were as follows (in millions):
2026$26.8 
2027$28.2 
2028$29.4 
2029$30.1 
2030$31.0 
2031-2035$159.1 
Retirement Savings
The Company provides a contributory employee savings plan to U.S. employees that permits participants to make contributions by salary reduction pursuant to section 401(k) of the Internal Revenue Code. For eligible employees, employee contributions of up to 50% of compensation are matched at a rate equaling 100% of the first 3% contributed and 50% of the next 2% contributed. In addition, the Company contributes 3% of compensation annually for eligible employees. Total contribution expense for this plan was $33.7 million, $32.7 million and $28.6 million for the years ended July 31, 2025, 2024 and 2023, respectively.
Deferred Compensation and Other Benefit Plans
The Company provides various deferred compensation and other benefit plans to certain executives. The deferred compensation plan allows eligible employees to defer the receipt of all or a portion of their cash bonus and other stock-related compensation and up to 75% of their salary to future periods. Other benefit plans are provided to supplement the benefits for a select group of highly compensated individuals that are reduced because of compensation limitations set by the Internal Revenue Code. The Company has recorded a liability of $0.4 million and $1.2 million as of July 31, 2025 and 2024, respectively, related primarily to its deferred compensation plans.
v3.25.2
Derivative Instruments and Hedging
 12 Months Ended
Jul. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging
Note 15. Derivative Instruments and Hedging
Derivative Fair Value Measurements
The Company enters into derivative instrument agreements, including foreign currency forward contracts and net investment hedges, to manage risk in connection with changes in foreign currency. The Company only enters into derivative instrument agreements with counterparties who have highly rated credit. There is risk the counterparties to derivative contracts will fail to meet their contractual obligations. In order to mitigate counterparty credit risk, the Company only enters into contracts with carefully selected financial institutions based upon their credit ratings and certain other financial factors.
Contract provisions may require the posting of collateral or settlement of the contracts for various reasons, including if the Company’s credit ratings are downgraded below its investment grade credit rating by any of the major credit agencies or for cross default contractual provisions if there is a failure under other financing arrangements related to payment terms or covenants. As of July 31, 2025 and 2024, no collateral was posted.
The Company does not enter into derivative instrument agreements for trading or speculative purposes. For discussion on the fair value of the Company’s derivatives, see Note 16.
Foreign Currency Forward Contracts - Cash Flow Hedges and Derivatives Not Designated as Hedging Instruments
The Company buys materials from foreign suppliers. Those transactions can be denominated in those suppliers’ local currency. The Company also sells to customers in foreign countries. Those transactions can be denominated in those customers’ local currency. Both of these transaction types can create volatility in the Company’s financial statements. The Company uses foreign currency forward contracts to manage those exposures and fluctuations. These contracts generally mature in 15 months or less, which is consistent with the forecasts of the related purchases and sales. Certain contracts are designated as cash flow hedges, whereas the remaining contracts, most of which are related to certain intercompany transactions which offset balance sheet exposure, are not designated as hedging instruments. The total notional amount of the foreign currency forward contracts designated as hedges as of July 31, 2025 and 2024 were $35.7 million and $32.3 million, respectively. The total notional amount of the foreign currency forward contracts not designated as hedges as of July 31, 2025 and 2024 were $189.6 million and $249.7 million, respectively.
Changes in the fair value of the Company’s designated hedges are reported in accumulated other comprehensive loss on the Consolidated Balance Sheets until the related transaction occurs, see Note 12. Designated hedges are recognized as a component of either net sales, cost of sales, selling, general and administrative expenses or other income, net in the Consolidated Statements of Earnings upon occurrence of the related hedged transaction.
Hedges and subsequent changes in the fair value of hedges that are not designated are recognized in other income, net in the Consolidated Statements of Earnings along with the related hedged transactions.
Amounts related to foreign currency forward contracts designated as hedges are expected to be reclassified into earnings during the next 15 months based upon the timing of inventory purchases and sales.
Net Investment Hedges
The Company uses fixed-to-fixed cross-currency swap agreements to hedge its exposure to adverse foreign currency exchange rate movements for its operations in Europe. The Company has elected the spot method for designating these contracts as net investment hedges.
The total notional amount of net investment hedges as of July 31, 2025 and 2024 was €80 million, or $88.8 million. The maturity dates range from 2027 to 2029.
Gains and losses resulting from a change in fair value of the net investment hedge are offset by gains and losses on the underlying foreign currency exposure and are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Amounts related to excluded components associated with the net investment hedge are expected to be reclassified into earnings in interest expense in the Consolidated Statements of Earnings through their maturity.
Interest Rate Swaps - Cash Flow Hedges
The Company did not enter into any interest rate swap arrangements during fiscal years 2025 or 2024. As of July 31, 2025 and 2024, there were no outstanding interest rate swap arrangements.
Cash Flows
Cash flows from derivative transactions are recorded in operating activities in the Consolidated Statements of Cash Flows.
v3.25.2
Fair Value Measurements
 12 Months Ended
Jul. 31, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Note 16. Fair Value Measurements
Fair value measurements of financial instruments are reported in one of three levels based on the lowest level of significant input used. For Level 1, inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities. For Level 2, inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. For Level 3, inputs to the fair value measurement are unobservable inputs or are based on valuation techniques.
Short-Term Financial Instruments
As of July 31, 2025 and 2024, the carrying values of cash and cash equivalents, accounts receivable, short-term borrowings and accounts payable approximate fair value because of the short-term nature of these instruments. Short-term financial instruments are classified as Level 1 in the fair value hierarchy.
Long-Term Debt
As of July 31, 2025, the estimated fair values of fixed interest rate long-term debt were $247.5 million compared to the carrying values of $275.0 million. As of July 31, 2024, the estimated fair values of fixed interest rate long-term debt were $267.7 million compared to the carrying values of $300.0 million. The fair values are estimated by discounting the projected cash flows using the interest rates at which similar amounts of debt could currently be borrowed. The carrying values of total variable interest rate long-term debt were $364.9 million and $209.9 million as of July 31, 2025 and 2024, respectively and approximate their fair values. Long-term debt is classified as Level 2 in the fair value hierarchy.
Investment in Joint Ventures and a Non-Controlling Interest
The Company holds investments in joint ventures and a non-controlling interest, which are accounted for as equity method investments at fair value and are included in other long-term assets on the Consolidated Balance Sheets. The aggregate carrying amount of these investments was $103.6 million and $26.9 million as of July 31, 2025 and 2024, respectively. The increase is primarily driven by the $69.7 million equity method investment in Medica as of July 31, 2025. These equity method investments are measured at fair value on a non-recurring basis. The fair value of the Company’s equity method investments has not been adjusted as there have been no triggering events or changes in circumstance that would have had an adverse impact on the value of these investments. In the event these investments are required to be measured, they would fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value, as the investments are in privately-held entities.
Derivative Fair Value Measurements
The fair values of the Company’s foreign currency forward contracts, net investment hedges and interest rate swaps reflect the amounts that would be received to sell the assets or paid to transfer the liabilities in an orderly transaction between market participants at the measurement date (exit price). The fair values are based on inputs other than quoted prices that are observable for the asset or liability and are determined by standard calculations and models that use readily observable market parameters. These inputs include foreign currency exchange rates and interest rates. Industry standard data providers are the primary source for forward and spot rate information for both interest rates and foreign currency exchange rates. The fair values of the Company’s foreign currency forward contracts, net investment hedges and interest rate swaps are classified as Level 2 in the fair value hierarchy. For discussion of the Company’s derivatives and hedging, see Note 15.
Fair Value of Derivative Contracts
The fair value of the Company’s derivative contracts, recorded on the Consolidated Balance Sheets, was as follows (in millions):
Assets
Liabilities
July 31,July 31,
Balance Sheet Location2025202420252024
Designated as hedging instruments
Foreign currency forward contracts
Other current assets, other current liabilities
$0.4 $0.1 $0.3 $— 
Net investment hedges
Other current assets, other long-term assets, other long-term liabilities
1.6 3.7 2.9 — 
Total designated2.0 3.8 3.2 — 
Not designated as hedging instruments
Foreign currency forward contracts
Other current assets, other current liabilities
0.9 1.0 0.4 0.3 
Total not designated0.9 1.0 0.4 0.3 
Total$2.9 $4.8 $3.6 $0.3 
Amounts related to excluded components, such as forward points, are excluded from the assessment of hedge effectiveness of net investment hedges and are expected to be reclassified into earnings throughout their maturity dates. See Note 12 for additional information on accumulated other comprehensive loss.
Fair Value of Contingent Consideration
The fair value of the contingent consideration liability is determined using a probability-weighted discounted cash flow method. This fair value measurement is based on unobservable inputs in the market and thus, represents a Level 3 measurement within the fair value hierarchy. This analysis reflects the contractual terms of the purchase agreement (e.g., potential payment amounts, length of measurement periods, manner of calculating any amounts due) and utilizes assumptions with regard to future financial and operational milestones, probabilities of achieving such milestones and a discount rate. Depending on the contractual terms of the purchase agreement, the probability of achieving milestones generally represents the only significant unobservable input. The contingent consideration liability is measured at fair value each reporting period and changes in estimates of fair value are recognized in earnings.
A reconciliation of the fair value of the Company’s contingent consideration liability that use unobservable inputs was as follows (in millions):
Balance as of July 31, 2024
$21.8 
Issuances1.5
Settlements
(5.8)
Adjustments to fair value(6.2)
Balance as of July 31, 2025
$11.3 
Maximum potential payout$22.5 
Balance as of July 31, 2023
$25.0 
Issuances1.0
Settlements(2.0)
Adjustments to fair value(2.2)
Balance as of July 31, 2024
$21.8 
Maximum potential payout$29.8 
The fair value of the Company’s contingent consideration liability that uses unobservable inputs was $11.3 million as of July 31, 2025 and $21.8 million as of July 31, 2024. The decrease of the contingent consideration liability was driven by a reduction in the assessed probability of achieving certain milestones and $5.8 million of total contingent consideration paid during fiscal 2025. The maximum potential payout of the contingent consideration was $22.5 million and $29.8 million as of July 31, 2025 and July 31, 2024, respectively, see Note 18.
v3.25.2
Guarantees
 12 Months Ended
Jul. 31, 2025
Product Warranties Disclosures [Abstract]  
Guarantees
Note 17. Guarantees
Letters of Credit
The Company has letters of credit which guarantee payment to third parties in the event the Company is in breach of contract terms as detailed in each letter of credit. The outstanding debt contingent liability for standby letters of credit was as follows (in millions):
Year Ended July 31,
20252024
Contingent liability for standby letters of credit issued under the Company’s revolving credit facility$7.9 $7.5 
Amounts drawn for letters of credit under the Company’s revolving credit facility$— $— 
Advanced Filtration Systems Inc. (AFSI)
The Company has an unconsolidated joint venture, AFSI, established by the Company and Caterpillar Inc. (Caterpillar) in 1986. AFSI designs and manufactures high-efficiency fluid filters used in Caterpillar’s machinery worldwide. The Company and Caterpillar equally own the shares of AFSI and both companies guarantee certain debt and banking services, including credit and debit cards, merchant processing and treasury management services, of the joint venture. The Company accounts for AFSI as an equity method investment.
The outstanding debt relating to AFSI, of which the Company guarantees half, was $43.9 million and $51.0 million as of July 31, 2025 and 2024, respectively. AFSI has $63.0 million in a revolving credit facility which expires on July 31, 2027 and $17.0 million in an additional multi-currency revolving credit facility which terminates upon notification of either party.
Earnings from AFSI, which are recorded in other income, net in the Consolidated Statements of Earnings were $12.9 million and $12.3 million as of July 31, 2025 and 2024, respectively
v3.25.2
Commitments and Contingencies
 12 Months Ended
Jul. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 18. Commitments and Contingencies
The Company records provisions when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. Claims and litigation are reviewed quarterly and provisions are taken or adjusted to reflect the status of a particular matter. The Company believes the estimated liability in its Consolidated Financial Statements for claims or litigation is adequate and appropriate for the probable and estimable outcomes. Liabilities recorded were not material to the Company’s financial position, results of operations or liquidity. The Company believes it is remote that the settlement of any of the currently identified claims or litigation will be materially in excess of what is accrued.
The Company is party to agreements that include deferred payment provisions representing potential milestone payments for former owners of acquired businesses. The provisions are made up of two general types of arrangements, contingent compensation and contingent consideration. A contingent compensation arrangement is contingent on the former owner’s future employment with the Company and the related amounts are recognized over the required employment period. A contingent consideration agreement is contingent on the achievement of certain revenue and manufacturing milestones, regardless of the former owners’ employment status. Contingent consideration was recorded as purchase consideration at the time of the initial acquisition based on the fair value of the estimated liability.
The Company primarily determines the contingent consideration liability based on the forecasted probability of achieving certain milestones.
The arrangement liabilities, recorded on the Consolidated Balance Sheets, were as follows (in millions):
Arrangement Liability
Maximum Payout (1)
Balance Sheet LocationJuly 31,
2025		July 31,
2024		July 31,
2025		July 31,
2024
Expires in
Contingent compensation arrangements
Purilogics (4)
Accrued employee compensation and related taxes$— $2.1 $— $3.0 — 
Other
Accrued employee compensation and related taxes, other long-term liabilities
$0.2 $0.3 $0.2 $0.8 
FY27
Contingent consideration liability
Purilogics (2)
Other current liabilities, other long-term liabilities
$9.8 $19.0 $21.0 $27.0 

FY27
Other (3)
Other current liabilities $1.5 $2.8 $1.5 $2.8 
FY26
(1)The maximum payout values are inclusive of the respective arrangement liability balance.
(2)The decrease in the Purilogics’ contingent consideration liability in fiscal 2025 was primarily driven by a $6.2 million reduction of the fair value during the twelve months ended July 31, 2025 based on the probability of achieving certain milestones. The total contingent consideration paid as of July 31, 2025 was $5.0 million, of which $3.0 million was paid during fiscal 2025 and $2.0 million was paid during fiscal 2024.
(3)A contingent consideration liability of $1.5 million was added in fiscal 2025 due to a non-material acquisition. The total contingent consideration paid as of July 31, 2025 was $2.8 million, which was all paid in fiscal 2025.
(4)Purilogics contingent compensation of $3.0 million was paid in fiscal 2025.
For additional discussion regarding the fair value of the Company’s contingent consideration liability, see Note 16.
Warranty Reserves
The Company estimates warranty expense on certain products at the time of sale using quantitative measures based on historical warranty claim experience and evaluation of specific customer warranty issues. The Company’s accrued warranty reserves were $6.9 million and $10.2 million as of July 31, 2025 and 2024, respectively. During the year ended July 31, 2025, there were no individually or collectively material specific warranty matters accrued for, and there was a $4.1 million specific reserve settled for one customer. During the year ended July 31, 2024, there was a $4.1 million specific warranty reserved for one customer, and there were no other individually or collectively material specific warranty matters accrued for, or significant settlements made.
v3.25.2
Segment Reporting
 12 Months Ended
Jul. 31, 2025
Segment Reporting, Measurement Disclosures [Abstract]  
Segment Reporting
Note 19. Segment Reporting
The Company’s reportable segments are: Mobile Solutions, Industrial Solutions and Life Sciences. The organizational structure also includes Corporate and Unallocated which includes interest expense and certain corporate expenses determined to be non-allocable to the segments, such as restructuring charges and business development expenses. The Company determines its operating segments consistent with the manner in which the chief operating decision maker (CODM) manages operations and evaluates performance for internal review and decision-making. The CODM evaluates trends in earnings (loss) before income taxes to assess performance of the segments. The CODM considers variances in reported results to budget and variances to prior periods to make decisions about allocating resources to each segment. The Company’s CODM is the Chief Executive Officer. In fiscal 2025 and 2024, Corporate and Unallocated included a charge of $16.8 million and $6.4 million, respectively, related to restructuring, see Note 20.
The Mobile Solutions segment is organized based on a combination of customers and products and consists of the Off-Road, On-Road and Aftermarket business units. Within these business units, products consist of replacement filters for both air and liquid filtration applications and filtration housings for new equipment production and systems related to exhaust and emissions. Applications include air filtration systems, fuel, lube and hydraulic systems, emissions systems and sensors, indicators and monitoring systems. Mobile Solutions sells to original equipment manufacturers (OEMs) in the construction, mining, agriculture and transportation end markets and to independent distributors and OEM dealer networks.
The Industrial Solutions segment is organized based on product type and consists of Industrial Air Filtration, Industrial Gases, Industrial Hydraulics, Power Generation and Aerospace and Defense products. These products are further organized by the Industrial Filtration Solutions and Aerospace and Defense business units. Within our industrial portfolio, the Company provides a wide product offering in the market to industrial customers consisting of equipment, ancillary components, replacement parts, performance monitoring and service globally, that cost-effectively enhances productivity and manufacturing efficiency. Industrial Air Filtration, Industrial Gases and Industrial Hydraulics products consist of dust, fume and mist collectors, compressed air and industrial gases purification systems, hydraulic and lubricated rotating filtration applications as well as gas and liquid filtration for industrial processes. Power Generation products consist of air inlet systems and filtration sold to gas compression, power generation and natural gas liquification industries. Aerospace and Defense products consist of air, fuel, lubrication and hydraulic filtration for fixed-wing and rotorcraft aerospace applications and ground defense vehicle and naval platforms. Industrial Solutions businesses sell through multiple channels which include OEMs, distributors and direct-to-consumer in some markets.
The Life Sciences segment is organized by end market and consists of the Food and Beverage, Disk Drive, Vehicle Electrification and Medical Device, Microelectronics and Bioprocessing Equipment and Consumables markets. Within these markets, products consist of micro-environment gas and liquid filtration for food and beverage and industrial processes, bioprocessing equipment, including bioreactors and fermenters, bioprocessing consumables including chromatography devices, reagents and filters, polytetrafluoroethylene membrane-based products, as well as specialized air and gas filtration systems for applications including hard disk drives, semiconductor manufacturing, sensors, battery systems and powertrain components. Life Sciences primarily sells to large OEMs and directly to various end users requiring cell growth, separation, purification, high purity filtration and device protection.
The Company has manufacturing facilities that serve multiple reportable segments. As such, capital expenditure information by reportable segment has not been provided because the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each reportable segment’s operating results, it is not discretely identifiable as a result of the shared manufacturing facilities.
The Company is an integrated enterprise, characterized by substantial intersegment cooperation, cost allocations and sharing of assets. Therefore, the Company does not represent these segments, if operated independently, would report earnings before income taxes and other financial information as stated below.
Segment details were as follows (in millions):
Mobile Solutions SegmentIndustrial Solutions SegmentLife Sciences Segment
Total Segment
Corporate and
Unallocated (1)
Total
Company
Year ended July 31, 2025
Net sales$2,291.0 $1,104.4 $295.5 $3,690.9 $— $3,690.9 
Cost of sales1,544.0 654.9 177.9 
Other segment items (2)
329.4 251.8 113.2 
Earnings (loss) before income taxes
$417.6 $197.7 $4.4 $619.7 $(127.5)$492.2 
Equity earnings in unconsolidated affiliates$8.1 $0.2 $— $8.3 $— $8.3 
Assets$1,334.8 $883.7 $458.4 $2,676.9 $300.3 $2,977.2 
Equity investments in unconsolidated affiliates$33.5 $0.5 $— $34.0 $— $34.0 
Year ended July 31, 2024
Net sales$2,250.8 $1,066.5 $269.0 $3,586.3 $— $3,586.3 
Cost of sales1,524.6 624.0 156.5 
Other segment items (2)
321.7 243.7 122.9 
Earnings (loss) before income taxes
$404.5 $198.8 $(10.4)$592.9 $(57.6)$535.3 
Equity earnings in unconsolidated affiliates$7.3 $0.1 $— $7.4 $— $7.4 
Assets$1,339.5 $821.7 $512.1 $2,673.3 $241.0 $2,914.3 
Equity investments in unconsolidated affiliates$26.8 $0.1 $— $26.9 $— $26.9 
Year ended July 31, 2023
Net sales$2,174.8 $1,014.7 $241.3 $3,430.8 $— $3,430.8 
Cost of sales1,535.4 594.3 136.8 
Other segment items (2)
309.0 234.2 94.6 
Earnings (loss) before income taxes$330.4 $186.2 $9.9 $526.5 $(57.8)$468.7 
Equity earnings in unconsolidated affiliates$3.6 $— $— $3.6 $— $3.6 
Assets$1,243.8 $788.1 $513.8 $2,545.7 $224.8 $2,770.5 
Equity investments in unconsolidated affiliates$24.2 $0.2 $— $24.4 $— $24.4 
(1) Corporate and unallocated includes interest expense and certain corporate expenses determined to be non-allocable to the segments, such as restructuring charges and portions of incentive compensation.
(2) Other segment items consist primarily of selling, general and administrative expenses, research and development expense and other income (expense).
Net sales by business unit were as follows (in millions):
Year Ended July 31,
202520242023
Mobile Solutions segment
Off-Road$359.5 $380.8 $428.7 
On-Road110.6 139.8 145.8 
Aftermarket1,820.9 1,730.2 1,600.3 
Total Mobile Solutions segment2,291.0 2,250.8 2,174.8 
Industrial Solutions segment
Industrial Filtration Solutions
914.2 901.1 872.2 
Aerospace and Defense190.2 165.4 142.5 
Total Industrial Solutions segment1,104.4 1,066.5 1,014.7 
Life Sciences segment
Total Life Sciences segment295.5 269.0 241.3 
Total Company$3,690.9 $3,586.3 $3,430.8 
Net sales, generally disaggregated by location where the customer’s order was received, property, plant and equipment, net and right-of-use asset by geographic region were as follows (in millions):
Net Sales Property, Plant and Equipment, Net
Right-Of-Use Asset
Year ended July 31, 2025
U.S. and Canada$1,632.3 $225.7 $26.8 
EMEA1,027.2 195.2 16.5 
APAC635.7 76.2 11.0 
LATAM395.7 147.4 6.2 
Total$3,690.9 $644.5 $60.5 
Year ended July 31, 2024
U.S. and Canada$1,583.1 $209.7 $23.3 
EMEA1,012.9 199.6 19.1 
APAC601.5 75.5 10.6 
LATAM388.8 160.7 6.7 
Total$3,586.3 $645.5 $59.7 
Year ended July 31, 2023
U.S. and Canada$1,464.7 $219.7 $25.3 
EMEA1,007.8 202.4 15.5 
APAC608.8 76.5 11.6 
LATAM349.5 154.3 7.1 
Total$3,430.8 $652.9 $59.5 
Concentrations
There were no customers that accounted for over 10% of net sales for the years ended July 31, 2025, 2024 or 2023. There were no customers that accounted for over 10% of gross accounts receivable as of July 31, 2025 or 2024.
v3.25.2
Restructuring
 12 Months Ended
Jul. 31, 2025
Restructuring and Related Activities [Abstract]  
Restructuring
Note 20. Restructuring
During fiscal 2025, the Company continued its global footprint and cost optimization actions to further improve the operating and manufacturing cost structure, which began in fiscal 2024. These activities resulted in restructuring expenses, primarily related to severance, of $16.8 million and $6.4 million for the years ended July 31, 2025 and 2024, respectively. Charges of $6.5 million and $3.8 million were included in cost of sales in the Consolidated Statements of Earnings for the years ended July 31, 2025 and 2024, respectively. Charges of $10.3 million and $2.6 million were included in operating expenses in the Consolidated Statements of Earnings for the years ended July 31, 2025 and 2024, respectively. As of July 31, 2025 and July 31, 2024, $7.1 million and $6.4 million of accrued expenses were included in accrued employee compensation and related taxes in the Consolidated Balance Sheets, respectively.
During fiscal 2023, the Company announced a company-wide organizational redesign to further support the Company’s growth strategies and better serve its customers. In conjunction with the organizational redesign, the Company recorded $21.8 million of charges consisting of $15.3 million of severance charges and other organizational redesign costs and $6.5 million of costs mainly associated with the exiting of a lower-margin customer program and a lower-margin product. Charges of $2.9 million were included in cost of sales and $18.9 million were included in selling, general and administrative expenses in the accompanying Consolidated Statements of Earnings.
v3.25.2
Insider Trading Arrangements
 3 Months Ended
Jul. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.2
Insider Trading Policies and Procedures
 12 Months Ended
Jul. 31, 2025
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
v3.25.2
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Jul. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Donaldson recognizes the critical importance of cybersecurity. Protecting the confidentiality, integrity and availability of our data, we focus on building resilience into the very fabric of our enterprise digital ecosystem. Our cybersecurity program is comprehensively integrated within our enterprise risk management and encompasses the enterprise information technology (IT) and operational technology (OT) environments. Our cyber risk management program controls are based on industry-recognized best practices and standards, including the National Institute of Standards and Technology (NIST) Cyber Security Framework and the International Organization for Standardization (ISO) 27001 information security management system requirements.
Our cybersecurity processes include the following:
Technical safeguards – We seek to maintain an information technology infrastructure that implements risk-based physical, administrative and technical controls to safeguard our information systems and information stored on our networks, including customer information, personal information, intellectual property and proprietary information.
Cybersecurity incident response plan and testing – We perform 24x7 security monitoring and execute a cybersecurity incident response plan with a dedicated team to respond to cybersecurity incidents. When a potential material cybersecurity incident is identified, we deploy cross-functional teams responsible for leading the initial assessment of priority and severity, and external experts may also be engaged as appropriate. Our cybersecurity teams prioritize responses to incidents depending on severity levels. We continuously improve our cybersecurity incident management plan through periodic tabletop exercises or simulations at the enterprise and business levels.
Education and Awareness – We require annual training for personnel for information security, including information about the latest cybersecurity threats. To equip employees with the knowledge to identify potential risks with tools to report any suspicious activities, we implemented monthly phishing exercises that encompass various real-life simulations. We also practice scenario-based simulation drills, such as tabletop exercises for employees and contractors, to enhance awareness and vigilance of potential threats. For fast-developing threat situations, we utilize enterprise-wide corporate communication channels to broadcast security alerts for the timely delivery of important information to our employees.
Technology managed by third parties – We have IT systems essential to business operations managed by third parties. These systems process, transmit, store electronic information and manage or support a variety of business processes and activities. Before any engagement, we conduct holistic risk assessments of third-party providers. We scrutinize multiple dimensions of risk factors including information security, regulatory compliance and architectural design. We established monitoring procedures to mitigate risks related to data breaches or other security incidents originating from third parties.
Third-party assessments of the Company – We regularly engage third-party consultants, legal advisors and audit firms in evaluating and testing our risk management processes, compliance with international standards and regulations, and assessing potential cybersecurity threats, as appropriate. Any recommendations are tracked with senior IT ownership and timelines for remediation.
We consider cyber risks among the top risks for us within our enterprise risk management framework. This framework includes internal reporting at the business and enterprise levels, with consideration of key risk indicators, trends and countermeasures for cybersecurity and other types of significant risks. As of the date of this Form 10-K, we are not aware of any cybersecurity incidents that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, and that are required to be reported in this Form 10-K. We do not believe we have experienced any risks from cybersecurity threats or previous cybersecurity incidents that have materially affected or are reasonably likely to materially affect us, our business strategy or our results of operations or financial condition, including for any of the three years ended July 31, 2025, 2024 or 2023.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block]
Donaldson recognizes the critical importance of cybersecurity. Protecting the confidentiality, integrity and availability of our data, we focus on building resilience into the very fabric of our enterprise digital ecosystem. Our cybersecurity program is comprehensively integrated within our enterprise risk management and encompasses the enterprise information technology (IT) and operational technology (OT) environments. Our cyber risk management program controls are based on industry-recognized best practices and standards, including the National Institute of Standards and Technology (NIST) Cyber Security Framework and the International Organization for Standardization (ISO) 27001 information security management system requirements.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block]
Our board of directors has oversight of overall risk management, prioritizing the most significant risks including strategic, operational, financial and legal compliance risks. The board’s risk oversight process builds upon management’s risk management processes, which include processes for identifying, assessing and managing material risks from cybersecurity threats. The board implements its risk oversight function primarily through its audit committee, which receives reports about our practices, programs, notable threats or incidents, and other developments related to cybersecurity throughout the year. To this extent, the audit committee receives information about cybersecurity risks as part of our enterprise risk management framework and reporting. The audit committee then assesses implemented cybersecurity controls to monitor and evaluate the mitigation of cybersecurity risks.
Our Chief Information Officer (CIO) provides annual reports, with additional updates as necessary to the board of directors. Our CIO also attends annual audit committee meetings and provides cybersecurity updates which include specific cybersecurity topics, covering material risks and threats. Our CIO oversees the cybersecurity program. With an extensive background in the IT industry, our CIO has previously held CISO positions, and other top global leadership roles, that drove digital transformation and owned technology from end to end. Our CIO leads a cross-functional information security team, comprised of experienced professionals from the global infrastructure and cybersecurity, legal and compliance organizations. Beyond information technology, this leadership team also partners with our Enterprise Operations team managing the operational technology security of our manufacturing facilities.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Our board of directors has oversight of overall risk management, prioritizing the most significant risks including strategic, operational, financial and legal compliance risks
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] The board implements its risk oversight function primarily through its audit committee, which receives reports about our practices, programs, notable threats or incidents, and other developments related to cybersecurity throughout the year. To this extent, the audit committee receives information about cybersecurity risks as part of our enterprise risk management framework and reporting.
Cybersecurity Risk Role of Management [Text Block] The board’s risk oversight process builds upon management’s risk management processes, which include processes for identifying, assessing and managing material risks from cybersecurity threats. The board implements its risk oversight function primarily through its audit committee, which receives reports about our practices, programs, notable threats or incidents, and other developments related to cybersecurity throughout the year. To this extent, the audit committee receives information about cybersecurity risks as part of our enterprise risk management framework and reporting. The audit committee then assesses implemented cybersecurity controls to monitor and evaluate the mitigation of cybersecurity risks.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Our Chief Information Officer (CIO) provides annual reports, with additional updates as necessary to the board of directors.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] comprised of experienced professionals from the global infrastructure and cybersecurity, legal and compliance organizations.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Our Chief Information Officer (CIO) provides annual reports, with additional updates as necessary to the board of directors. Our CIO also attends annual audit committee meetings and provides cybersecurity updates which include specific cybersecurity topics, covering material risks and threats.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.2
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Jul. 31, 2025
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
The Consolidated Financial Statements include the accounts of the Company and all its majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
The Company’s joint ventures are not majority-owned and are accounted for under the equity method. The Company is party to joint ventures with Advanced Filtration Systems Inc. (AFSI) and PT Panata Jaya Mandiri (PTPJM), as well as a non-controlling interest in Medica S.p.A. (Medica), all of which are considered related parties. The investment and earnings from joint ventures are not material.
Certain reclassifications to previously reported financial information have been made to conform to the current period presentation.
Use of Estimates
Use of Estimates
The preparation of the Company’s financial statements in conformity with generally accepted accounting principles (GAAP) in the United States (U.S.) requires management to make estimates and assumptions that affect the amount of assets and liabilities and the disclosures regarding contingent assets and liabilities at period end and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Foreign Currency Translation
Foreign Currency Translation
For most foreign operations, local currencies are considered the functional currency. Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at fiscal year end exchange rates and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as a cumulative translation adjustment, a component of accumulated other comprehensive loss on the Consolidated Balance Sheets. Elements of the Consolidated Statements of Earnings are translated at average exchange rates in effect during the fiscal year.
Cash Equivalents
Cash Equivalents
The Company considers all highly liquid temporary investments with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at cost which approximates market value.
Revenue Recognition
Revenue Recognition
Revenue is measured as the amount of consideration the Company expects to receive in exchange for the fulfillment of performance obligations. The transaction price of a contract could be reduced by variable consideration including volume purchase rebates and discounts, product refunds and returns. At the time of sale to a customer, the Company records an estimate of variable consideration as a reduction from gross sales. The Company primarily relies on historical experience and anticipated future performance to estimate the variable consideration. Revenue is recognized to the extent it is probable a significant reversal of revenue will not occur when the contingency is resolved. The Company accounts for amounts billed to customers for reimbursement of shipping and handling costs by recording these amounts as revenue and accruing costs when the related revenue is recognized.
For most customer contracts, the Company recognizes revenue at a point in time when control of the goods or services is transferred to the customer. For product sales, control is typically deemed to have transferred in accordance with the shipping terms, either at the time of shipment from the plants or distribution centers or the time of delivery to the customers. Revenue is recognized for services upon completion of those services. Payment terms vary by customer and the geographic location of the customer. The Company’s contracts with customers do not include significant financing components or non-cash consideration.
The Company has some contracts with customers where the performance obligations are satisfied over time. Certain customer contracts provide the Company with an enforceable right to payment of the transaction price for performance completed to date and the Company uses either an input or an output method of production to measure the progress towards the completion of the performance obligation in these arrangements, depending on the nature of the contract. The timing of revenue recognized from these products is slightly accelerated compared to revenue recognized at the time of shipment or delivery.
The Company generally does not incur significant incremental costs related to obtaining or fulfilling a contract prior to the start of a project. The Company may incur certain fulfillment costs such as initial design or mobilization costs which are capitalized if they relate directly to the contract, if they are expected to generate resources that will be used to satisfy the Company’s performance obligation under the contract and if they are expected to be recovered through revenues generated under the contract. Such costs, which are amortized over the life of the respective project, were not material for any period presented.
The Company does not pay upfront sales commissions on contracts when the related contract period is greater than one year and thus has not capitalized any amounts as of July 31, 2025 and 2024, see Note 3.
Shipping and Handling
Shipping and Handling
Shipping and handling costs on products sold of $95.3 million, $91.5 million and $91.2 million are classified as a component of selling, general and administrative expenses in the Consolidated Statements of Earnings for the years ended July 31, 2025, 2024 and 2023, respectively.
Accounts Receivable, Net and Allowance for Doubtful Accounts
Accounts Receivable, Net and Allowance for Doubtful Accounts
Accounts receivable, net are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of credit losses in its existing accounts receivable. The Company determines the allowance based on utilization of a combination of aging schedules with reserve rates applied to both current and aged receivables using historical write-off experience, regional economic data and evaluation of specific customer accounts for risk of loss and changes in current or projected conditions to calculate the allowances related to accounts receivable, net. The Company reviews its allowance for doubtful accounts monthly. Account balances are reviewed on a pooled basis by reporting unit and geographic region and are reserved when the Company determines it is probable the receivable will not be recovered. The Company reduces the receivable and corresponding allowance when it confirms an account is uncollectible.
Accounts Receivable, Net and Allowance for Doubtful Accounts
Accounts Receivable, Net and Allowance for Doubtful Accounts
Accounts receivable, net are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of credit losses in its existing accounts receivable. The Company determines the allowance based on utilization of a combination of aging schedules with reserve rates applied to both current and aged receivables using historical write-off experience, regional economic data and evaluation of specific customer accounts for risk of loss and changes in current or projected conditions to calculate the allowances related to accounts receivable, net. The Company reviews its allowance for doubtful accounts monthly. Account balances are reviewed on a pooled basis by reporting unit and geographic region and are reserved when the Company determines it is probable the receivable will not be recovered. The Company reduces the receivable and corresponding allowance when it confirms an account is uncollectible.
Factoring Arrangements
Factoring Arrangements
The Company has agreements with financial institutions to sell certain trade receivables from customers without recourse. The Company accounts for trade receivable transfers as sales and de-recognizes the sold receivables from the Consolidated Balance Sheets. During fiscal 2025 and 2024, the Company sold receivables under factoring agreements of $86.1 million and $29.9 million, respectively. Costs incurred on these sales during the years ended July 31, 2025 and 2024 were $4.1 million and $1.7 million, respectively, and are included in the cost of sales within the Consolidated Statements of Earnings. Cash received from selling receivables in fiscal 2025 and 2024 of $82.0 million and $28.2 million, respectively, is presented as a change in accounts receivable within the operating section of the Consolidated Statements of Cash Flow.
Inventories
Inventories
Inventories are stated at the lower of cost and net realizable value. U.S. inventories are valued using the last-in, first-out (LIFO) method while the non-U.S. inventories are valued using the first-in, first-out (FIFO) method.
Property, Plant and Equipment
Property, Plant and Equipment
Property, plant and equipment are stated at cost. Additions, improvements or major renewals are capitalized while expenditures that do not enhance or extend the asset’s useful life are expensed as incurred. Depreciation is computed using the straight-line method.
Internal-Use Software
Internal-Use Software and Cloud Computing Arrangements
The Company capitalizes direct costs of materials and services used in the development and purchase of internal-use software. Amounts capitalized are amortized on a straight-line basis over a period of two to six years and are reported as a component of property, plant and equipment.
The Company capitalizes certain costs incurred during the application development stage of implementation of internal-use software in cloud computing arrangements. Amounts capitalized are amortized on a straight-line basis over a period of three to 10 years and are reported as a component of other long-term assets.
Cloud Computing Arrangements
Internal-Use Software and Cloud Computing Arrangements
The Company capitalizes direct costs of materials and services used in the development and purchase of internal-use software. Amounts capitalized are amortized on a straight-line basis over a period of two to six years and are reported as a component of property, plant and equipment.
The Company capitalizes certain costs incurred during the application development stage of implementation of internal-use software in cloud computing arrangements. Amounts capitalized are amortized on a straight-line basis over a period of three to 10 years and are reported as a component of other long-term assets.
Goodwill and Intangible Assets
Goodwill and Intangible Assets
Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations under the purchase method of accounting. Goodwill is assessed for impairment annually or if an event occurs or circumstances change that would indicate the carrying amount may be impaired. The Company performed its annual impairment assessment during the third quarter of fiscal 2025. The goodwill impairment assessment is conducted at a reporting unit level, which is one level below the operating segment level and utilizes either a qualitative or quantitative assessment. The Company determined the fair value for all its reporting units was substantially in excess of their respective carrying values and there were no indicators of impairment for any of the reporting units evaluated. An impairment loss would be recognized when the carrying amount of a reporting unit’s net assets exceeds the estimated fair value of the reporting unit, see Note 6.
Intangible assets, comprised of customer relationships, trademarks, technology and patents and non-compete agreements, are amortized on a straight-line basis over their estimated useful lives of three to 22 years.
Business Combinations
Business Combinations
The Company allocates the purchase price of acquired businesses to the estimated fair values of the assets acquired and liabilities assumed, as well as any contingent consideration, where applicable, as of the date of acquisition. The fair values of the long-lived assets acquired, primarily intangible assets, are determined using calculations which can be complex and require significant judgment. Estimates include many factors such as the nature of the acquired company’s business, its historical financial position and results, technology obsolescence, customer retention rates, discount rates, royalty rates and expected future performance. Independent valuation specialists are used to assist in determining certain fair value calculations.
During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Any adjustments required after the measurement period are recorded in the Consolidated Statements of Earnings.
Recoverability of Long-Lived Assets
Recoverability of Long-Lived Assets
The Company reviews its long-lived assets, including identifiable intangibles, for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If impairment indicators are present and the estimated future undiscounted cash flows are less than the carrying value of the assets, the carrying value is reduced to the fair market value.
In fiscal 2025, the Company identified a triggering event related to certain asset groups and performed a valuation of certain long-lived intangible assets in accordance with ASC 360, Impairment and Disposal of Long-Lived Assets. The Company used a discounted cash flow analysis to estimate the fair value of each long-lived asset group.
Income Taxes
Income Taxes
The provision for income taxes is computed based on the pretax income reported for financial statement purposes. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are anticipated to reverse. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not a tax benefit will not be realized.
The Company maintains a reserve for uncertain tax benefits. Benefits of tax return positions are recognized in the financial statements when the position is more likely than not to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that is greater than 50% likely to be realized, in the Company’s judgment,
Leases
Leases
The Company determines whether an arrangement that provides control over the use of an asset to the Company is a lease. The Company recognizes a lease liability and corresponding right-of-use asset on the Consolidated Balance Sheets based on the present value of future lease payments and recognizes lease expense on a straight-line basis over the lease term. Operating lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term (or at fair values in the case of those leases assumed in an acquisition). Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets and are expensed on a straight-line basis over the lease term. Variable lease expense is immaterial and primarily includes leases with payments indexed to inflation when the index changes after lease commencement.
The Company has elected to separate payments for lease components from non-lease components for all asset classes. Lease agreements may include extension, termination or purchase options, all of which are considered in calculating the lease liability and right-of-use asset when it is reasonably certain the Company will exercise an option. The Company’s incremental borrowing rate on the commencement date is used to calculate the present value of future payments for most leases since the rate implicit in the lease is generally not readily determinable. These rates are assessed on a quarterly basis for measurement of new lease obligations,
Stock-Based Compensation
Stock-Based Compensation
Stock-based compensation expense is recognized using the fair value method for all awards,
Treasury Stock
Treasury Stock
Repurchased common stock is stated at cost, determined on an average cost basis and is presented as a reduction of stockholders’ equity on the Consolidated Balance Sheets.
Research and Development Expenses
Research and Development Expenses
Research and development expenses include scientific research costs such as salaries, facility costs, testing, technical information technology and administrative expenditures. Research and development expenses are for the application of scientific advances to the development of new and improved products and their uses. Substantially all research and development is performed in-house. Expenses are charged against earnings in the year incurred.
Foreign Currency Forward Contracts - Cash Flow Hedges and Derivatives not Designated as Hedging Instruments
Foreign Currency Forward Contracts - Cash Flow Hedges and Derivatives Not Designated as Hedging Instruments
The Company buys materials from foreign suppliers. Those transactions can be denominated in those suppliers’ local currency. The Company also sells to customers in foreign countries. Those transactions can be denominated in those customers’ local currency. Both of these transaction types can create volatility in the Company’s financial statements. The Company uses foreign currency forward contracts to manage those exposures and fluctuations. These contracts generally mature in 15 months or less, which is consistent with the forecasts of the related purchases and sales. Certain contracts are designated as cash flow hedges, whereas the remaining contracts, most of which are related to certain intercompany transactions which offset balance sheet exposure, are not designated as hedging instruments, see Notes 12, 15 and 16.
Net Investment Hedges
The Company uses fixed-to-fixed cross-currency swap agreements to hedge its exposure to adverse foreign currency exchange rate movements for its operations in Europe. The Company has elected the spot method for designating these contracts as net investment hedges. The maturity dates range from 2027 to 2029, see Notes 12, 15 and 16.
Interest Rate Swaps - Cash Flow Hedges
The Company uses swap agreements to hedge exposure related to interest expense and to manage its exposure to interest rate movements. The Company enters into interest rate swap agreements designated as cash flow hedges to hedge future fixed-rate debt issuances, which effectively fix a portion of interest payments.
Product Warranties
Product Warranties
The Company provides for estimated warranty expense at the time of sale and accrues for specific items at the time their existence is known and the amounts are determinable. The Company estimates warranty expense on certain products at the time of sale using quantitative measures based on historical warranty claim experience and evaluation of specific customer warranty issues,
New Significant Accounting Standards Recently Adopted and Not Yet Adopted
New Significant Accounting Standards Recently Adopted
In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions,” which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair values; it also requires additional disclosures, including the nature and remaining duration of such restrictions. The guidance is effective for fiscal years beginning after December 15, 2023, with early application permitted. The Company adopted ASU 2022-03 in the first quarter of fiscal 2025. The adoption did not have an impact on its Consolidated Financial Statements or Condensed Consolidated Financial Statements.
In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), “Improvements to Reportable Segment Disclosures,” which improves the segment disclosures to include reportable segment’s expenses. The guidance is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. This ASU is applicable beginning with annual reporting for the Company’s fiscal 2025 and interim reporting for the first quarter of the Company’s fiscal 2026. The Company adopted ASU 2023-07 in the fourth quarter of fiscal 2025 for its fiscal year ended July 31, 2025 and all interim periods thereafter.
New Significant Accounting Standards Not Yet Adopted
The Company considers the applicability and impact of the FASB’s ASUs issued but not yet adopted.
In November 2024, FASB issued ASU No. 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40), “Disaggregation of Income Statement Expenses,” which improves disclosures about a company’s expenses and provides more detailed information about the types of expenses in commonly presented expense captions. The guidance is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. This ASU is applicable beginning with annual reporting for the Company’s fiscal 2028 and interim reporting for the first quarter of the Company’s fiscal 2029. The Company will adopt ASU 2024-03 for the annual reporting period ending July 31, 2028 and for interim reporting periods thereafter. The Company is in the process of evaluating the impact of the ASU on its related disclosures.
In December 2023, FASB issued ASU No. 2023-09, Income Taxes (Topic 740), “Improvements to Income Tax Disclosures,” which enhances the transparency and decision usefulness of income tax disclosures. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU is applicable beginning with annual reporting for the Company’s fiscal 2026 and interim reporting for the first quarter of the Company’s fiscal 2027. The Company will adopt ASU 2023-09 for the annual reporting period ending July 31, 2026 and for interim reporting periods thereafter. The Company does not expect adoption of this standard will have a material impact on the Consolidated Financial Statements and is in the process of evaluating the effects of this guidance on its related disclosures.
In October 2023, FASB issued ASU No. 2023-06, "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative," which modifies the disclosure or presentation requirements of various FASB topics in the Codification. The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-K becomes effective, with early adoption prohibited. The Company is in the process of evaluating the impact of the ASU on its related disclosures.
Earnings Per Share Basic net earnings per share (EPS) is computed by dividing net earnings by the weighted average number of outstanding common shares. Diluted net EPS is computed by dividing net earnings by the weighted average number of outstanding common shares and common share equivalents relating to stock options and other stock incentive plans.
v3.25.2
Revenue (Tables)
 12 Months Ended
Jul. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Net sales, generally disaggregated by location where the customer’s order was placed, were as follows (in millions):
Year Ended July 31,
202520242023
U.S. and Canada$1,632.3 $1,583.1 $1,464.7 
Europe, Middle East and Africa (EMEA)1,027.2 1,012.9 1,007.8 
Asia Pacific (APAC)635.7 601.5 608.8 
Latin America (LATAM)395.7 388.8 349.5 
Total net sales$3,690.9 $3,586.3 $3,430.8 
v3.25.2
Inventories, Net (Tables)
 12 Months Ended
Jul. 31, 2025
Inventory Disclosure [Abstract]  
Schedule of Components of Inventory
The components of inventories, net were as follows (in millions):
July 31,
20252024
Raw materials$175.5 $177.4 
Work in process69.6 61.2 
Finished products268.5 238.1 
Total inventories, net$513.6 $476.7 
v3.25.2
Property, Plant and Equipment, Net (Tables)
 12 Months Ended
Jul. 31, 2025
Property, Plant and Equipment [Abstract]  
Schedule of Components of Property, Plant And Equipment
The components of property, plant and equipment, net were as follows (in millions):
July 31,
20252024
Land$29.5 $29.5 
Buildings493.8 451.9 
Machinery and equipment1,118.6 1,052.1 
Computer software129.5 134.7 
Construction in progress31.5 68.4 
Less accumulated depreciation(1,158.4)(1,091.1)
Total property, plant and equipment, net$644.5 $645.5 
v3.25.2
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Jul. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Reconciliation of Goodwill
Goodwill by reportable segment was as follows (in millions):
Mobile
Solutions
Segment		Industrial
Solutions
Segment		Life Sciences SegmentTotal
Goodwill
Balance as of July 31, 2023$25.5 $289.1 $166.5 $481.1 
Goodwill acquired— 1.9 — 1.9 
Purchase price adjustments— — (1.1)(1.1)
Foreign exchange translation(0.1)(1.1)(2.3)(3.5)
 Balance as of July 31, 2024$25.4 $289.9 $163.1 $478.4 
Goodwill acquired— 3.2 — 3.2 
Foreign exchange translation— 5.1 6.9 12.0 
Balance as of July 31, 2025$25.4 $298.2 $170.0 $493.6 
Schedule of Reconciliation of Intangibles
Intangible asset classes were as follows (in millions):
Year Ended July 31, 2025
Weighted Amortizable Life (in Years)Gross Carrying AmountAccumulated AmortizationNet
Customer relationships8.5$74.7 $(43.7)$31.0 
Trademarks6.73.8 (2.0)1.8 
Technology and patents
16.682.9 (19.1)63.8 
Non-compete agreements2.92.5 (1.7)0.8 
Total intangible assets$163.9 $(66.5)$97.4 
Year Ended July 31, 2024
Weighted Amortizable Life (in Years)Gross Carrying AmountAccumulated AmortizationNet
Customer relationships9.4$77.4 $(39.9)$37.5 
Trademarks8.114.2 (3.8)10.4 
Technology and patents
16.7142.4 (20.4)122.0 
Non-compete agreements2.73.9 (1.9)2.0 
Total intangible assets$237.9 $(66.0)$171.9 
Schedule of Expected Amortization Expense Amortization expense relating to existing intangible assets as of July 31, 2025 was as follows (in millions):
2026$9.4 
20279.0 
20288.6 
20297.5 
20307.1 
Thereafter55.8 
Total amortization expense$97.4 
v3.25.2
Short-Term Borrowings and Long-Term Debt (Tables)
 12 Months Ended
Jul. 31, 2025
Debt Disclosure [Abstract]  
Schedule of Short-term Borrowings
Short-term borrowings were as follows (in millions):
European Commercial Paper ProgramU.S. Credit FacilitiesEuropean Operations Credit FacilitiesRest of the World Credit FacilitiesTotal
Year Ended July 31,
2025202420252024202520242025202420252024
Available credit facilities$114.5 $108.3 $100.0 $100.0 $50.3 $48.4 $52.7 $46.7 $317.5 $303.4 
Reductions to borrowing capacity:
Outstanding borrowings — 22.8 31.2 0.2 — — — 5.3 31.2 28.3 
Other non-borrowing reductions— — — — 30.1 38.9 28.7 25.7 58.8 64.6 
Total reductions— 22.8 31.2 0.2 30.1 38.9 28.7 31.0 90.0 92.9 
Remaining borrowing capacity$114.5 $85.5 $68.8 $99.8 $20.2 $9.5 $24.0 $15.7 $227.5 $210.5 
Weighted average interest rate as of July 31, 2025 and 2024
N/A4.34 %5.20 %6.44 %N/AN/AN/A0.56 %5.20 %3.62 %
Schedule of Long-term Debt
Long-term debt was as follows:
Interest RateOutstanding Balance
(in millions)
Financial InstrumentFixed or VariableAmountMaturity DateJuly 31, 2025July 31, 2024July 31, 2025July 31, 2024
Unsecured term loan
Variable
$200.0  millionJune 12, 20285.57 %— %200.0 — 
Unsecured senior notesFixed
$125.0 million
June 17, 20303.18 %3.18 %125.0 125.0 
Unsecured senior notes
Fixed
$100.0 million
August 5, 20312.50 %2.50 %100.0 100.0 
Unsecured revolving credit facilityVariable
$600.0 million
June 12, 20305.44 %6.44 %60.0 110.0 
Unsecured term loanVariable
 €80.0 million
March 26, 20292.83 %4.69 %91.6 86.6 
Unsecured senior notes
Fixed
$50.0 million
November 5, 20282.12 %2.12 %50.0 50.0 
Unsecured senior notesFixed
$25.0 million
April 16, 20252.93 %2.93 %— 25.0 
Unsecured term loanVariable¥1.0  billionJuly 31, 20281.28 %0.76 %6.7 6.7 
Unsecured term loanVariable¥1.0  billionJuly 15, 20261.20 %0.68 %6.7 6.7 
Debt issuance costs, net(2.9)(1.6)
Subtotal637.1 — 508.4 
Less current maturities(6.7)(25.0)
Total long-term debt$630.4 $483.4 
Schedule of Maturities of Long-term Debt
Future maturities of the Company’s long-term debt as of July 31, 2025 were as follows (in millions):
2026$6.7 
2027— 
2028206.7 
2029141.6 
2030185.0 
Thereafter100.0 
Total future maturities payments640.0 
Less debt issuance costs, net(2.9)
Total future maturities payments, net of debt issuance costs$637.1 
v3.25.2
Income Taxes (Tables)
 12 Months Ended
Jul. 31, 2025
Income Tax Disclosure [Abstract]  
Schedule of Components of Earnings Before Income Taxes
The components of earnings before income taxes were as follows (in millions):
Year Ended July 31,
202520242023
U.S.$245.5 $233.4 $178.0 
Foreign246.7 301.9 290.7 
Total$492.2 $535.3 $468.7 
Schedule of Components of the Provision For Income Taxes
The components of the provision for income taxes were as follows (in millions):
Year Ended July 31,
202520242023
Current
Federal$52.0 $47.2 $38.1 
State9.2 8.8 7.3 
Foreign88.0 89.6 79.8 
Total current149.2 145.6 125.2 
Deferred
Federal(13.5)(16.1)(13.3)
State(1.3)(1.7)(1.8)
Foreign(9.2)(6.5)(0.2)
Total deferred(24.0)(24.3)(15.3)
Total provision for income taxes$125.2 $121.3 $109.9 
Schedule of Reconciliation of the U.S. Statutory Income Tax Rate with the Effective Income Tax Rate
The reconciliation of the U.S. statutory federal income tax rate with the effective income tax rate was as follows:
Year Ended July 31,
202520242023
U.S. statutory federal income tax rate21.0 %21.0 %21.0 %
State income taxes1.8 1.2 0.9 
Foreign operations2.5 2.7 3.8 
Global intangible low tax income
0.2 0.2 0.2 
Foreign derived intangible income
(1.5)(1.3)(1.6)
Research and development credit(1.0)(0.9)(0.7)
Change in unrecognized tax benefits0.2 1.2 — 
Tax benefits on stock-based compensation (0.9)(1.2)(0.7)
Change in valuation allowance related to impairment
2.6 — — 
Other0.5 (0.2)0.5 
Effective income tax rate25.4 %22.7 %23.4 %
Schedule of the Tax Effects of Temporary Differences that Give Rise to Deferred Tax Assets and Liabilities
The tax effects of temporary differences that give rise to deferred tax assets and liabilities were as follows (in millions):
July 31,
20252024
Deferred tax assets
Accrued expenses$14.6 $14.3 
Compensation and retirement plans30.4 26.6 
Capitalization of R&D costs42.1 32.9 
Net operating loss (NOL) and tax credit carryforwards26.7 17.6 
Operating lease assets15.5 15.6 
Other12.6 6.2 
Gross deferred tax assets141.9 113.2 
Valuation allowance(30.0)(9.1)
Deferred tax assets, net of valuation allowance111.9 104.1 
Deferred tax liabilities
Depreciation and amortization(55.9)(74.5)
Operating lease liabilities(15.1)(14.9)
Other(2.8)(3.8)
Deferred tax liabilities(73.8)(93.2)
Net deferred tax asset (liability)
$38.1 $10.9 
Schedule of NOL and Tax Credit Valuation Allowances
The activity in the NOL and tax credit valuation allowances was as follows (in millions):
Year Ended July 31,
202520242023
Balance as of beginning of year$(9.1)$(6.4)$(3.4)
Additions charged to costs and expenses(14.0)(3.6)(3.0)
Deductions from reserves0.4 0.9 — 
Balance as of end of year$(22.7)$(9.1)$(6.4)
Schedule of Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits
The reconciliation of the beginning and ending amount of gross unrecognized tax benefits was as follows (in millions):
Year Ended July 31,
202520242023
Balance as of beginning of year$20.8 $15.0 $15.2 
Additions for tax positions of the current year3.3 2.8 2.5 
Additions for tax positions of prior years0.6 6.2 — 
Reductions for tax positions of prior years— (0.1)0.1 
Reductions due to lapse of applicable statute of limitations(2.7)(3.1)(2.8)
Balance as of end of year$22.0 $20.8 $15.0 
v3.25.2
Leases (Tables)
 12 Months Ended
Jul. 31, 2025
Leases [Abstract]  
Schedule of Lease Cost
The Company’s operating lease costs were as follows (in millions):
Year Ended July 31,
20252024
Operating lease cost$33.5 $29.5 
Short-term lease cost3.3 3.0 
Total lease costs$36.8 $32.5 
Schedule of Supplemental Balance Sheet Information
Supplemental balance sheet information for the Company was as follows (in millions):
July 31,
Balance Sheet Location20252024
Right-of-use lease assetsOther long-term assets$60.5 $59.7 
Current lease liabilitiesOther current liabilities$24.1 $20.2 
Long-term lease liabilitiesOther long-term liabilities$37.8 $41.3 
Additional information related to operating leases was as follows:
July 31,
20252024
Weighted average remaining lease term (years)4.13.5
Weighted average discount rate6.44 %4.61 %
Schedule of Operating Lease Liability
Remaining payments for operating leases having initial terms of more than one year as of July 31, 2025 were as follows (in millions):
2026$26.4 
202719.8 
202812.5 
20295.5 
20302.2 
Thereafter0.3 
Total future lease payments66.7 
Less imputed interest4.8 
Present value of future lease payments$61.9 
v3.25.2
Earnings Per Share (Tables)
 12 Months Ended
Jul. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Information Necessary to Calculate Basic and Diluted Earnings Per Share
Basic and diluted net EPS calculations were as follows (in millions, except per share amounts):
Year Ended July 31,
202520242023
Net earnings$367.0 $414.0 $358.8 
Weighted average common shares outstanding
Weighted average common shares – basic118.7 120.7 121.8 
Dilutive impact of stock-based awards1.7 1.9 1.8 
Weighted average common shares – diluted120.4 122.6 123.6 
Net EPS – basic$3.09 $3.43 $2.95 
Net EPS – diluted$3.05 $3.38 $2.90 
Stock options excluded from net EPS calculation0.70.00.0
v3.25.2
Stockholders' Equity (Tables)
 12 Months Ended
Jul. 31, 2025
Stockholders' Equity Note [Abstract]  
Schedule of Treasury Stock Activity
Treasury stock share activity was as follows:
Year Ended July 31,
20252024
Balance as of beginning of year31,533,192 30,528,696 
Stock repurchases4,875,000 2,465,000 
Net issuance upon exercise of stock options(678,540)(1,294,475)
Issuance under compensation plans(121,769)(149,329)
Other activity(7,143)(16,700)
Balance as of end of year35,600,740 31,533,192 
v3.25.2
Accumulated Other Comprehensive Loss (Tables)
 12 Months Ended
Jul. 31, 2025
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Loss By Component
Changes in accumulated other comprehensive loss for the years ended July 31, 2025 and 2024 were as follows (in millions):
Foreign
Currency
Translation
Adjustment		Pension
Benefits		Derivative
Financial
Instruments		Total
Balance as of July 31, 2024, net of tax$(133.8)$(69.1)$4.0 $(198.9)
Other comprehensive income (loss) before reclassifications and tax
29.6 (11.1)(1)(5.5)13.0 
Tax benefit— 2.6 1.3 3.9 
Other comprehensive income (loss) before reclassifications, net of tax
29.6 (8.5)(4.2)16.9 
Reclassifications, before tax— 1.3 (2)0.4 1.7 
Tax expense— (0.3)(0.1)(0.4)
Reclassifications, net of tax— 1.0 0.3 (3)1.3 
Other comprehensive income (loss), net of tax
29.6 (7.5)(3.9)18.2 
Balance as of July 31, 2025, net of tax$(104.2)$(76.6)$0.1 $(180.7)
Balance as of July 31, 2023, net of tax$(109.6)$(67.2)$4.3 $(172.5)
Other comprehensive loss before reclassifications and tax
(24.2)(9.0)(1)(0.8)(34.0)
Tax benefit
— 2.3 0.2 2.5 
Other comprehensive loss before reclassifications, net of tax
(24.2)(6.7)(0.6)(31.5)
Reclassifications, before tax— 6.3 (2)0.3 6.6 
Tax expense
— (1.5)— (1.5)
Reclassifications, net of tax— 4.8 0.3 (3)5.1 
Other comprehensive loss, net of tax
(24.2)(1.9)(0.3)(26.4)
Balance as of July 31, 2024, net of tax$(133.8)$(69.1)$4.0 $(198.9)
(1)In fiscal 2024, pension settlement accounting was triggered. In addition, pension curtailment accounting was triggered in fiscal 2024. Remeasurements of the Company’s pension obligations resulted in an increase of $11.1 million and $9.0 million in fiscal 2025 and 2024, respectively, to accumulated other comprehensive loss on the Consolidated Balance Sheets, see Note 14.
(2)Amounts include reclassifications of $0.0 million and $4.8 million, a foreign currency translation gain of $0.9 million and loss of $0.1 million and net amortization of prior service costs and actuarial losses of $2.2 million and $1.4 million in fiscal 2025 and 2024, respectively. Amounts are included in other income, net in the Consolidated Statements of Earnings, see Note 14.
(3)Relates to designated foreign currency forward contracts that were reclassified from accumulated other comprehensive loss on the Consolidated Balance Sheets to net sales, cost of sales and operating expenses in the Consolidated Statements of Earnings, see Note 15.
v3.25.2
Stock-Based Compensation (Tables)
 12 Months Ended
Jul. 31, 2025
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Schedule of Valuation Assumption Used to Determine Fair Value of Stock-Based Compensation Awards
The fair value of these awards was determined using the following inputs:
Year Ended July 31,
202520242023
Risk-free interest rate
3.6% - 4.5%
3.8% - 4.6%
3.8% - 4.2%
Expected volatility
26.1% - 27.0%
26.8% - 27.2%
26.8% - 27.5%
Expected dividend yield1.6 %1.6 %1.6 %
Expected life:
Director grants8 years8 years8 years
Officer grants7 years7 years7 years
Non-officer grants7 years7 years7 years
Schedule of Stock Option Activity
Option activity was as follows:
 OptionsWeighted
Average Exercise
Price
Balance outstanding as of July 31, 20246,163,056 $50.57 
Granted800,025 72.87 
Exercised(692,308)42.46 
Expired/forfeited(47,693)63.45 
Balance outstanding as of July 31, 20256,223,080 $54.24 
Schedule of Outstanding and Exercisable Options
Outstanding and exercisable stock options as of July 31, 2025 were as follows:
Range of Exercise PricesNumber
Outstanding		Weighted
Average
Remaining
Contractual
Life (Years)		Weighted
Average
Exercise
Price		Number
Exercisable		Weighted
Average
Remaining
Contractual
Life (Years)		Weighted
Average
Exercise
Price
$28.00 to $37.99
231,143 0.4$28.17 231,143 0.4$28.17 
$38.00 to $47.99
1,625,429 3.244.85 1,625,429 3.244.85 
$48.00 to $57.99
1,519,987 5.651.44 1,251,934 5.351.56 
$58.00 to $67.99
2,096,337 6.259.66 1,537,904 5.459.40 
$68.00 and above
750,184 9.273.13 1,629 8.772.68 
6,223,080 5.4$54.24 4,648,039 4.4$50.65 
Schedule of Status of Options that Contain Vesting Provisions
For the year ended July 31, 2025, activity for non-vested stock options that contain vesting provisions was as follows:
OptionsWeighted
Average Grant
Date Fair
Value
Balance outstanding as of beginning of year1,657,970 $17.02 
Granted800,025 21.67 
Vested(835,261)16.24 
Forfeited(47,693)19.29 
Balance outstanding as of end of year1,575,041 $19.73 
Schedule of Performance Shares Activity
The weighted average grant date fair value related to the Company’s performance-based awards was as follows:
Year Ended July 31,
202520242023
Weighted average grant date fair value$73.18 $59.66 $50.89 
Performance-based awards for non-vested activity were as follows:
Performance SharesWeighted
Average Grant
Date Fair
Value
Balance outstanding as of July 31, 2024
227,900 $55.31 
Granted111,900 73.18 
Vested(106,723)50.89 
Forfeited(35,393)64.39 
Balance outstanding as of July 31, 2025
197,684 $66.19 
v3.25.2
Employee Benefit Plans (Tables)
 12 Months Ended
Jul. 31, 2025
Defined Benefit Plan Disclosure  
Schedule of Net Periodic Pension Costs and Amounts Recognized in Other Comprehensive Income
Net periodic pension costs for the Company’s pension plans were as follows (in millions):
Year Ended July 31,
202520242023
Net periodic pension costs
Service cost$4.3 $5.2 $6.7 
Interest cost19.6 20.4 17.0 
Expected return on assets(25.7)(25.7)(25.3)
Prior service cost amortization— 0.1 — 
Actuarial loss amortization2.3 1.5 2.1 
Settlement loss
— 4.9 5.5 
Curtailment loss
— 0.2 0.2 
Net periodic pension costs0.5 6.6 6.2 
Other changes recognized in other comprehensive loss:
Prior service cost— 0.1 (0.4)
Net actuarial loss
(11.6)(9.1)(5.9)
Amortization of prior service cost— 0.3 0.2 
Amortization of net actuarial loss2.3 6.4 7.7 
Total recognized in other comprehensive loss
(9.3)(2.3)1.6 
Total recognized in net periodic pension costs and other comprehensive loss
$(9.8)$(8.9)$(4.6)
Schedule of Changes in Projected Benefit Obligations, Fair Value of Plan Assets and Funded Status
The changes in projected benefit obligations, fair value of plan assets and funded status of the Company’s pension plans for the years ended July 31, 2025 and 2024 were as follows (in millions):
Year Ended July 31,
20252024
Change in projected benefit obligation
Projected benefit obligation, beginning of year$403.7 $401.1 
Service cost4.3 5.2 
Interest cost19.6 20.4 
Plan amendments— (0.1)
Participant contributions0.8 0.8 
Actuarial (gain) loss
(7.1)11.7 
Foreign currency exchange rates6.5 (1.8)
Settlements paid— (15.6)
Acquisition
— 0.6 
Benefits paid(25.4)(18.6)
Projected benefit obligation, end of year402.4 403.7 
Change in fair value of plan assets
Fair value of plan assets, beginning of year413.3 416.0 
Actual return on plan assets8.1 28.4 
Company contributions2.7 2.8 
Participant contributions0.8 0.8 
Foreign currency exchange rates5.6 (1.1)
Settlements paid— (15.6)
Acquisition
— 0.6 
Benefits paid(25.4)(18.6)
Fair value of plan assets, end of year405.1 413.3 
Funded status of plans, end of year
$2.7 $9.6 
Amounts recognized on the Consolidated Balance Sheets
Other long-term assets$33.9 $35.8 
Other current liabilities(1.4)(1.5)
Other long-term liabilities(29.8)(24.7)
Net recognized asset $2.7 $9.6 
Schedule of Weighted-Average Discount Rates in Determining Actuarial Present Value of Projected Benefit Obligation
The significant assumptions used in determining the actuarial present value of the projected benefit obligation were as follows:
Year Ended July 31,
20252024
U.S. plans
Discount rate5.60 %5.44 %
Rate of compensation increaseN/AN/A
Non-U.S. plans
Discount rate4.82 %4.33 %
Rate of compensation increase3.07 %3.05 %
Schedule of Assumptions Used to Determine Net Periodic Benefit Cost
The weighted average discount rates, expected returns on plan assets and rates of increase in future compensation levels used to determine the net periodic pension costs were as follows:
Year Ended July 31,
202520242023
U.S. plans
Discount rate5.44 %5.58 %4.62 %
Expected rate of return on plan assets6.41 %6.16 %5.66 %
Rate of compensation increaseN/AN/AN/A
Non-U.S. plans
Discount rate4.33 %4.80 %3.26 %
Expected rate of return on plan assets4.88 %5.01 %4.39 %
Rate of compensation increase3.02 %3.05 %3.12 %
Schedule of Estimated Fair Value of Pension Plan Assets and their Respective Levels in the Fair Value Hierarchy During the year ended July 31, 2025, the Company’s asset allocation was as follows:
Salaried Pension PlanHourly Pension Plan
Global equity securities15 %15 %
Fixed income securities85 85 
Total100 %100 %
Schedule of Certain Investments at NAV
Certain investments, valued at NAV, had the following unfunded commitments and/or redemption restrictions (in millions):
July 31, 2025July 31, 2024
NAVUnfunded CommitmentsNAVUnfunded CommitmentsRedemption Frequency
(If Currently Eligible)		Redemption Notice (Days)
Global equity securities$37.8 $1.8 $31.1 $1.8 
Daily and Not Eligible(1)
N/A
Fixed income securities228.6 — 10.2 — Daily and Quarterly
0 - 60
Real asset funds2.9 4.2 2.9 4.2 
Not Eligible(1)
N/A
Total U.S. assets$269.3 $6.0 $44.2 $6.0 
Schedule of the Changes in the Fair Value of Non-U.S. Pension Plans' Assets with Unobservable Inputs
The changes in the fair values of the pension plans’ Level 3 assets were as follows (in millions):
Year Ended July 31,
202520242023
Balance as of beginning of year$42.7 $41.3 $35.4 
Unrealized gains3.3 3.4 2.7 
Foreign currency exchange2.6 (0.8)3.0 
Purchases and sales, net0.9 (1.2)0.2 
Balance as of end of year$49.5 $42.7 $41.3 
Schedule of Estimated Future Benefit Payments
Estimated future benefit required payments for the Company’s pension plans as of July 31, 2025 were as follows (in millions):
2026$26.8 
2027$28.2 
2028$29.4 
2029$30.1 
2030$31.0 
2031-2035$159.1 
U.S. Plan  
Defined Benefit Plan Disclosure  
Schedule of Estimated Fair Value of Pension Plan Assets and their Respective Levels in the Fair Value Hierarchy
The estimated fair value of pension plan assets and their respective levels in the fair value hierarchy by asset category were as follows (in millions):
Level 1Level 2Level 3Total
Balances as of July 31, 2025
Cash and cash equivalents$0.3 $2.9 $— $3.2 
Global equity securities3.9 55.2 — 59.1 
Fixed income securities5.0 22.1 — 27.1 
Insurance contracts— — 49.5 49.5 
Total investments in the fair value hierarchy$9.2 $80.2 $49.5 138.9 
Investments using NAV as practical expedient269.3 
Total investment, at fair value
408.2 
Accrued expense
(3.1)
Total assets
$405.1 
Balances as of July 31, 2024
Cash and cash equivalents$2.4 $0.5 $— $2.9 
Global equity securities58.2 54.5 — 112.7 
Fixed income securities80.4 128.0 — 208.4 
Insurance contracts— — 42.7 42.7 
Total investments in the fair value hierarchy$141.0 $183.0 $42.7 366.7 
Investments using NAV as practical expedient44.2 
Total investment, at fair value
410.9 
Accrued income
2.4 
Total assets
$413.3 
v3.25.2
Fair Value Measurements (Tables)
 12 Months Ended
Jul. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of Derivatives on Balance Sheet
The fair value of the Company’s derivative contracts, recorded on the Consolidated Balance Sheets, was as follows (in millions):
Assets
Liabilities
July 31,July 31,
Balance Sheet Location2025202420252024
Designated as hedging instruments
Foreign currency forward contracts
Other current assets, other current liabilities
$0.4 $0.1 $0.3 $— 
Net investment hedges
Other current assets, other long-term assets, other long-term liabilities
1.6 3.7 2.9 — 
Total designated2.0 3.8 3.2 — 
Not designated as hedging instruments
Foreign currency forward contracts
Other current assets, other current liabilities
0.9 1.0 0.4 0.3 
Total not designated0.9 1.0 0.4 0.3 
Total$2.9 $4.8 $3.6 $0.3 
Amounts related to excluded components, such as forward points, are excluded from the assessment of hedge effectiveness of net investment hedges and are expected to be reclassified into earnings throughout their maturity dates. See Note 12 for additional information on accumulated other comprehensive loss.
Schedule of Company’s Contingent Consideration Obligations
A reconciliation of the fair value of the Company’s contingent consideration liability that use unobservable inputs was as follows (in millions):
Balance as of July 31, 2024
$21.8 
Issuances1.5
Settlements
(5.8)
Adjustments to fair value(6.2)
Balance as of July 31, 2025
$11.3 
Maximum potential payout$22.5 
Balance as of July 31, 2023
$25.0 
Issuances1.0
Settlements(2.0)
Adjustments to fair value(2.2)
Balance as of July 31, 2024
$21.8 
Maximum potential payout$29.8 
v3.25.2
Guarantees (Tables)
 12 Months Ended
Jul. 31, 2025
Product Warranties Disclosures [Abstract]  
Schedule of Guarantor obligations The outstanding debt contingent liability for standby letters of credit was as follows (in millions):
Year Ended July 31,
20252024
Contingent liability for standby letters of credit issued under the Company’s revolving credit facility$7.9 $7.5 
Amounts drawn for letters of credit under the Company’s revolving credit facility$— $— 
v3.25.2
Commitments and Contingencies (Tables)
 12 Months Ended
Jul. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Schedule of contingent consideration arrangement liabilities
The arrangement liabilities, recorded on the Consolidated Balance Sheets, were as follows (in millions):
Arrangement Liability
Maximum Payout (1)
Balance Sheet LocationJuly 31,
2025		July 31,
2024		July 31,
2025		July 31,
2024
Expires in
Contingent compensation arrangements
Purilogics (4)
Accrued employee compensation and related taxes$— $2.1 $— $3.0 — 
Other
Accrued employee compensation and related taxes, other long-term liabilities
$0.2 $0.3 $0.2 $0.8 
FY27
Contingent consideration liability
Purilogics (2)
Other current liabilities, other long-term liabilities
$9.8 $19.0 $21.0 $27.0 

FY27
Other (3)
Other current liabilities $1.5 $2.8 $1.5 $2.8 
FY26
(1)The maximum payout values are inclusive of the respective arrangement liability balance.
(2)The decrease in the Purilogics’ contingent consideration liability in fiscal 2025 was primarily driven by a $6.2 million reduction of the fair value during the twelve months ended July 31, 2025 based on the probability of achieving certain milestones. The total contingent consideration paid as of July 31, 2025 was $5.0 million, of which $3.0 million was paid during fiscal 2025 and $2.0 million was paid during fiscal 2024.
(3)A contingent consideration liability of $1.5 million was added in fiscal 2025 due to a non-material acquisition. The total contingent consideration paid as of July 31, 2025 was $2.8 million, which was all paid in fiscal 2025.
(4)Purilogics contingent compensation of $3.0 million was paid in fiscal 2025.
v3.25.2
Segment Reporting (Tables)
 12 Months Ended
Jul. 31, 2025
Segment Reporting, Measurement Disclosures [Abstract]  
Schedule of Segment Details
Segment details were as follows (in millions):
Mobile Solutions SegmentIndustrial Solutions SegmentLife Sciences Segment
Total Segment
Corporate and
Unallocated (1)
Total
Company
Year ended July 31, 2025
Net sales$2,291.0 $1,104.4 $295.5 $3,690.9 $— $3,690.9 
Cost of sales1,544.0 654.9 177.9 
Other segment items (2)
329.4 251.8 113.2 
Earnings (loss) before income taxes
$417.6 $197.7 $4.4 $619.7 $(127.5)$492.2 
Equity earnings in unconsolidated affiliates$8.1 $0.2 $— $8.3 $— $8.3 
Assets$1,334.8 $883.7 $458.4 $2,676.9 $300.3 $2,977.2 
Equity investments in unconsolidated affiliates$33.5 $0.5 $— $34.0 $— $34.0 
Year ended July 31, 2024
Net sales$2,250.8 $1,066.5 $269.0 $3,586.3 $— $3,586.3 
Cost of sales1,524.6 624.0 156.5 
Other segment items (2)
321.7 243.7 122.9 
Earnings (loss) before income taxes
$404.5 $198.8 $(10.4)$592.9 $(57.6)$535.3 
Equity earnings in unconsolidated affiliates$7.3 $0.1 $— $7.4 $— $7.4 
Assets$1,339.5 $821.7 $512.1 $2,673.3 $241.0 $2,914.3 
Equity investments in unconsolidated affiliates$26.8 $0.1 $— $26.9 $— $26.9 
Year ended July 31, 2023
Net sales$2,174.8 $1,014.7 $241.3 $3,430.8 $— $3,430.8 
Cost of sales1,535.4 594.3 136.8 
Other segment items (2)
309.0 234.2 94.6 
Earnings (loss) before income taxes$330.4 $186.2 $9.9 $526.5 $(57.8)$468.7 
Equity earnings in unconsolidated affiliates$3.6 $— $— $3.6 $— $3.6 
Assets$1,243.8 $788.1 $513.8 $2,545.7 $224.8 $2,770.5 
Equity investments in unconsolidated affiliates$24.2 $0.2 $— $24.4 $— $24.4 
(1) Corporate and unallocated includes interest expense and certain corporate expenses determined to be non-allocable to the segments, such as restructuring charges and portions of incentive compensation.
(2) Other segment items consist primarily of selling, general and administrative expenses, research and development expense and other income (expense).
Schedule of Reconciliation of Net Sales by Product Group Per Segment
Net sales by business unit were as follows (in millions):
Year Ended July 31,
202520242023
Mobile Solutions segment
Off-Road$359.5 $380.8 $428.7 
On-Road110.6 139.8 145.8 
Aftermarket1,820.9 1,730.2 1,600.3 
Total Mobile Solutions segment2,291.0 2,250.8 2,174.8 
Industrial Solutions segment
Industrial Filtration Solutions
914.2 901.1 872.2 
Aerospace and Defense190.2 165.4 142.5 
Total Industrial Solutions segment1,104.4 1,066.5 1,014.7 
Life Sciences segment
Total Life Sciences segment295.5 269.0 241.3 
Total Company$3,690.9 $3,586.3 $3,430.8 
Schedule of Net Sales by Origination and Property, Plant and Equipment by Geographic Region
Net sales, generally disaggregated by location where the customer’s order was received, property, plant and equipment, net and right-of-use asset by geographic region were as follows (in millions):
Net Sales Property, Plant and Equipment, Net
Right-Of-Use Asset
Year ended July 31, 2025
U.S. and Canada$1,632.3 $225.7 $26.8 
EMEA1,027.2 195.2 16.5 
APAC635.7 76.2 11.0 
LATAM395.7 147.4 6.2 
Total$3,690.9 $644.5 $60.5 
Year ended July 31, 2024
U.S. and Canada$1,583.1 $209.7 $23.3 
EMEA1,012.9 199.6 19.1 
APAC601.5 75.5 10.6 
LATAM388.8 160.7 6.7 
Total$3,586.3 $645.5 $59.7 
Year ended July 31, 2023
U.S. and Canada$1,464.7 $219.7 $25.3 
EMEA1,007.8 202.4 15.5 
APAC608.8 76.5 11.6 
LATAM349.5 154.3 7.1 
Total$3,430.8 $652.9 $59.5 
v3.25.2
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Apr. 30, 2025
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative        
Foreign currency transaction losses   $ 2.5 $ 1.7 $ 6.4
Cost of sales   2,404.7 2,311.9 2,270.2
Accounts receivable, sale   86.1 29.9  
Loss on sales of receivables   4.1 1.7  
Proceeds from sale of other receivables   $ 82.0 $ 28.2  
LIFO inventory (as a percent)   34.40% 35.30%  
Excess of FIFO over LIFO inventory   $ 60.3 $ 51.3  
Depreciation   85.6 82.8 80.9
Loss on impairment of intangible assets   $ 62.0 $ 0.0 0.0
Foreign currency forward contracts        
Collaborative Arrangement and Arrangement Other than Collaborative        
Derivative instrument term (in months)   15 months    
Univercells Technologies        
Collaborative Arrangement and Arrangement Other than Collaborative        
Loss on impairment of intangible assets   $ 46.6    
Life Sciences Segment        
Collaborative Arrangement and Arrangement Other than Collaborative        
Loss on impairment of intangible assets $ 62.0      
Life Sciences Segment | Univercells Technologies        
Collaborative Arrangement and Arrangement Other than Collaborative        
Loss on impairment of intangible assets 46.6      
Non-compete agreements        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   2 years 10 months 24 days 2 years 8 months 12 days  
Non-compete agreements | Life Sciences Segment        
Collaborative Arrangement and Arrangement Other than Collaborative        
Loss on impairment of intangible assets 0.2      
Customer relationships        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   8 years 6 months 9 years 4 months 24 days  
Customer relationships | Life Sciences Segment        
Collaborative Arrangement and Arrangement Other than Collaborative        
Loss on impairment of intangible assets 1.0      
Trademarks        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   6 years 8 months 12 days 8 years 1 month 6 days  
Trademarks | Life Sciences Segment        
Collaborative Arrangement and Arrangement Other than Collaborative        
Loss on impairment of intangible assets 7.7      
Minimum        
Collaborative Arrangement and Arrangement Other than Collaborative        
Capitalization of direct cost, amortization period (in years)   3 years    
Minimum | Patents and technology        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   3 years    
Minimum | Non-compete agreements        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   3 years    
Minimum | Customer relationships        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   3 years    
Minimum | Trademarks        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   3 years    
Minimum | Building and Building Improvements        
Collaborative Arrangement and Arrangement Other than Collaborative        
Property, plant and equipment, useful life (in years)   10 years    
Minimum | Machinery and equipment        
Collaborative Arrangement and Arrangement Other than Collaborative        
Property, plant and equipment, useful life (in years)   3 years    
Minimum | Computer software        
Collaborative Arrangement and Arrangement Other than Collaborative        
Property, plant and equipment, useful life (in years)   2 years    
Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative        
Capitalization of direct cost, amortization period (in years)   10 years    
Maximum | Patents and technology        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   22 years    
Maximum | Non-compete agreements        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   22 years    
Maximum | Customer relationships        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   22 years    
Maximum | Trademarks        
Collaborative Arrangement and Arrangement Other than Collaborative        
Finite lived intangible asset estimated useful life (in years)   22 years    
Maximum | Building and Building Improvements        
Collaborative Arrangement and Arrangement Other than Collaborative        
Property, plant and equipment, useful life (in years)   40 years    
Maximum | Machinery and equipment        
Collaborative Arrangement and Arrangement Other than Collaborative        
Property, plant and equipment, useful life (in years)   10 years    
Maximum | Computer software        
Collaborative Arrangement and Arrangement Other than Collaborative        
Property, plant and equipment, useful life (in years)   6 years    
Shipping and Handling        
Collaborative Arrangement and Arrangement Other than Collaborative        
Cost of sales   $ 95.3 $ 91.5 $ 91.2
Solaris        
Collaborative Arrangement and Arrangement Other than Collaborative        
Loss on impairment of intangible assets   $ 15.4    
Solaris | Life Sciences Segment        
Collaborative Arrangement and Arrangement Other than Collaborative        
Loss on impairment of intangible assets $ 15.4      
v3.25.2
Acquisitions and Equity Method Investments (Details)
€ in Millions, $ in Millions
 12 Months Ended
Aug. 09, 2024
USD ($)
Aug. 09, 2024
EUR (€)
Jul. 31, 2025
USD ($)
Jul. 31, 2024
USD ($)
Jul. 31, 2023
USD ($)
Aug. 09, 2024
EUR (€)
Business Combination            
Payments to acquire equity method investments     $ 71.2 $ 0.0 $ 0.0  
Medica S.p.A            
Business Combination            
Remaining equity interest (as a percent) 51.00%         51.00%
Additional ownership acquisition, term (in years) 3 years         3 years
Medica S.p.A            
Business Combination            
Equity method investment (as a percent) 49.00%         49.00%
Payments to acquire equity method investments $ 67.9 € 62.1        
Capitalized transaction costs $ 5.8         € 5.1
v3.25.2
Revenue (Disaggregation of Revenue by Geographic Region) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Disaggregation of Revenue      
Net sales $ 3,690.9 $ 3,586.3 $ 3,430.8
U.S. and Canada      
Disaggregation of Revenue      
Net sales 1,632.3 1,583.1 1,464.7
Europe, Middle East and Africa (EMEA)      
Disaggregation of Revenue      
Net sales 1,027.2 1,012.9 1,007.8
Asia Pacific (APAC)      
Disaggregation of Revenue      
Net sales 635.7 601.5 608.8
Latin America (LATAM)      
Disaggregation of Revenue      
Net sales $ 395.7 $ 388.8 $ 349.5
v3.25.2
Revenue (Narrative) (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Revenue from Contract with Customer [Abstract]    
Contract with customer asset $ 24.3 $ 15.9
Contract with customer liability $ 20.8 $ 19.7
v3.25.2
Inventories, Net (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Inventory, Net [Abstract]    
Raw materials $ 175.5 $ 177.4
Work in process 69.6 61.2
Finished products 268.5 238.1
Total inventories, net $ 513.6 $ 476.7
v3.25.2
Property, Plant and Equipment, Net (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Property, Plant and Equipment    
Less accumulated depreciation $ (1,158.4) $ (1,091.1)
Total property, plant and equipment, net 644.5 645.5
Land    
Property, Plant and Equipment    
Property, plant and equipment, gross 29.5 29.5
Buildings    
Property, Plant and Equipment    
Property, plant and equipment, gross 493.8 451.9
Machinery and equipment    
Property, Plant and Equipment    
Property, plant and equipment, gross 1,118.6 1,052.1
Computer software    
Property, Plant and Equipment    
Property, plant and equipment, gross 129.5 134.7
Construction in progress    
Property, Plant and Equipment    
Property, plant and equipment, gross $ 31.5 $ 68.4
v3.25.2
Goodwill and Intangible Assets (Reconciliation of Goodwill) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Goodwill    
Beginning balance $ 478.4 $ 481.1
Goodwill acquired 3.2 1.9
Purchase price adjustments   (1.1)
Foreign exchange translation 12.0 (3.5)
Ending balance 493.6 478.4
Mobile Solutions Segment    
Goodwill    
Beginning balance 25.4 25.5
Goodwill acquired 0.0 0.0
Purchase price adjustments   0.0
Foreign exchange translation 0.0 (0.1)
Ending balance 25.4 25.4
Industrial Solutions Segment    
Goodwill    
Beginning balance 289.9 289.1
Goodwill acquired 3.2 1.9
Purchase price adjustments   0.0
Foreign exchange translation 5.1 (1.1)
Ending balance 298.2 289.9
Life Sciences Segment    
Goodwill    
Beginning balance 163.1 166.5
Goodwill acquired 0.0 0.0
Purchase price adjustments   (1.1)
Foreign exchange translation 6.9 (2.3)
Ending balance $ 170.0 $ 163.1
v3.25.2
Goodwill and Intangible Assets (Reconciliation of Intangible Assets) (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Finite-Lived Intangible Assets    
Gross Carrying Amount $ 163.9 $ 237.9
Accumulated Amortization (66.5) (66.0)
Net $ 97.4 $ 171.9
Customer relationships    
Finite-Lived Intangible Assets    
Weighted Amortizable Life (in Years) 8 years 6 months 9 years 4 months 24 days
Gross Carrying Amount $ 74.7 $ 77.4
Accumulated Amortization (43.7) (39.9)
Net $ 31.0 $ 37.5
Trademarks    
Finite-Lived Intangible Assets    
Weighted Amortizable Life (in Years) 6 years 8 months 12 days 8 years 1 month 6 days
Gross Carrying Amount $ 3.8 $ 14.2
Accumulated Amortization (2.0) (3.8)
Net $ 1.8 $ 10.4
Technology and patents    
Finite-Lived Intangible Assets    
Weighted Amortizable Life (in Years) 16 years 7 months 6 days 16 years 8 months 12 days
Gross Carrying Amount $ 82.9 $ 142.4
Accumulated Amortization (19.1) (20.4)
Net $ 63.8 $ 122.0
Non-compete agreements    
Finite-Lived Intangible Assets    
Weighted Amortizable Life (in Years) 2 years 10 months 24 days 2 years 8 months 12 days
Gross Carrying Amount $ 2.5 $ 3.9
Accumulated Amortization (1.7) (1.9)
Net $ 0.8 $ 2.0
v3.25.2
Goodwill and Intangible Assets (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Apr. 30, 2025
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets   $ 62.0 $ 0.0 $ 0.0
Foreign currency transaction loss   3.0 (1.4)  
Intangible asset amortization expense   13.9 $ 15.7 $ 11.4
Solaris        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets   15.4    
Univercells Technologies        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets   $ 46.6    
Life Sciences Segment        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets $ 62.0      
Life Sciences Segment | Solaris        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets 15.4      
Life Sciences Segment | Univercells Technologies        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets 46.6      
Life Sciences Segment | Technology and Patents        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets 53.1      
Life Sciences Segment | Trademarks        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets 7.7      
Life Sciences Segment | Customer relationships        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets 1.0      
Life Sciences Segment | Non-compete agreements        
Finite-Lived Intangible Assets        
Loss on impairment of intangible assets $ 0.2      
v3.25.2
Goodwill and Intangible Assets (Expected Amortization Expense Relating to Existing Intangible Assets) (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity    
2026 $ 9.4  
2027 9.0  
2028 8.6  
2029 7.5  
2030 7.1  
Thereafter 55.8  
Net $ 97.4 $ 171.9
v3.25.2
Short-Term Borrowings and Long-Term Debt (Short-term Borrowings) (Details) - USD ($)
Jul. 31, 2025
Jul. 31, 2024
Short-term Debt    
Short-term borrowings $ 31,200,000 $ 28,300,000
Line of Credit    
Short-term Debt    
Available credit facilities 317,500,000 303,400,000
Short-term borrowings 90,000,000.0 92,900,000
Remaining borrowing capacity $ 227,500,000 $ 210,500,000
Weighted average interest rate (as a percent) 5.20% 3.62%
Line of Credit | Outstanding borrowings    
Short-term Debt    
Short-term borrowings $ 31,200,000 $ 28,300,000
Line of Credit | Other non-borrowing reductions    
Short-term Debt    
Short-term borrowings 58,800,000 64,600,000
European Commercial Paper Program | European Commercial Paper Program    
Short-term Debt    
Available credit facilities 114,500,000 108,300,000
Short-term borrowings 0 22,800,000
Remaining borrowing capacity 114,500,000 $ 85,500,000
Weighted average interest rate (as a percent)   4.34%
European Commercial Paper Program | European Commercial Paper Program | Outstanding borrowings    
Short-term Debt    
Short-term borrowings 0 $ 22,800,000
European Commercial Paper Program | European Commercial Paper Program | Other non-borrowing reductions    
Short-term Debt    
Short-term borrowings 0 0
European Commercial Paper Program | Line of Credit    
Short-term Debt    
Available credit facilities 50,300,000 48,400,000
Short-term borrowings 30,100,000 38,900,000
Remaining borrowing capacity 20,200,000 9,500,000
European Commercial Paper Program | Line of Credit | Outstanding borrowings    
Short-term Debt    
Short-term borrowings 0 0
European Commercial Paper Program | Line of Credit | Other non-borrowing reductions    
Short-term Debt    
Short-term borrowings 30,100,000 38,900,000
U.S. Credit Facilities | Line of Credit    
Short-term Debt    
Available credit facilities 100,000,000.0 100,000,000.0
Short-term borrowings 31,200,000 200,000
Remaining borrowing capacity $ 68,800,000 $ 99,800,000
Weighted average interest rate (as a percent) 5.20% 6.44%
U.S. Credit Facilities | Line of Credit | Outstanding borrowings    
Short-term Debt    
Short-term borrowings $ 31,200,000 $ 200,000
U.S. Credit Facilities | Line of Credit | Other non-borrowing reductions    
Short-term Debt    
Short-term borrowings 0 0
Rest of the World Credit Facilities | Line of Credit    
Short-term Debt    
Available credit facilities 52,700,000 46,700,000
Short-term borrowings 28,700,000 31,000,000.0
Remaining borrowing capacity 24,000,000.0 $ 15,700,000
Weighted average interest rate (as a percent)   0.56%
Rest of the World Credit Facilities | Line of Credit | Outstanding borrowings    
Short-term Debt    
Short-term borrowings 0 $ 5,300,000
Rest of the World Credit Facilities | Line of Credit | Other non-borrowing reductions    
Short-term Debt    
Short-term borrowings $ 28,700,000 $ 25,700,000
v3.25.2
Short-Term Borrowings and Long-Term Debt (Long-term Debt) (Details)
Jul. 31, 2025
USD ($)
Jul. 31, 2025
EUR (€)
Jul. 31, 2025
JPY (¥)
Jul. 31, 2024
USD ($)
Debt Instrument        
Debt issuance costs, net $ (2,900,000)     $ (1,600,000)
Subtotal 637,100,000     508,400,000
Less current maturities (6,700,000)     (25,000,000.0)
Long-term debt 630,400,000     $ 483,400,000
Unsecured Senior Notes Due June 2028 | Unsecured Notes        
Debt Instrument        
Amount $ 200,000,000      
Debt instrument interest rate (as a percent) 5.57% 5.57% 5.57% 0.00%
Long-term debt, gross $ 200,000,000.0     $ 0
Unsecured Senior Notes Due June 2030 | Unsecured Notes        
Debt Instrument        
Amount $ 125,000,000.0      
Debt instrument interest rate (as a percent) 3.18% 3.18% 3.18% 3.18%
Long-term debt, gross $ 125,000,000.0     $ 125,000,000.0
Unsecured Senior Notes Due 2031 | Unsecured Notes        
Debt Instrument        
Amount $ 100,000,000.0      
Debt instrument interest rate (as a percent) 2.50% 2.50% 2.50% 2.50%
Long-term debt, gross $ 100,000,000.0     $ 100,000,000.0
Variable Rate Committed Revolving Credit Facility Due 2026 | Unsecured Notes | Unsecured Revolving Credit Facility        
Debt Instrument        
Amount $ 600,000,000.0      
Debt instrument interest rate (as a percent) 5.44% 5.44% 5.44% 6.44%
Long-term debt, gross $ 60,000,000.0     $ 110,000,000.0
Variable Rate Committed Unsecured Term Loan Due 2029 | Unsecured Notes        
Debt Instrument        
Amount | €   € 80,000,000.0    
Debt instrument interest rate (as a percent) 2.83% 2.83% 2.83% 4.69%
Long-term debt, gross $ 91,600,000     $ 86,600,000
Unsecured Senior Notes Due 2028 | Unsecured Notes        
Debt Instrument        
Amount $ 50,000,000.0      
Debt instrument interest rate (as a percent) 2.12% 2.12% 2.12% 2.12%
Long-term debt, gross $ 50,000,000.0     $ 50,000,000.0
Unsecured Senior Notes Due 2025 | Unsecured Notes        
Debt Instrument        
Amount $ 25,000,000.0      
Debt instrument interest rate (as a percent) 2.93% 2.93% 2.93% 2.93%
Long-term debt, gross $ 0     $ 25,000,000.0
Variable Rate Guaranteed Senior Note Due 2028 | Unsecured Notes        
Debt Instrument        
Amount | ¥     ¥ 1,000,000,000  
Debt instrument interest rate (as a percent) 1.28% 1.28% 1.28% 0.76%
Long-term debt, gross $ 6,700,000     $ 6,700,000
Variable Rate Guaranteed Senior Note Due 2026 | Unsecured Notes        
Debt Instrument        
Amount | ¥     ¥ 1,000,000,000  
Debt instrument interest rate (as a percent) 1.20% 1.20% 1.20% 0.68%
Long-term debt, gross $ 6,700,000     $ 6,700,000
v3.25.2
Short-Term Borrowings and Long-Term Debt (Narrative) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jul. 31, 2025
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Jul. 30, 2025
Debt Instrument          
Proceeds from long-term debt   $ 388,100,000 $ 119,700,000 $ 189,200,000  
Line of Credit          
Debt Instrument          
Borrowing capacity $ 317,500,000 317,500,000 $ 303,400,000    
Unsecured Senior Notes Due June 2028 | Unsecured Notes          
Debt Instrument          
Amount 200,000,000 200,000,000      
New Unsecured Senior Notes Due June Twelve Two Thousand Twenty Eight | Unsecured Notes          
Debt Instrument          
Proceeds from long-term debt 200,000,000        
Unsecured Revolving Credit Facility          
Debt Instrument          
Borrowing capacity 63,000,000 63,000,000      
Long-term remaining borrowing capacity 532,100,000 $ 532,100,000      
Unsecured Revolving Credit Facility | Minimum          
Debt Instrument          
Commitment fee (as a percent)   0.08%      
Unsecured Revolving Credit Facility | Maximum          
Debt Instrument          
Commitment fee (as a percent)   0.25%      
Unsecured Revolving Credit Facility | Variable Rate Committed Revolving Credit Facility Due June Twelfth Two Thousand Thirty          
Debt Instrument          
Borrowing capacity 600,000,000 $ 600,000,000     $ 500,000,000
Unsecured Revolving Credit Facility | New Unsecured Senior Notes Due June Twelve Two Thousand Twenty Eight          
Debt Instrument          
Borrowing capacity 350,000,000 350,000,000     $ 250,000,000
Multi-currency revolving credit facility          
Debt Instrument          
Borrowing capacity 17,000,000 17,000,000      
Multi-currency revolving credit facility | Line of Credit          
Debt Instrument          
Additional borrowing capacity on line of credit under certain conditions $ 350,000,000.0 $ 350,000,000.0      
v3.25.2
Short-Term Borrowings and Long-Term Debt (Future Maturities of Long Term Debt) (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Maturities of Long-term Debt    
2026 $ 6.7  
2027 0.0  
2028 206.7  
2029 141.6  
2030 185.0  
Thereafter 100.0  
Total future maturities payments 640.0  
Debt issuance costs, net (2.9) $ (1.6)
Subtotal $ 637.1  
v3.25.2
Income Taxes (Components of Earnings Before Income Taxes) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Earnings before income taxes:      
U.S. $ 245.5 $ 233.4 $ 178.0
Foreign 246.7 301.9 290.7
Total $ 492.2 $ 535.3 $ 468.7
v3.25.2
Income Taxes (Components of the Provision for Income Taxes) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Current      
Federal $ 52.0 $ 47.2 $ 38.1
State 9.2 8.8 7.3
Foreign 88.0 89.6 79.8
Total current 149.2 145.6 125.2
Deferred      
Federal (13.5) (16.1) (13.3)
State (1.3) (1.7) (1.8)
Foreign (9.2) (6.5) (0.2)
Total deferred (24.0) (24.3) (15.3)
Total provision for income taxes $ 125.2 $ 121.3 $ 109.9
v3.25.2
Income Taxes (Reconciliation of U.S. Statutory Income Tax Rate with Effective Income Tax Rate) (Details)
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Income Tax Disclosure [Abstract]      
U.S. statutory federal income tax rate 21.00% 21.00% 21.00%
State income taxes 1.80% 1.20% 0.90%
Foreign operations 2.50% 2.70% 3.80%
Global intangible low tax income 0.20% 0.20% 0.20%
Foreign derived intangible income (1.50%) (1.30%) (1.60%)
Research and development credit (1.00%) (0.90%) (0.70%)
Change in unrecognized tax benefits 0.20% 1.20% 0.00%
Tax benefits on stock-based compensation (0.90%) (1.20%) (0.70%)
Change in valuation allowance related to impairment 2.60% 0.00% 0.00%
Other 0.50% (0.20%) 0.50%
Effective income tax rate 25.40% 22.70% 23.40%
v3.25.2
Income Taxes (Temporary Differences that Give Rise to Deferred Tax Assets and Liabilities) (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Deferred tax assets    
Accrued expenses $ 14.6 $ 14.3
Compensation and retirement plans 30.4 26.6
Capitalization of R&D costs 42.1 32.9
Net operating loss (NOL) and tax credit carryforwards 26.7 17.6
Operating lease assets 15.5 15.6
Other 12.6 6.2
Gross deferred tax assets 141.9 113.2
Valuation allowance (30.0) (9.1)
Deferred tax assets, net of valuation allowance 111.9 104.1
Deferred tax liabilities    
Depreciation and amortization (55.9) (74.5)
Operating lease liabilities (15.1) (14.9)
Other (2.8) (3.8)
Deferred tax liabilities (73.8) (93.2)
Net deferred tax asset (liability) $ 38.1 $ 10.9
v3.25.2
Income Taxes (NOL and Tax Credit Valuation Allowances) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Valuation Allowance, Deferred Tax Asset      
Balance as of beginning of year $ (9.1)    
Balance as of end of year (30.0) $ (9.1)  
Net Operating Loss And Tax Credit      
Valuation Allowance, Deferred Tax Asset      
Balance as of beginning of year (9.1) (6.4) $ (3.4)
Additions charged to costs and expenses (14.0) (3.6) (3.0)
Deductions from reserves 0.4 0.9 0.0
Balance as of end of year $ (22.7) $ (9.1) $ (6.4)
v3.25.2
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Jul. 31, 2022
Income Tax Contingency        
Deferred tax asset, federal foreign tax credit $ 10.7      
Deferred tax asset, research and development credit 3.8      
Tax credit carryforwards 10.6      
Operating losses and tax credit carryforward valuation allowance 30.0 $ 9.1    
Undistributed earnings 1,500.0      
Undistributed earnings not considered reinvested 1,100.0      
Undistributed earnings tax charge 6.0      
Undistributed earnings considered reinvested 396.7      
Transition tax not due within 12 months 22.1      
Gross accrued interest and penalties 2.7 2.2    
Interest expense recognized $ 0.8      
Unrecognized tax benefits, statue of limitation term (in years) 5 years      
Unrecognized tax benefits $ 2.8      
Federal Tax Credits | Minimum        
Income Tax Contingency        
Credit carry forward term (in years) 10 years      
Research And Development Credits | Minimum        
Income Tax Contingency        
Credit carry forward term (in years) 1 year      
Research And Development Credits | Maximum        
Income Tax Contingency        
Credit carry forward term (in years) 20 years      
Net Operating Loss And Tax Credit        
Income Tax Contingency        
Operating losses and tax credit carryforward valuation allowance $ 22.7 $ 9.1 $ 6.4 $ 3.4
v3.25.2
Income Taxes (Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Reconciliation of the Beginning and Ending Amounts of Gross Unrecognized Tax Benefits      
Balance as of beginning of year $ 20.8 $ 15.0 $ 15.2
Additions for tax positions of the current year 3.3 2.8 2.5
Additions for tax positions of prior years 0.6 6.2 0.0
Reductions for tax positions of prior years 0.0 (0.1)  
Reductions for tax positions of prior years     0.1
Reductions due to lapse of applicable statute of limitations (2.7) (3.1) (2.8)
Balance as of end of year $ 22.0 $ 20.8 $ 15.0
v3.25.2
Leases (Lease Cost) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Leases [Abstract]    
Operating lease cost $ 33.5 $ 29.5
Short-term lease cost 3.3 3.0
Total lease costs $ 36.8 $ 32.5
v3.25.2
Leases (Supplemental Information) (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Leases [Abstract]      
Right-of-use lease assets $ 60.5 $ 59.7 $ 59.5
Current lease liabilities 24.1 20.2  
Long-term lease liabilities $ 37.8 $ 41.3  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other current liabilities Other current liabilities  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities Other long-term liabilities  
Weighted average remaining lease term (years) 4 years 1 month 6 days 3 years 6 months  
Weighted average discount rates (as a percentage) 6.44% 4.61%  
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other long-term assets Other long-term assets Other long-term assets
v3.25.2
Leases (Maturities) (Details)
$ in Millions
Jul. 31, 2025
USD ($)
Lessee, Operating Lease, Liability, Payment, Due  
2026 $ 26.4
2027 19.8
2028 12.5
2029 5.5
2030 2.2
Thereafter 0.3
Total future lease payments 66.7
Less imputed interest 4.8
Present value of future lease payments $ 61.9
v3.25.2
Earnings Per Share (Information Necessary to Calculate Basic and Diluted Net Earnings Per Common Share) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Earnings Per Share [Abstract]      
Net earnings $ 367.0 $ 414.0 $ 358.8
Weighted average common shares outstanding      
Weighted average common shares – basic (in shares) 118.7 120.7 121.8
Dilutive impact of share-based awards (in shares) 1.7 1.9 1.8
Weighted average common shares – diluted (in shares) 120.4 122.6 123.6
Net EPS – basic (in usd per share) $ 3.09 $ 3.43 $ 2.95
Net EPS – diluted (in usd per share) $ 3.05 $ 3.38 $ 2.90
Stock options excluded from net EPS calculation (in shares) 0.7 0.0 0.0
v3.25.2
Stockholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Jul. 31, 2025
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Nov. 30, 2023
Stockholders' Equity Note [Abstract]          
Stock repurchase program, additional shares authorized for repurchase (in shares)         12,000,000
Stock repurchases (in shares)   4,900,000 2,500,000    
Stock repurchased during the period including excise tax   $ 333.6 $ 163.3    
Purchase of treasury stock   $ 331.5 $ 162.7 $ 141.8  
Remaining number of shares authorized to be repurchased (in shares) 5,900,000 5,900,000      
Dividends paid per share (in usd per share)   $ 1.11 $ 1.02    
Cash dividend declared per common share (in usd per share) $ 0.300 $ 1.14 $ 1.04 $ 0.96  
v3.25.2
Stockholders' Equity (Treasury Stock) (Details) - shares
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Schedule of Treasury Shares Activity    
Balance as of beginning of year (in shares) 31,533,192  
Stock repurchases (in shares) 4,900,000 2,500,000
Net issuance upon exercise of stock options (in shares) (692,308)  
Balance as of end of year (in shares) 35,600,740 31,533,192
Treasury Stock    
Schedule of Treasury Shares Activity    
Balance as of beginning of year (in shares) 31,533,192 30,528,696
Stock repurchases (in shares) 4,875,000 2,465,000
Net issuance upon exercise of stock options (in shares) (678,540) (1,294,475)
Issuance under compensation plans (in shares) (121,769) (149,329)
Other activity (in shares) (7,143) (16,700)
Balance as of end of year (in shares) 35,600,740 31,533,192
v3.25.2
Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax      
Beginning balance $ 1,489.1 $ 1,320.7 $ 1,133.2
Other comprehensive income (loss) before reclassifications and tax 13.0 (34.0)  
Tax benefit 3.9 2.5  
Other comprehensive income (loss) before reclassifications, net of tax 16.9 (31.5)  
Reclassifications, before tax 1.7 6.6  
Tax expense (0.4) (1.5)  
Reclassifications, net of tax 1.3 5.1  
Net other comprehensive income (loss) 18.2 (26.4) 33.1
Ending balance 1,453.5 1,489.1 1,320.7
Total      
Accumulated Other Comprehensive Income (Loss), Net of Tax      
Beginning balance (198.9) (172.5) (205.6)
Ending balance (180.7) (198.9) (172.5)
Foreign Currency Translation Adjustment      
Accumulated Other Comprehensive Income (Loss), Net of Tax      
Beginning balance (133.8) (109.6)  
Other comprehensive income (loss) before reclassifications and tax 29.6 (24.2)  
Tax benefit 0.0 0.0  
Other comprehensive income (loss) before reclassifications, net of tax 29.6 (24.2)  
Reclassifications, before tax 0.0 0.0  
Tax expense 0.0 0.0  
Reclassifications, net of tax 0.0 0.0  
Net other comprehensive income (loss) 29.6 (24.2)  
Ending balance (104.2) (133.8) (109.6)
Pension Benefits      
Accumulated Other Comprehensive Income (Loss), Net of Tax      
Beginning balance (69.1) (67.2)  
Other comprehensive income (loss) before reclassifications and tax (11.1) (9.0)  
Tax benefit 2.6 2.3  
Other comprehensive income (loss) before reclassifications, net of tax (8.5) (6.7)  
Reclassifications, before tax 1.3 6.3  
Tax expense (0.3) (1.5)  
Reclassifications, net of tax 1.0 4.8  
Net other comprehensive income (loss) (7.5) (1.9)  
Ending balance (76.6) (69.1) (67.2)
Pension Benefits | Adjustments      
Accumulated Other Comprehensive Income (Loss), Net of Tax      
Reclassifications, before tax 0.0 4.8  
Derivative Financial Instruments      
Accumulated Other Comprehensive Income (Loss), Net of Tax      
Beginning balance 4.0 4.3  
Other comprehensive income (loss) before reclassifications and tax (5.5) (0.8)  
Tax benefit 1.3 0.2  
Other comprehensive income (loss) before reclassifications, net of tax (4.2) (0.6)  
Reclassifications, before tax 0.4 0.3  
Tax expense (0.1) 0.0  
Reclassifications, net of tax 0.3 0.3  
Net other comprehensive income (loss) (3.9) (0.3)  
Ending balance 0.1 4.0 $ 4.3
Accumulated Defined Benefit Plans Adjustment, Foreign Currency Translation Attributable To Parent | Adjustments      
Accumulated Other Comprehensive Income (Loss), Net of Tax      
Reclassifications, before tax (0.9) 0.1  
Net Amortization of Prior Service Cost and Actuarial Losses | Adjustments      
Accumulated Other Comprehensive Income (Loss), Net of Tax      
Other comprehensive income (loss) before reclassifications and tax $ (2.2) $ (1.4)  
v3.25.2
Stock-Based Compensation (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award      
Stock options, weighted average grant date fair value (in usd per share) $ 21.67 $ 19.00 $ 15.67
Intrinsic value of stock options exercised $ 20.2 $ 35.9 $ 20.2
Intrinsic value of shares outstanding 111.2    
Intrinsic value of shares exercisable 99.1    
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award      
Pre-tax compensation expense associated with stock options $ 16.1 14.2 12.4
Shares reserved for outstanding options and future grants (in shares) 11,144,365    
Total unrecognized compensation expense related to non-vested stock options $ 8.9    
Stock Options | 2019 Master Stock Incentive Plan      
Share-based Compensation Arrangement by Share-based Payment Award      
Stock options exercisable term (in years) 10 years    
Stock option, award vesting period (in years) 3 years    
Performance Shares      
Share-based Compensation Arrangement by Share-based Payment Award      
Total unrecognized compensation expense related to non-vested stock options $ 6.1    
Performance Shares | 2019 Master Stock Incentive Plan      
Share-based Compensation Arrangement by Share-based Payment Award      
Pre-tax compensation expense associated with stock options $ 5.7 $ 5.8 $ 6.3
Performance awards measurement period (in years) 3 years    
Expiration period (in years) 3 years    
Performance Shares | 2019 Master Stock Incentive Plan | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award      
Payout percentage based on target award (as a percent) 0.00%    
Performance Shares | 2019 Master Stock Incentive Plan | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award      
Payout percentage based on target award (as a percent) 200.00%    
v3.25.2
Stock-Based Compensation (Weighted Average Assumptions for Recognized Fair Value of Stock-Based Employee Compensation Cost) (Details)
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award      
Risk-free interest rate, min (as a percent) 3.60% 3.80% 3.80%
Risk-free interest rate, max (as a percent) 4.50% 4.60% 4.20%
Expected volatility, min (as a percent) 26.10% 26.80% 26.80%
Expected volatility, max (as a percent) 27.00% 27.20% 27.50%
Expected dividend yield (as a percent) 1.60% 1.60% 1.60%
Director grants      
Share-based Compensation Arrangement by Share-based Payment Award      
Expected life (in years) 8 years 8 years 8 years
Officer grants      
Share-based Compensation Arrangement by Share-based Payment Award      
Expected life (in years) 7 years 7 years 7 years
Non-officer grants      
Share-based Compensation Arrangement by Share-based Payment Award      
Expected life (in years) 7 years 7 years 7 years
v3.25.2
Stock-Based Compensation (Stock Option Activity) (Details)
 12 Months Ended
Jul. 31, 2025
$ / shares
shares
Options  
Beginning balance (in shares) | shares 6,163,056
Granted (in shares) | shares 800,025
Exercised (in shares) | shares (692,308)
Expired/forfeited (in shares) | shares (47,693)
Ending balance (in shares) | shares 6,223,080
Weighted Average Exercise Price  
Beginning balance (in usd per share) | $ / shares $ 50.57
Granted (in usd per share) | $ / shares 72.87
Exercised (in usd per share) | $ / shares 42.46
Expired/forfeited (in usd per share) | $ / shares 63.45
Ending balance (in usd per share) | $ / shares $ 54.24
v3.25.2
Stock-Based Compensation (Information Concerning Outstanding and Exercisable Options) (Details) - $ / shares
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range    
Number outstanding (in shares) 6,223,080 6,163,056
Weighted average remaining contractual life (in years) 5 years 4 months 24 days  
Weighted average exercise price (in usd per share) $ 54.24  
Number exercisable (in shares) 4,648,039  
Weighted average remaining contractual life (in years) 4 years 4 months 24 days  
Weighted average exercise price (in usd per share) $ 50.65  
$28.00 to $37.99    
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range    
Stock options, exercise price range, lower range limit (in usd per share) 28.00  
Share options, exercise price range, upper range limit (in usd per share) $ 37.99  
Number outstanding (in shares) 231,143  
Weighted average remaining contractual life (in years) 4 months 24 days  
Weighted average exercise price (in usd per share) $ 28.17  
Number exercisable (in shares) 231,143  
Weighted average remaining contractual life (in years) 4 months 24 days  
Weighted average exercise price (in usd per share) $ 28.17  
$38.00 to $47.99    
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range    
Stock options, exercise price range, lower range limit (in usd per share) 38.00  
Share options, exercise price range, upper range limit (in usd per share) $ 47.99  
Number outstanding (in shares) 1,625,429  
Weighted average remaining contractual life (in years) 3 years 2 months 12 days  
Weighted average exercise price (in usd per share) $ 44.85  
Number exercisable (in shares) 1,625,429  
Weighted average remaining contractual life (in years) 3 years 2 months 12 days  
Weighted average exercise price (in usd per share) $ 44.85  
$48.00 to $57.99    
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range    
Stock options, exercise price range, lower range limit (in usd per share) 48.00  
Share options, exercise price range, upper range limit (in usd per share) $ 57.99  
Number outstanding (in shares) 1,519,987  
Weighted average remaining contractual life (in years) 5 years 7 months 6 days  
Weighted average exercise price (in usd per share) $ 51.44  
Number exercisable (in shares) 1,251,934  
Weighted average remaining contractual life (in years) 5 years 3 months 18 days  
Weighted average exercise price (in usd per share) $ 51.56  
$58.00 to $67.99    
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range    
Stock options, exercise price range, lower range limit (in usd per share) 58.00  
Share options, exercise price range, upper range limit (in usd per share) $ 67.99  
Number outstanding (in shares) 2,096,337  
Weighted average remaining contractual life (in years) 6 years 2 months 12 days  
Weighted average exercise price (in usd per share) $ 59.66  
Number exercisable (in shares) 1,537,904  
Weighted average remaining contractual life (in years) 5 years 4 months 24 days  
Weighted average exercise price (in usd per share) $ 59.40  
$68.00 and above    
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range    
Stock options, exercise price range, lower range limit (in usd per share) $ 68.00  
Number outstanding (in shares) 750,184  
Weighted average remaining contractual life (in years) 9 years 2 months 12 days  
Weighted average exercise price (in usd per share) $ 73.13  
Number exercisable (in shares) 1,629  
Weighted average remaining contractual life (in years) 8 years 8 months 12 days  
Weighted average exercise price (in usd per share) $ 72.68  
v3.25.2
Stock-Based Compensation (Status for Options Which Contain Vesting Provisions) (Details) - $ / shares
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Options      
Balance outstanding as of beginning of year (in shares) 1,657,970    
Granted (in shares) 800,025    
Vested (in shares) (835,261)    
Forfeited (in shares) (47,693)    
Balance outstanding as of ending of year (in shares) 1,575,041 1,657,970  
Weighted Average Grant Date Fair Value      
Balance outstanding as of beginning of year (in usd per share) $ 17.02    
Granted (in usd per share) 21.67 $ 19.00 $ 15.67
Vested (in usd per share) 16.24    
Forfeited (in usd per share) 19.29    
Balance outstanding as of beginning of year (in usd per share) $ 19.73 $ 17.02  
v3.25.2
Stock-Based Compensation (Status for Performance-Based Awards Which Contain Vesting Provisions) (Details) - Performance Shares - $ / shares
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Performance Shares      
Beginning balance (in shares) 227,900    
Granted (in shares) 111,900    
Vested (in shares) (106,723)    
Forfeited (in shares) (35,393)    
Ending balance (in shares) 197,684 227,900  
Weighted Average Grant Date Fair Value      
Beginning balance (in usd per share) $ 55.31    
Granted (in usd per share) 73.18 $ 59.66 $ 50.89
Vested (in usd per share) 50.89    
Forfeited (in usd per share) 64.39    
Ending balance (in usd per share) $ 66.19 $ 55.31  
v3.25.2
Employee Benefit Plans (Components of Net Periodic Pension Costs) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Net periodic pension costs      
Service cost $ 4.3 $ 5.2 $ 6.7
Interest cost 19.6 20.4 17.0
Expected return on assets (25.7) (25.7) (25.3)
Prior service cost amortization 0.0 0.1 0.0
Actuarial loss amortization 2.3 1.5 2.1
Settlement loss 0.0 4.9 5.5
Curtailment loss 0.0 0.2 0.2
Net periodic pension costs $ 0.5 $ 6.6 $ 6.2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Other Nonoperating Income (Expense)
Other changes recognized in other comprehensive loss:      
Prior service cost $ 0.0 $ 0.1 $ (0.4)
Net actuarial loss (11.6) (9.1) (5.9)
Amortization of prior service cost 0.0 0.3 0.2
Amortization of net actuarial loss 2.3 6.4 7.7
Total recognized in other comprehensive loss (9.3) (2.3) 1.6
Total recognized in net periodic pension costs and other comprehensive loss $ (9.8) $ (8.9) $ (4.6)
v3.25.2
Employee Benefit Plans (Obligations and Funded Status of Company's Pension Plans) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Change in projected benefit obligation      
Service cost $ 4.3 $ 5.2 $ 6.7
Interest cost 19.6 20.4 17.0
Actuarial (gain) loss 2.3 1.5 2.1
Pension Plan      
Change in projected benefit obligation      
Projected benefit obligation, beginning of year 403.7 401.1  
Service cost 4.3 5.2  
Interest cost 19.6 20.4  
Plan amendments 0.0 (0.1)  
Participant contributions 0.8 0.8  
Actuarial (gain) loss (7.1) 11.7  
Foreign currency exchange rates 6.5 (1.8)  
Settlements paid 0.0 (15.6)  
Acquisition 0.0 0.6  
Benefits paid (25.4) (18.6)  
Projected benefit obligation, end of year 402.4 403.7 401.1
Change in fair value of plan assets      
Fair value of plan assets, beginning of year 413.3 416.0  
Actual return on plan assets 8.1 28.4  
Company contributions 2.7 2.8  
Participant contributions 0.8 0.8  
Foreign currency exchange rates 5.6 (1.1)  
Settlements paid 0.0 (15.6)  
Acquisition 0.0 0.6  
Benefits paid (25.4) (18.6)  
Fair value of plan assets, end of year 405.1 413.3 $ 416.0
Defined Benefit Plan, Funded (Unfunded) Status of Plan      
Funded status of plans, end of year 2.7 9.6  
Amounts recognized on the Consolidated Balance Sheets      
Other long-term assets 33.9 35.8  
Other current liabilities (1.4) (1.5)  
Other long-term liabilities (29.8) (24.7)  
Net recognized asset $ 2.7 $ 9.6  
v3.25.2
Employee Benefit Plans (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Defined Benefit Plan Disclosure      
Deferred compensation arrangement with individual, maximum future deferred receipts allowed (as a percent) 75.00%    
Deferred compensation arrangement with individual, recorded liability $ 0.4 $ 1.2  
Pension Plan      
Defined Benefit Plan Disclosure      
Net overfunded (underfunded) 2.7 9.6  
Unrealized losses recognized 120.5 111.3  
Accumulated benefit obligation 380.5 385.1  
Projected benefit obligation for pension plans with projected benefit obligations in excess of plan assets 82.8 75.3  
Fair value of plan assets for pension plans with projected benefit obligations in excess of plan assets 51.6 49.1  
Projected benefit obligation for pension plans with accumulated benefit obligations in excess of plan assets 82.8 17.7  
Accumulated benefit obligation for plans with projected benefit obligations in excess of plan assets 60.6 16.4  
Fair value of plan assets for plans with projected benefit obligations in excess of plan assets 51.6 7.3  
Cash and credit contributions 2.7    
Company contributions $ 2.7 2.8  
Pension Plan | Minimum | Fixed income securities | Level 3 | Independent Insurance Company      
Defined Benefit Plan Disclosure      
Pension plan target allocation (as a percent) 80.00%    
Pension Plan | Minimum | Global equity securities | Level 3 | Independent Insurance Company      
Defined Benefit Plan Disclosure      
Pension plan target allocation (as a percent) 10.00%    
Pension Plan | Maximum | Fixed income securities | Level 3 | Independent Insurance Company      
Defined Benefit Plan Disclosure      
Pension plan target allocation (as a percent) 90.00%    
Pension Plan | Maximum | Global equity securities | Level 3 | Independent Insurance Company      
Defined Benefit Plan Disclosure      
Pension plan target allocation (as a percent) 20.00%    
Retirement Savings and Employee Stock Ownership Plan | U.S. Plan      
Defined Benefit Plan Disclosure      
Contributory employee saving plan, employee contribution threshold limit from compensation, maximum (as a percent) 50.00%    
Contributory employee saving plan, percentage match of participants, first contributions (as a percent) 100.00%    
Contributory employee saving plan, percentage of participants, first eligible compensation (as a percent) 3.00%    
Contributory employee saving plan, percentage match of participants, second contributions (as a percent) 50.00%    
Contributory employee saving plan, percentage of participants, second eligible compensation (as a percent) 2.00%    
Defined contribution plan, annual retirement contributions (as a percent) 3.00%    
Company contributions $ 33.7 $ 32.7 $ 28.6
v3.25.2
Employee Benefit Plans (Weighted-Average Discount Rates in Determining Actuarial Present Value of Projected Benefit Obligation) (Details) - Pension Plan
Jul. 31, 2025
Jul. 31, 2024
U.S. Plan    
Defined Benefit Plan Disclosure    
Discount rate (as a percent) 5.60% 5.44%
Non - U.S. Plan    
Defined Benefit Plan Disclosure    
Discount rate (as a percent) 4.82% 4.33%
Rate of compensation increase (as a percent) 3.07% 3.05%
v3.25.2
Employee Benefit Plans (Assumptions Used to Determine Net Periodic Benefit Cost) (Details) - Pension Plan
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
U.S. Plan      
Defined Benefit Plan Disclosure      
Discount rate (as a percent) 5.44% 5.58% 4.62%
Expected rate of return on plan assets (as a percent) 6.41% 6.16% 5.66%
Non - U.S. Plan      
Defined Benefit Plan Disclosure      
Discount rate (as a percent) 4.33% 4.80% 3.26%
Expected rate of return on plan assets (as a percent) 4.88% 5.01% 4.39%
Rate of compensation increase (as a percent) 3.02% 3.05% 3.12%
v3.25.2
Employee Benefit Plans (Fair Value of Assets Held) (Details) - Pension Plan - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Jul. 31, 2022
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy $ 405.1 $ 413.3 $ 416.0  
U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 138.9 366.7    
Total investment, at fair value 408.2 410.9    
Accrued expense (3.1) 2.4    
Total assets 405.1 413.3    
Level 1 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 9.2 141.0    
Level 2 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 80.2 183.0    
Level 3        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 49.5 42.7 $ 41.3 $ 35.4
Level 3 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 49.5 42.7    
Investments using NAV as practical expedient | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy   44.2    
Investments using NAV as practical expedient 269.3 44.2    
Cash and cash equivalents | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 3.2 2.9    
Cash and cash equivalents | Level 1 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 0.3 2.4    
Cash and cash equivalents | Level 2 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 2.9 0.5    
Cash and cash equivalents | Level 3 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 0.0 0.0    
Global equity securities | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 59.1 112.7    
Global equity securities | Level 1 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 3.9 58.2    
Global equity securities | Level 2 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 55.2 54.5    
Global equity securities | Level 3 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 0.0 0.0    
Global equity securities | Investments using NAV as practical expedient | U.S. Plan        
Defined Benefit Plan Disclosure        
Investments using NAV as practical expedient 37.8 31.1    
Fixed income securities | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 27.1 208.4    
Fixed income securities | Level 1 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 5.0 80.4    
Fixed income securities | Level 2 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 22.1 128.0    
Fixed income securities | Level 3 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 0.0 0.0    
Fixed income securities | Investments using NAV as practical expedient | U.S. Plan        
Defined Benefit Plan Disclosure        
Investments using NAV as practical expedient 228.6 10.2    
Insurance contracts | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 49.5 42.7    
Insurance contracts | Level 1 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 0.0 0.0    
Insurance contracts | Level 2 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy 0.0 0.0    
Insurance contracts | Level 3 | U.S. Plan        
Defined Benefit Plan Disclosure        
Total investments in the fair value hierarchy $ 49.5 $ 42.7    
v3.25.2
Employee Benefit Plans (Unfunded Commitments and Redemption Restrictions) (Details) - U.S. Plan - Pension Plan - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Unfunded Commitments $ 6.0 $ 6.0
NAV    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
NAV 269.3 44.2
Global equity securities    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Unfunded Commitments 1.8 1.8
Global equity securities | NAV    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
NAV 37.8 31.1
Fixed income securities    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Unfunded Commitments $ 0.0 0.0
Fixed income securities | Minimum    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Redemption Notice (Days) 0 days  
Fixed income securities | Maximum    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Redemption Notice (Days) 60 days  
Fixed income securities | NAV    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
NAV $ 228.6 10.2
Real asset funds    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Unfunded Commitments 4.2 4.2
Real asset funds | NAV    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
NAV $ 2.9 $ 2.9
v3.25.2
Employee Benefit Plans (Changes in Fair Value of U.S. Pension Plans' Level 3 Assets) (Details) - Pension Plan - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Change in fair value of plan assets      
Fair value of plan assets, beginning of year $ 413.3 $ 416.0  
Fair value of plan assets, end of year 405.1 413.3 $ 416.0
Level 3      
Change in fair value of plan assets      
Fair value of plan assets, beginning of year 42.7 41.3 35.4
Unrealized gains 3.3 3.4 2.7
Foreign currency exchange 2.6 (0.8) 3.0
Purchases and sales, net 0.9 (1.2) 0.2
Fair value of plan assets, end of year $ 49.5 $ 42.7 $ 41.3
v3.25.2
Employee Benefit Plans (Pension Plan Target Allocation) (Details) - Pension Plan
Jul. 31, 2025
Salaried Pension Plan  
Defined Benefit Plan Disclosure  
Pension plan target allocation (as a percent) 100.00%
Hourly Pension Plan  
Defined Benefit Plan Disclosure  
Pension plan target allocation (as a percent) 100.00%
Global equity securities | Salaried Pension Plan  
Defined Benefit Plan Disclosure  
Pension plan target allocation (as a percent) 15.00%
Global equity securities | Hourly Pension Plan  
Defined Benefit Plan Disclosure  
Pension plan target allocation (as a percent) 15.00%
Fixed income securities | Salaried Pension Plan  
Defined Benefit Plan Disclosure  
Pension plan target allocation (as a percent) 85.00%
Fixed income securities | Hourly Pension Plan  
Defined Benefit Plan Disclosure  
Pension plan target allocation (as a percent) 85.00%
v3.25.2
Employee Benefit Plans (Estimated Future Benefit Payments for U.S. and Non U.S. Plans) (Details)
$ in Millions
Jul. 31, 2025
USD ($)
Defined Benefit Plan, Expected Future Benefit Payment  
2026 $ 26.8
2027 28.2
2028 29.4
2029 30.1
2030 31.0
2031-2035 $ 159.1
v3.25.2
Derivative Instruments and Hedging (Details)
€ in Millions, $ in Millions
 12 Months Ended
Jul. 31, 2025
USD ($)
derivative
Jul. 31, 2025
EUR (€)
derivative
Jul. 31, 2024
USD ($)
derivative
Designated as hedging instruments | Cash Flow Hedging      
Derivative      
Number of contracts (derivative) | derivative 0 0 0
Level 2 | Designated as hedging instruments | Net investment hedges      
Derivative      
Notional amount $ 88.8 € 80  
Foreign Currency Forward Contracts      
Derivative      
Derivative instrument term (in months) 15 months    
Foreign Currency Forward Contracts | Level 2 | Designated as hedging instruments      
Derivative      
Notional amount $ 35.7   $ 32.3
Foreign Currency Forward Contracts | Level 2 | Not designated as hedging instruments      
Derivative      
Notional amount $ 189.6   $ 249.7
v3.25.2
Fair Value Measurements (Narrative) (Details)
€ in Millions, $ in Millions
 12 Months Ended
Aug. 09, 2024
USD ($)
Aug. 09, 2024
EUR (€)
Jul. 31, 2025
USD ($)
Jul. 31, 2024
USD ($)
Jul. 31, 2023
USD ($)
Debt Instrument          
Payments to acquire equity method investments     $ 71.2 $ 0.0 $ 0.0
Payment of contingent consideration     5.5 1.7 $ 0.0
2024 Acquisitions          
Debt Instrument          
Maximum payout of contingent consideration     22.5 29.8  
Medica S.p.A          
Debt Instrument          
Payments to acquire equity method investments $ 67.9 € 62.1      
Level 3          
Debt Instrument          
Equity method investments     103.6 26.9  
Level 3 | Medica S.p.A          
Debt Instrument          
Payments to acquire equity method investments     69.7    
Fixed Interest Rate | Level 2 | Fair Value          
Debt Instrument          
Debt instrument, fair value disclosure     247.5 267.7  
Fixed Interest Rate | Level 2 | Carrying Value          
Debt Instrument          
Debt instrument, fair value disclosure     275.0 300.0  
Variable Interest Rate | Level 2 | Fair Value          
Debt Instrument          
Debt instrument, fair value disclosure     364.9 209.9  
Variable Interest Rate | Level 2 | Carrying Value          
Debt Instrument          
Debt instrument, fair value disclosure     $ 364.9 $ 209.9  
v3.25.2
Fair Value Measurements (Fair Value of Outstanding Derivatives in Consolidated Balance Sheets) (Details) - Fair Value, Inputs, Level 2 - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions    
Assets $ 2.9 $ 4.8
Liabilities 3.6 0.3
Designated as hedging instruments    
Fair Value, Balance Sheet Grouping, Financial Statement Captions    
Assets 2.0 3.8
Liabilities 3.2 0.0
Designated as hedging instruments | Net investment hedges    
Fair Value, Balance Sheet Grouping, Financial Statement Captions    
Assets 1.6 3.7
Liabilities 2.9 0.0
Not designated as hedging instruments    
Fair Value, Balance Sheet Grouping, Financial Statement Captions    
Assets 0.9 1.0
Liabilities 0.4 0.3
Foreign currency forward contracts | Designated as hedging instruments    
Fair Value, Balance Sheet Grouping, Financial Statement Captions    
Assets 0.4 0.1
Liabilities 0.3 0.0
Foreign currency forward contracts | Not designated as hedging instruments    
Fair Value, Balance Sheet Grouping, Financial Statement Captions    
Assets 0.9 1.0
Liabilities $ 0.4 $ 0.3
v3.25.2
Fair Value Measurements (Company’s Contingent Consideration Obligations) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation    
Balance at the beginning $ 21.8 $ 25.0
Issuances 1.5 1.0
Settlements $ (5.8) $ (2.0)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Adjustments to fair value $ (6.2) $ (2.2)
Balance at the end 11.3 21.8
Maximum potential payout $ 22.5 $ 29.8
v3.25.2
Guarantees (Balance Sheet) (Details) - USD ($)
$ in Millions
Jul. 31, 2025
Jul. 31, 2024
Product Warranties Disclosures [Abstract]    
Contingent liability for standby letters of credit issued under the Company’s revolving credit facility $ 7.9 $ 7.5
Amounts drawn for letters of credit under the Company’s revolving credit facility $ 0.0 $ 0.0
v3.25.2
Guarantees (Narrative) (Details) - USD ($)
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Guarantor Obligations      
Investment earnings $ 8,300,000 $ 7,400,000 $ 3,600,000
Advanced Filtration Systems Inc.      
Guarantor Obligations      
Investment earnings 12,900,000 12,300,000  
Unsecured Revolving Credit Facility      
Guarantor Obligations      
Available credit facilities 63,000,000    
Multi-currency revolving credit facility      
Guarantor Obligations      
Available credit facilities 17,000,000    
Advanced Filtration Systems Inc.      
Guarantor Obligations      
AFSI outstanding debt (the Company guarantees half) $ 43,900,000 $ 51,000,000.0  
v3.25.2
Commitments and Contingencies (Arrangement Liabilities) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Purilogics | Contingent compensation    
Business Combination    
Contingent consideration accrued $ 0.0 $ 2.1
Maximum payout of contingent consideration 0.0 3.0
Payment for contingent consideration liability 3.0  
Purilogics | Future Performance    
Business Combination    
Maximum payout of contingent consideration 21.0 27.0
Contingent consideration liability 9.8 19.0
Increase (decrease) in contingent consideration (6.2)  
Cumulative payment for contingent consideration liability 5.0  
Payment for contingent consideration liability 3.0 2.0
Other | Contingent compensation    
Business Combination    
Contingent consideration accrued 0.2 0.3
Maximum payout of contingent consideration 0.2 0.8
Other | Future Performance    
Business Combination    
Maximum payout of contingent consideration 1.5 2.8
Contingent consideration liability 1.5 $ 2.8
Increase (decrease) in contingent consideration 1.5  
Cumulative payment for contingent consideration liability $ 2.8  
v3.25.2
Commitments and Contingencies (Narrative) (Details)
$ in Millions
Jul. 31, 2025
USD ($)
customer
Jul. 31, 2024
USD ($)
Business Combination    
Accrued warranty reserves $ 6.9 $ 10.2
Revenue Benchmark | Customer Concentration Risk    
Business Combination    
Number of customer | customer 1  
Customer One    
Business Combination    
Accrued warranty reserves $ 4.1 $ 4.1
v3.25.2
Segment Reporting (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Segment Reporting Information      
Restructuring charges     $ 21.8
Corporate Non Segment      
Segment Reporting Information      
Restructuring charges $ 16.8 $ 6.4  
v3.25.2
Segment Reporting (Summary of Segments) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Segment Reporting Information      
Net sales $ 3,690.9 $ 3,586.3 $ 3,430.8
Cost of sales 2,404.7 2,311.9 2,270.2
Earnings (loss) before income taxes 492.2 535.3 468.7
Equity earnings in unconsolidated affiliates 8.3 7.4 3.6
Assets 2,977.2 2,914.3 2,770.5
Equity investments in unconsolidated affiliates 34.0 26.9 24.4
Operating Segments      
Segment Reporting Information      
Net sales 3,690.9 3,586.3 3,430.8
Cost of sales    
Earnings (loss) before income taxes 619.7 592.9 526.5
Equity earnings in unconsolidated affiliates 8.3 7.4 3.6
Assets 2,676.9 2,673.3 2,545.7
Equity investments in unconsolidated affiliates 34.0 26.9 24.4
Operating Segments | Mobile Solutions Segment      
Segment Reporting Information      
Net sales 2,291.0 2,250.8 2,174.8
Cost of sales 1,544.0 1,524.6 1,535.4
Other segment items 329.4 321.7 309.0
Earnings (loss) before income taxes 417.6 404.5 330.4
Equity earnings in unconsolidated affiliates 8.1 7.3 3.6
Assets 1,334.8 1,339.5 1,243.8
Equity investments in unconsolidated affiliates 33.5 26.8 24.2
Operating Segments | Industrial Solutions Segment      
Segment Reporting Information      
Net sales 1,104.4 1,066.5 1,014.7
Cost of sales 654.9 624.0 594.3
Other segment items 251.8 243.7 234.2
Earnings (loss) before income taxes 197.7 198.8 186.2
Equity earnings in unconsolidated affiliates 0.2 0.1 0.0
Assets 883.7 821.7 788.1
Equity investments in unconsolidated affiliates 0.5 0.1 0.2
Operating Segments | Life Sciences Segment      
Segment Reporting Information      
Net sales 295.5 269.0 241.3
Cost of sales 177.9 156.5 136.8
Other segment items 113.2 122.9 94.6
Earnings (loss) before income taxes 4.4 (10.4) 9.9
Equity earnings in unconsolidated affiliates 0.0 0.0 0.0
Assets 458.4 512.1 513.8
Equity investments in unconsolidated affiliates 0.0 0.0 0.0
Corporate and Unallocated      
Segment Reporting Information      
Net sales 0.0 0.0 0.0
Earnings (loss) before income taxes (127.5) (57.6) (57.8)
Equity earnings in unconsolidated affiliates 0.0 0.0 0.0
Assets 300.3 241.0 224.8
Equity investments in unconsolidated affiliates $ 0.0 $ 0.0 $ 0.0
v3.25.2
Segment Reporting (Net Sales by Product Within Engine Products Segment and Industrial Products Segment) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Segment Reporting Information      
Net sales $ 3,690.9 $ 3,586.3 $ 3,430.8
Operating Segments      
Segment Reporting Information      
Net sales 3,690.9 3,586.3 3,430.8
Mobile Solutions Segment | Operating Segments      
Segment Reporting Information      
Net sales 2,291.0 2,250.8 2,174.8
Mobile Solutions Segment | Off-Road | Operating Segments      
Segment Reporting Information      
Net sales 359.5 380.8 428.7
Mobile Solutions Segment | On-Road | Operating Segments      
Segment Reporting Information      
Net sales 110.6 139.8 145.8
Mobile Solutions Segment | Aftermarket | Operating Segments      
Segment Reporting Information      
Net sales 1,820.9 1,730.2 1,600.3
Industrial Solutions Segment | Operating Segments      
Segment Reporting Information      
Net sales 1,104.4 1,066.5 1,014.7
Industrial Solutions Segment | Industrial Filtration Solutions | Operating Segments      
Segment Reporting Information      
Net sales 914.2 901.1 872.2
Industrial Solutions Segment | Aerospace and Defense | Operating Segments      
Segment Reporting Information      
Net sales 190.2 165.4 142.5
Life Sciences Segment | Operating Segments      
Segment Reporting Information      
Net sales $ 295.5 $ 269.0 $ 241.3
v3.25.2
Segment Reporting (Geographic Sales by Origination and Property, Plant and Equipment) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Segment Reporting Information      
Net sales $ 3,690.9 $ 3,586.3 $ 3,430.8
Property, Plant and Equipment, Net 644.5 645.5 652.9
Right-Of-Use Asset 60.5 59.7 59.5
U.S. and Canada      
Segment Reporting Information      
Net sales 1,632.3 1,583.1 1,464.7
Property, Plant and Equipment, Net 225.7 209.7 219.7
Right-Of-Use Asset 26.8 23.3 25.3
EMEA      
Segment Reporting Information      
Net sales 1,027.2 1,012.9 1,007.8
Property, Plant and Equipment, Net 195.2 199.6 202.4
Right-Of-Use Asset 16.5 19.1 15.5
APAC      
Segment Reporting Information      
Net sales 635.7 601.5 608.8
Property, Plant and Equipment, Net 76.2 75.5 76.5
Right-Of-Use Asset 11.0 10.6 11.6
LATAM      
Segment Reporting Information      
Net sales 395.7 388.8 349.5
Property, Plant and Equipment, Net 147.4 160.7 154.3
Right-Of-Use Asset $ 6.2 $ 6.7 $ 7.1
v3.25.2
Restructuring (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2023
Restructuring Cost and Reserve      
Severance costs     $ 15.3
Restructuring reserve $ 7.1 $ 6.4  
Restructuring charges     21.8
Lower Margin Customer Programs      
Restructuring Cost and Reserve      
Business exit cost     6.5
Operating Segments      
Restructuring Cost and Reserve      
Severance costs 16.8 6.4  
Cost of Sales      
Restructuring Cost and Reserve      
Restructuring charges     $ 2.9
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]     Cost of sales
Cost of Sales | Operating Segments      
Restructuring Cost and Reserve      
Severance costs 6.5 3.8  
Operating Expense | Operating Segments      
Restructuring Cost and Reserve      
Severance costs $ 10.3 $ 2.6  
Selling, General and Administrative Expenses      
Restructuring Cost and Reserve      
Restructuring charges     $ 18.9
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]     Selling, general and administrative